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ABSTRACT 
 Cytochromes P450 (CYP450) are heme-containing monooxygenase enzymes that 
perform a variety of functions in humans, including xenobiotic metabolism and the production of 
endogenous signaling molecules.  Six isoforms of cytochrome P450 including cytochrome P450 
17A1 (CYP17A1) and cytochrome P450 21A2 (CYP21A2), are responsible for the generation of 
steroid hormones, making these enzymes crucial for development and homeostasis.  However in 
certain pathological conditions, inhibition of steroidogenic cytochrome P450 enzymes can be 
therapeutically useful.  For prostate cancers dependent on androgens such as dihydrotestosterone 
for tumor growth and proliferation, inhibition of CYP17A1, a required enzyme in androgen 
biosynthesis, is a promising treatment strategy. Although inhibition of CYP17A1 has been 
successful clinically, its additional roles in the biosynthesis of other steroid hormones and its 
similarity to other steroidogenic P450 enzymes can bring about off-target effects.  An 
understanding of the structure and function of CYP17A1, as well as other steroidogenic 
countertarget enzymes such as CYP21A2, could therefore be fundamental to developing 
improved inhibitors of this enzyme for the treatment of prostate cancer. 
CYP17A1 performs two different reactions in the same active site to generate androgens, 
a hydroxylation reaction followed by a carbon-carbon bond cleavage (or lyase) reaction.  While 
the second, carbon-carbon bond cleavage reaction commits a steroid to the androgen pathway, 
the initial hydroxylation reaction is also necessary for the production of glucocorticoids.  Human 
CYP17A1 performs the hydroxylation reaction on two structurally similar substrates, Δ4-
progesterone and Δ5-pregnenolone, which only exhibit differences on the A ring on the opposite 
end of the steroid from the carbon which is hydroxylated by CYP17A1.  Following 
hydroxylation, Δ5-17α-hydroxypregnenolone will undergo the second lyase reaction, but the Δ4-
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17α-hydroxyprogesterone does not.  To elucidate a structural basis for preferential lyase turnover 
of Δ5 steroids by human CYP17A1, the crystal structure of the enzyme containing a background 
mutation was determined in the presence of both hydroxylase substrates and both lyase 
substrates.  These structures reveal some similarities in binding among all four substrates but 
also differences in positions relative to the heme iron between hydroxylase substrates, the poor 
lyase substrate 17α-hydroxyprogesterone, and the efficient lyase substrate 17α-
hydroxypregnenolone.  Observed differences in distances between 17α-hydroxyprogesterone or 
17α-hydroxypregnenolone and the heme iron may reflect differential stabilization of the 
proposed intermediate for the 17,20-lyase reaction. In addition to substrates, steroidal inhibitors 
of CYP17A1 can have different configurations of the A ring.  X-ray crystal structures of a series 
of inhibitors with such modifications were also determined with CYP17A1 to compare active 
site interactions among A-ring modified steroidal inhibitors.  Modifications to the A ring of 
steroidal inhibitor abiraterone did not alter direct contacts with CYP17A1, but did change 
indirect contacts with the enzyme through active site water networks.  The structure of 
CYP17A1 with one A-ring modified inhibitor was resolved to 2.0 Å, making it the highest 
resolution crystal structure of CYP17A1 to date, and revealed an additional steroid binding site 
in the periphery of enzyme that had not been fully appreciated in previous CYP17A1 structures. 
 CYP17A1 and redox partner proteins were recombinantly expressed in E. coli and 
purified, providing a well-defined and well-controlled system for evaluation of CYP17A1 
function and inhibition.  This strategy was employed to compare hydroxylase and lyase 
deficiencies among clinically-reported mutants of the enzyme, as well as steroidal and non-
steroidal clinical inhibitors for selective inhibition of the lyase reaction compared to the 
hydroxylase reaction.  Most clinical inhibitors of CYP17A1 demonstrated 1- to 3- fold selectivity 
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for 17,20-lyase inhibition over 17α-hydroxylase inhibition.  Only one of the four inhibitors to 
reach clinical trials, S-orteronel, demonstrated 3- to 5- fold selectivity for 17,20-lyase inhibition 
compared to inhibition of progesterone and pregnenolone 17α-hydroxylase reactions.  However, 
its enantiomer, R-orteronel demonstrated 8- to 11-fold selectivity.  X-ray crystal structures of 
CYP17A1 with non-steroidal inhibitors reported to selectively inhibit the lyase reaction were 
also determined to investigate the structural basis for lyase selectivity.  
 Finally, some CYP17A1 inhibitors have also been shown to interact with another P450 
responsible for steroid biosynthesis, CYP21A2.  The physiological consequences of off-target 
CYP21A2 inhibition by compounds developed to target CYP17A1 are complex. The crystal 
structure of human CYP21A2 was determined to provide a structural comparison to CYP17A1 
and potentially aid in the design of inhibitors more selective for CYP17A1 over CYP21A2.  
Some structural features of the CYP17A1 active site, including a hydrophobic pocket over the I 
helix, are not conserved in CYP21A2.  Exploitation of this pocket is a potential strategy for the 
development of inhibitors with reduced affinity for CYP21A2. 
 In aggregate, the studies described herein use structural information coupled with 
functional analysis to better understand steroidogenic cytochromes P450. These enzymes act as 
targets and countertargets in the treatment of hormone dependent diseases including prostate 
cancer.  More detailed knowledge of how these enzymes interact with both substrates and 
inhibitors could inform the development of better prostate cancer therapeutics. 
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Chapter 1. 
Introduction 
Introduction to Cytochromes P450 
Cytochromes P450 are a superfamily of heme-containing monooxygenase enzymes 
expressed by a wide variety of life forms spanning from bacteria to humans. Under reducing 
conditions, these enzymes activate molecular oxygen to catalyze the insertion of a single oxygen 
atom onto a substrate carbon.  While members of the superfamily share a general structural motif 
and mechanism for activation of molecular oxygen, the reactions catalyzed by cytochromes P450 
can serve an array of functions.  The human genome encodes for 57 different cytochromes P450 
(Table 1.1).  Of the 38 isoforms that have a known substrate, nearly 40% primarily act on 
xenobiotics and appear to play a role in the clearance of exogenous compounds1.   The remaining 
cytochromes P450 turn over endogenous substrates, including steroid hormones, fatty acids, 
eicosanoids, and vitamins.  The work described in this dissertation focuses primarily on human 
cytochrome P450 enzymes responsible for the biosynthesis of steroid hormones. 
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Table 1.1: Human cytochrome P450 enzymes sorted by major substrate class 
 
 
Cytochrome P450 Spectroscopic Features and Catalytic Cycle 
 The reactions carried out by cytochromes P450 are mediated by a heme prosthetic group, 
which gives these enzymes their distinct spectroscopic profile.  The UV-visible absorbance 
maximum of the heme (known as the Soret peak) reflects both the redox state and the 
environment of the iron.  This iron is coordinated on the proximal face of the heme by the 
thiolate group of a cysteine (Figure 1.1).  In the absence of ligand, the ferric iron (Fe3+) is 
typically coordinated to a water molecule on the distal face of the heme, which results in a Soret 
peak at ~417 nm (Figure 1.1)2.  Binding of ligands in the active site on the distal side of the heme 
typically displaces the water, leaving the ferric iron coordinated only to the pyrrolic nitrogens of 
the porphyrin and the thiolate.  This results in a blue-shifting of the Soret peak to ~393 nm 
referred to as a “Type I shift”2.  In circumstances where the heteroatom of a ligand directly 
coordinates the heme iron upon displacement of the water molecule, the Soret peak is redshifted 
to ~424 nm, referred to as a “Type II shift”2.  The type of shift (I or II) can sometimes inform the 
 3 
orientation of ligands in the cytochrome P450 active site. Perhaps more importantly, the amount 
of absorbance change upon titration with a known concentration of ligand is used to determine 
dissociation constants (Kd) for enzyme-ligand complexes3. 
 
Figure 1.1: The absorbance maximum of the Soret band is dependent on the coordination state of 
the heme iron. The oxidized state, in which the heme iron binds to an active site water (black 
trace) absorbs at 417 nm.  The presence of a ligand can result in a type I spectrum in which the 
Soret band absorbs at ~393 nm (blue trace), or (if a heteroatom coordinates to the heme) a type II 
spectrum with Soret band absorbance at 424 nm (red trace). 
 
The Soret band absorbance can be used to determine the concentration of heme proteins, but for 
cytochromes P450 the protein concentration is often determined in the enzyme’s reduced state, 
with the heme bound to carbon monoxide.  Reduction of the heme iron from the ferric state 
(Fe3+) to the ferrous state (Fe2+) is accompanied by a less dramatic change in Soret band 
absorbance compared to those brought about by changes in the iron coordination state.  
However, subsequent addition of carbon monoxide results in a strong shift in Soret band 
absorbance to 450 nm upon coordination to ferrous cytochrome P450. Usually viewed as a 
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reduced carbon monoxide difference spectrum  (Figure 1.2), this spectral characteristic is 
distinctive for heme proteins with thiolate coordination to the iron.  Under the same conditions, a 
shift of the Soret band to 420 nm is sometimes observed, resulting in “P420”.  Although the 
underlying change in heme coordination state responsible for P420 remains debated4,5, species 
that demonstrate this spectral shift are considered catalytically inactive5. 
 
Figure 1.2: Treatment of reduced cytochrome P450 with carbon monoxide results in a 
characteristic shift of the Soret peak to 450 nm. 
 
 The phenomena underlying some of the aforementioned change in spectral characteristics 
(binding of substrate and reduction of the heme iron) comprise the first two steps of the 
cytochrome P450 catalytic cycle (Figure 1.3)6. Displacement of the active site water upon 
substrate binding (a to b) increases the iron redox potential and facilitates reduction of the heme 
iron from the ferric state to the ferrous state (b to c) by the redox partner protein NADPH-
cytochrome P450 reductase.  Ferrous heme binds molecular oxygen to form the dioxygen 
complex (d), and the dioxygen complex undergoes an additional one electron reduction by a 
redox partner protein (either NADPH-cytochrome P450 reductase or cytochrome b5) to generate 
a ferric peroxyanion intermediate (e).  A proton is delivered to the peroxyanion species to form 
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the ferric hydroperoxo complex (f).  Substrate hydroxylation requires a second protonation of the 
hydroperoxo species, which then undergoes homolytic cleavage to expel water.  The resulting 
ferryl oxo species (g) called “compound I” is postulated to be the key intermediate in P450 
hydroxylation.  Compound I abstracts a hydrogen from a substrate carbon to form a free radical, 
which then interacts with the oxygen of the ferryl species to yield a hydroxyl group on the 
substrate carbon (Figure 1.4).  This mechanism for substrate hydroxylation is known as the 
Groves’ rebound mechanism7,8. 
 
Figure 1.3: Catalytic cycle of cytochrome P450 enzymes.  Figure is adapted from Munro et al.9 
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Figure 1.4: Groves’ mechanism for cytochrome P450 hydroxylation reactions by hydrogen 
abstraction and rebound via the ferryl oxo intermediate. 
  
Although the Groves’ mechanism involving compound I as a key catalytic intermediate 
reflects our best understanding of how cytochromes P450 perform more common hydroxylation 
reactions, some P450 enzymes catalyze more unusual reactions including carbon-carbon bond 
cleavage, or lyase, reactions that are proposed to involve a different key catalytic intermediate.  
Catalysis of the lyase reaction has only been observed for a limited number of cytochrome P450 
enzymes.  Multiple mechanisms for the CYP17A1-mediated 17,20-lyase reaction have been 
reported in the literature10,11.  In a mechanism proposed by Akhtar and coworkers, the key 
catalytic intermediate for the carbon-carbon bond cleavage reaction is the dioxygen peroxo 
species (e) or (f) in contrast to the ferryl oxo complex (g) (Figure 1.3)10.  The distal oxygen of 
the peroxo intermediate is thought to act as a nucleophile on an acyl carbon, and subsequent 
homolytic cleavage of the O-O bond results in a deacetylation to form a free carbon radical 
(Figure 1.5).  Hydrogen abstraction by the Fe(III)-O complex affords a double bond yielding a 
ketone.  The most compelling studies to support this mechanism for carbon-carbon bond 
cleavage examined incorporation of isotopically-labeled oxygen into the deformylation products 
of CYP19A110, an enzyme that generates estrogens by aromatization of androgens.  However, 
more recent reexamination of these studies using more advanced instrumentation produced 
conflicting results suggesting that deformylation of testosterone proceeds through the ferryl oxo 
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catalytic intermediate11.  Consequently, the reactive oxygen species responsible for carbon-
carbon bond cleavage reactions in cytochrome P450 enzymes is still subject to debate. 
 
Figure 1.5: Proposed mechanism for cytochrome P450 carbon-carbon bond cleavage reaction via 
dioxygen catalytic intermediate10. 
 
General Structure of Cytochrome P450 Enzymes 
The first high-resolution crystal structure of a cytochrome P450 (a soluble, bacterial isoform 
known as P450cam) was reported in 198512. Since this time, over 600 X-ray crystal structures of 
cytochromes P450 have been deposited into the Protein Data Bank.  Although some members of 
the P450 superfamily share little more than 40% sequence identity, the overall fold of 
cytochromes P450 (Figure 1.6) is conserved among different organisms and subcellular 
localizations, from the first structure of P450cam to the membrane-associated mammalian 
isoforms investigated more recently.  All P450 enzymes are largely α-helical and are comprised 
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of 12 major helices (labeled A-L), with a number of minor helices that may or may not be 
present in a given P450 structure (one of the most common examples being the B! helix). The 
heme prosthetic group and adjacent active site is buried within the protein and isolated from the 
surface of the enzyme in most structures of cytochromes P450.  In addition to the structural 
elements described, the N-terminus of most mammalian cytochromes P450 forms a helix (20-30 
residues in length) that is embedded in the membrane of the endoplasmic reticulum.  Due to its 
positioning in the membrane, this N-terminal portion of the enzyme is unlikely to directly 
participate in catalysis.  This portion of the protein is usually truncated from the main catalytic 
domain for structural studies, and often for enzymology studies as well since cytochromes P450 
are functional in its absence13-15. 
 
Figure 1.6: Conserved fold of cytochrome P450 catalytic domain.  The protein is colored from 
N- to C-terminus in blue to red (Jones’ rainbow), and shown from the distal, membrane binding 
face of the enzyme (left) and perpendicular to the central I helix (right).  Heme cofactor is 
displayed in black sticks with orange iron sphere. 
 
 The most conserved elements of cytochromes P450 are the portions of the protein that 
interact directly with the heme cofactor and are necessary for general catalytic function.  This 
includes the catalytically-essential cysteine proximal to the heme iron and located on a loop 
region preceding the L helix, as well as the structural elements surrounding it including helices I 
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and L16.  The regions of cytochrome P450 structures showing the greatest degree of variation 
include the B! helix and the region between the F and G helices.  These elements converge to 
form a “roof” for the active site opposite to the heme “floor”.  Studies on prokaryotic 
cytochrome P450s first implicated the F and G structural elements in ligand entry and exit16-19.  
In membrane-associated mammalian cytochrome P450s, the F/G loop is longer, forms a highly 
hydrophobic surface of the enzyme’s catalytic domain, and is most likely buried into the 
membrane16,20. In most mammalian cytochrome P450 structures this region is also likely to 
undergo significant conformational changes to permit ligand penetration and egress from the 
otherwise buried active site.  The rabbit membrane P450 CYP2B4 has been crystallized in both 
an “open” conformation, in which the B! to C region and the F/G loop are dissociated to form a 
cleft into the active site, thereby enabling ligand entry and exit21, as well as a “closed” form18, 
suggesting transition between these states.  Similar smaller scale conformational changes have 
now been observed for other membrane cytochrome P450 enzymes and often involve these same 
structural elements22,23. 
 In addition to binding small molecule ligands, cytochrome P450 catalysis requires 
binding with partner proteins.  All cytochromes P450 rely on a redox partner for electron 
transfer.  NADPH-cytochrome P450 oxidoreductase (CPR or reductase) is the primary electron 
source for most membrane-associated mammalian P450 enzymes, although adrenodoxin can act 
as the redox partner for mitochondrial cytochromes P450.  CPR is a membrane-bound ~78 kDa 
multidomain protein that conducts electron transfer from NADPH to the heme iron of the 
cytochrome P450 through two separate flavin cofactors.  Binding of POR to cytochrome P450 is 
mediated by electrostatic interactions between a negatively charged surface on POR and 
positively charged residues on the proximal face of the P450, which is the same face of the P450 
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that bears the heme-coordinated proximal cysteine.  Residues of mammalian cytochrome P450 
enzymes involved in this interaction have been identified by mutagenesis and are largely located 
on helices B, C, J, K, H, and L surrounding the proximal cysteine (Figure 1.6)24.  Cytochromes 
P450 are also known to interact with a smaller heme-containing protein also anchored in the 
membrane, cytochrome b5.  The site of cytochrome b5 binding on the CYP450 has been shown to 
partially overlap with that of CPR via mutagenesis studies25, consistent with mutually exclusive 
reductase and cytochrome b5 binding demonstrated using NMR26.  The presence of cytochrome 
b5  can variably augment, inhibit, or have no effect on catalytic turnover by cytochrome P450, 
depending on the individual cytochrome P450 isoform and often the substrate of the reaction24. 
Although cytochrome b5 is potentially capable of electron transfer to P450, the apo form of the 
enzyme in which the heme cofactor has been extracted also has been shown to augment the 
catalytic activity of some P450 enzymes27,28.  This suggests that cytochrome b5 may also alter 
P450 catalysis through allosteric effects by inducing a conformational change in the P450.  The 
nature of such a conformational change remains largely unexplored, although initial studies 
suggest that cytochrome b5 binding on the proximal face of CYP17A1 changes the backbone 
conformation of residues on the distal face involved in substrate entry and product exit26. 
 
Cytochrome P450 Enzymes in Steroid Biosynthesis 
Human cytochromes P450 play a major role in a variety of physiological processes 
including the biosynthesis and metabolism of steroid hormones.  The steroidal scaffold is 
ubiquitous in human biology, with small changes to its structure resulting in very different 
physiological effects.  The processes controlled or influenced by steroid hormones depend on the 
hormone class (Table 1.2) and include development of secondary sex characteristics 
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(masculinization or feminization), fertility, stress response/inflammation, and salt/fluid balance.  
These hormones function by activating their cognate nuclear receptors, which in turn promote 
transcription of specific target genes. 
 
Table 1.2: Members of steroid classes and associated bioactivity. 
 
 
 To date, there are six human isoforms of cytochrome P450 enzymes known to contribute 
to the production of steroid hormones (Figure 1.7).  CYP450scc (CYP11A1) is required for 
conversion of cholesterol (a 27-carbon steroid) to pregnenolone, a 21-carbon progestagen from 
which all other steroid hormones are derived. Pregnenolone and its derivatives are referred to as 
“Δ5” steroids because of a double bond between carbons 5 and 6.  This configuration of the 
steroid A ring can be altered to a configuration known as “Δ4” by shifting the placement of the 
double bond between carbons 4 and 5, and oxidizing carbon 3 to a ketone by 3β-hydroxysteroid 
dehydrogenase (3βHSD), as occurs to form progesterone and its derivatives.  Both Δ4 and Δ5 
progestagens (progesterone and pregnenolone, respectively) act as substrates for CYP17A1 
which converts 21-carbon progestagens to 19-carbon androgens.  CYP17A1 accomplishes this 
task via two discrete reactions that were once believed to be performed by two completely 
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different enzymes29. CYP17A1 first hydroxylates the progestagen substrate at carbon 17, called 
the17α-hydroxylase reaction, followed by cleavage of the bond between carbons 17 and 20, 
called the 17,20-lyase reaction.  The product of the first reaction is capable of dissociating from 
the enzyme and undergoing catalysis by different steroidogenic enzymes.  The Δ4 progestagens, 
including progesterone and the intermediate CYP17A1 product 17α-hydroxyprogesterone can be 
converted to weak corticosteroids deoxycorticosterone and 11-deoxycortisol, respectively, by 
CYP21A2.  These products can under go further hydroxylations by CYP11B1 and CYP11B2, 
which are responsible for generating more potent corticosteroids with glucocorticoid bioactivity 
(specifically cortisol) or mineralocorticoid bioactivity (specifically aldosterone).  Generally, the 
downstream products of 17-hydroxylation by CYP17A1 tend to act as glucocorticoids, while 
corticosteroids without hydroxylation at C17 act as mineralocorticoids, making CYP17A1 a 
crucial enzyme in mediating the levels of both classes of corticosteroids. 
 When the 17α-hydroxylase metabolite undergoes the second CYP17A1-mediated 17,20-
lyase reaction, it is converted to a 19-carbon androgen.  These 17,20-lyase products can 
subsequently be converted into testosterone and the most potent androgen, dihydrotestosterone, 
via 17α-hydroxysteroid dehydrogenase and 5α-reductase, respectively.  Androgens with Δ4 
configuration (androstenedione and testosterone) can be converted to 18-carbon estrogens via 
aromatization and carbon-carbon bond cleavage by CYP19A1. 
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Figure 1.7: Biosynthesis of steroids.  Figure adapted with permission from Mikael Haggestrom30. 
 
 Although CYP17A1-mediated androgen production typically proceeds via Δ4 or Δ5 
steroids, androgens can also be generated through an alternate “backdoor” pathway as a 
consequence of pathological states31,32.  This alternate route for androgen production relies of 
conversion of 17α-hydroxyprogesterone to the reduced 17α-hydroxyallopregnanolone (Figure 
1.8).  17α-hydroxyallopregnanolone is an efficient substrate for the CYP17A1-mediated 17,20-
lyase reaction33.  The 17,20-lyase product, androsterone, is then converted to dihydrotestosterone 
by hydroxysteroid dehydrogenase enzymes.   
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Figure 1.8: Dihydrotestosterone can be generated from 5α-reduced 17α-
hydroxyallopregnanolone via the backdoor pathway.  Participating enzymes include 5α-
reductase, 3β-hydroxysteroid dehydrogenase (3β-HSD), and 17β-hydroxysteroid dehydrogenase 
(17β-HSD). 
 
The role of P450 enzymes in steroid biosynthesis makes them crucial players in human 
health and disease.  Some illnesses are the result of cytochrome 450 deficiencies or mutation of 
key residues in some steroidogenic cytochrome P450 enzymes.  For example, congenital adrenal 
hyperplasia, a disorder characterized by ineffective glucocorticoid production and the androgen 
overproduction, is almost always the result of mutations on CYP21A2 or CYP11B134.  Inhibition 
of steroidogenic cytochrome P450 enzymes is desirable in some disease states, including sex 
hormone dependent cancers.  Inhibition of CYP19A1 via small molecule inhibitors has been 
successfully utilized to treat estrogen-dependent breast cancer35.  Inhibition of CYP17A1 is 
becoming a more common strategy for the treatment of androgen-dependent prostate cancer, but 
its ancillary role in corticosteroid biosynthesis and its similarity to other steroidogenic 
cytochrome P450 enzymes such as CYP21A2 complicate efforts to selectively target androgen 
biosynthesis by this enzyme. 
 
CYP17A1 as a Target for the Treatment of Prostate Cancer 
 Prostate cancer is the most common cancer among American men and the second-leading 
cause of cancer-related deaths within the aforementioned demographic36.  More than 80% of 
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prostate cancers rely on androgens, normally produced in the testes and adrenal gland, for tumor 
growth and proliferation37.  Androgen deprivation therapy reduces the amount of circulating 
tumor-promoting androgens and has become the first line of treatment for more advanced stages 
of the disease.  This can be achieved through either surgical orchiectomy or by preventing the 
secretion of gonadotropins that initiate androgen production in the testes (the primary site of 
androgen production) through the use of gonadotropin-releasing hormone (GnRH) agonists or 
antagonists.  Although traditional androgen deprivation therapy significantly reduces the amount 
of circulating androgens, it does not prevent androgen biosynthesis in the adrenal gland.  In 
addition to androgens produced through the normal function of the adrenal gland, tumor cells in 
advanced prostate cancer frequently develop the capacity for androgen production38. Androgen 
receptor antagonists are often administered in conjunction with GnRH agonists or antagonists to 
prevent receptor activation by such extragonadal androgens.  Unfortunately long-term 
antagonism of the androgen receptor promotes the acquisition of various mutations that increase 
its affinity for the androgens responsible for its activation, or render it constitutively active39. 
 Androgen deprivation therapy will often achieve an initial response in patients as 
indicated by a drop in the cancer biomarker prostate specific antigen (PSA).  Unfortunately, over 
80% of patients receiving this therapy relapse within 24 months of its outset and are diagnosed 
with “castration-resistant” prostate cancer40.  A different treatment strategy is therefore necessary 
to manage advanced prostate cancer. 
 The most promising alternative to traditional ADT is the inhibition of androgen 
biosynthesis by inhibition of CYP17A1, which is required for production of androgens in all 
tissues via both normal and “backdoor” biosynthetic pathways.  Preventing CYP17A1 catalysis 
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should therefore eliminate all circulating androgens capable of activating the androgen receptor 
and fueling tumor progression. 
 The first identified inhibitor of CYP17A1 was the antifungal agent ketoconazole, which 
was used off-label to treat castration-resistant prostate cancer.  Although ketoconazole was 
shown to temporarily decrease PSA levels in patients, its promiscuous inhibition of xenobiotic-
metabolizing cytochrome P450 enzymes made it a strong risk factor for drug-drug interactions 
and hepatotoxicity41. 
Knowledge of the role played by CYP17A1 in androgen biosynthesis allowed the development 
of more rationally-designed inhibitors. Analogs of pregnenolone, a steroidal substrate of the 
enzyme, were designed with iron-coordinating heteroaromatic rings built onto carbon 17, which 
is known to be hydroxylated by CYP17A142.  One such inhibitor, abiraterone, progressed rapidly 
through clinical trials.  The prodrug form, abiraterone acetate, received FDA approval in 2012 
for administration in combination with glucocorticoid predinsone.  The X-ray crystal structure of 
CYP17A1 with abiraterone43 shows that the pyridine ring on C17 does indeed coordinate the 
heme iron (Figure 1.9).  The 3-hydroxyl group on the A-ring of the steroid participates in the 
only other direct interaction with CYP17A1, forming a hydrogen bond to asparagine 202 in the F 
helix. 
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Figure 1.9: X-ray crystal structure of CYP17A1 with abiraterone43 (shown in green sticks) 
demonstrates coordination of the inhibitor to the heme cofactor (shown in black sticks) and 
hydrogen bonding to residue N202. 
 
In clinical trials, abiraterone in combination with prednisone was shown to reduce levels 
of circulating testosterone (and other androgens),44,45 lower serum PSA levels,45,46 and improve 
overall survival47.   However, many patients also reported serious side effects from this course of 
treatment including hypertension, hypokalemia, and peripheral edema—all of which suggested 
an uncontrolled excess of mineralocorticoids47.   
As discussed previously in this chapter, CYP17A1 is not only responsible for androgen 
biosynthesis.  It is also crucial to the production of glucocorticoids.  The first of two reactions 
performed by CYP17A1 is a 17α-hydroxylase reaction, which generates intermediate products 
that can be converted into glucocorticoids (via CYP21A2 and CYP11B1) or androgens (via the 
17,20-lyase reaction performed by CYP17A1).  Inhibition of the first reaction (17α-hydroxylase) 
therefore results not only in lower circulating levels of androgens, but also decreases in the levels 
of circulating glucocorticoids.  Glucocorticoid deficiency promotes the secretion of 
adrenocorticotropin hormone (ACTH), which then stimulates production of the 
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mineralocorticoids 11-deoxycorticosterone and corticosterone.  This eventually leads to the 
secondary mineralocorticoid excess and the observed side effects in patients receiving 
abiraterone, even when prednisone is administered alongside abiraterone to mitigate such side 
effects.  This secondary mineralocorticoid excess affects not only individuals undergoing 
CYP17A1 inhibition as prostate cancer treatment, but is also seen in individuals with CYP17A1 
mutations that prevent normal 17α-hydroxyation by the enzyme34, supporting the importance of 
CYP17A1 17α-hydroxylase function in maintaining corticosteroid balance. 
 The second reaction performed by CYP17A1 commits the 17α-hydroxylated steroids to 
the androgen pathway, and its inhibition is therefore crucial to achieve the desired response in 
patients with prostate cancer.  Recently, there has been an initiative to develop compounds that 
selectively inhibit the 17,20-lyase reaction necessary for androgen biosynthesis, while allowing 
the 17α-hydroxylation crucial to corticosteroid balance to proceed normally. 
 It is not clear whether it would even be possible to selectively inhibit a single reaction in 
contrast to another reaction performed within a single shared active site.  To do so requires 
extensive functional knowledge of the enzyme responsible.  The studies conducted as part of this 
dissertation seek not only to expand functional knowledge of CYP17A1, but to also place it 
within a structural context by examining how CYP17A1 interacts with various substrates and 
inhibitors through X-ray crystallography. 
 Although the 17α-hydroxylase and 17,20 lyase reactions performed by CYP17A1 share 
an active site, there are some marked differences between the two that include the type of 
substrate turned over, requirement of partner proteins, and likely even the reactive oxygen 
species responsible for catalysis.  As described earlier, both Δ4 steroids (such as progesterone) 
and Δ5 steroids (such as pregnenolone) are substrates for CYP17A1.  The 17α-hydroxylase 
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reaction is known to proceed efficiently for both Δ4 progesterone and Δ5 pregnenolone, with 
some differences in the regioselectivity of the hydroxylation between the two.  For example, 10-
30% of the progesterone hydroxylation product is a secondary 16α-hydroxylated metabolite, 
while the corresponding metabolite is not observed for pregnenolone48,49.  In contrast, the 17,20-
lyase reaction proceeds with 11-fold higher efficiency for the Δ5 steroid, 17α-
hydroxypregnenolone compared to its Δ4 counterpart, 17α-hydroxyprogesterone28,50.  The 
structural basis for substrate preference based on the configuration of the steroid A ring in 17,20-
lyase turnover and hydroxylase regioselectivity is explored in further detail as part of Chapter 3.  
The effects of A ring configuration on steroidal inhibitor interactions with CYP17A1 were also 
investigated and will be discussed in Chapter 4.  
 Another distinct difference in the 17-hydroxylase and 17,20 lyase reactions performed by 
CYP17A1 is the dependence of reaction rate on the partner protein cytochrome b5.  As 
mentioned previously, cytochrome b5 can enhance, inhibit, or have no effect on cytochrome 
P450 turnover.  While cytochrome b5 is reported to have little effect on the rate of the CYP17A1 
hydroxylase reaction, it significantly enhances turnover of 17,20-lyase reaction, and is virtually 
required for this reaction to proceed28,51. 
 Finally, the two reactions performed by CYP17A1 are suggested to proceed via two 
different reactive oxygen species within the P450 catalytic cycle.  Hydroxylation by cytochrome 
P450 enzymes is fairly well understood, and the 17α-hydroxylation is therefore most likely to 
proceed through the Groves’ rebound mechanism, mediated by the ferryl oxo species called 
compound I(Figure 1.4, g).  The 17,20-lyase reaction is a carbon-carbon bond cleavage reaction, 
which is more unusual for a cytochrome P450. The lyase reaction is not well understood as 
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alluded to previously, though studies with isotopically-labeled molecular oxygen have suggested 
that a ferric dioxygen species is responsible for catalysis of this reaction (Figure 1.5).   
 The possibility of selective inhibition of the 17,20-lyase reaction compared to 
hydroxylation is supported by some evidence based on clinically-observed mutations of 
CYP17A1.  There are dozens of reported mutations in CYP17A1, most of which compromise 
both hydroxylation and 17,20-lyase function43.  Examples include F114V and D116V, mutations 
of active site residues identified in patients with diagnosed 17α-hydroxylase/17,20-lyase 
deficiencies52.  However, there have also been some reports of single-site mutations that appear 
to selectively prevent the 17,20-lyase reaction while allowing 17α-hydroxylation.  Some of these 
residues (R347 and R358) are located on the proximal face of the enzyme and are known to 
contribute to binding of cytochrome b5, which is necessary for 17,20-lyase turnover53.  Mutation 
of residue E305 on the I helix to a glycine has been observed in a human male evaluated for 
gynecomastia resulting from very low androgen levels, but showed no abnormalities in 
corticosteroid balance.  Further evaluation of this active site mutation similarly has confirmed 
that the mutation permits hydroxylation of both progesterone and pregnenolone, but prevents 
turnover of 17α-hydroxypregnenolone to DHEA54.  This suggests that some features of the 
CYP17A1 active site may have different roles in the 17,20 lyase and hydroxylase reactions.  
Chapter 5 will examine the functional characterization of clinically-observed mutations in 
CYP17A1. 
 In addition to lyase-selective mutations, small molecule inhibitors of CYP17A1 have 
been identified that are reported to show selectivity for inhibition of the 17,20-lyase reaction 
over inhibition of 17α-hydroxylation, among them orteronel and VT-464.  These inhibitors are 
not based on the steroidal scaffold, but instead share a naphthalene ring core and a 
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heteroaromatic substituent.  Orteronel, an inhibitor developed by Takeda Pharmaceuticals, was 
reported to show 5-fold selectivity for inhibition of the 17,20-lyase reaction compared to the 
17α-hydroxylase reaction in vitro55.  Throughout clinical trials, orteronel was still administered 
in combination with prednisone, so it is not known if 5-fold selectivity for the 17,20-lyase 
reaction would substantially alleviate the mineralocorticoid-associated side effects, although 
some adverse effects (peripheral edema and hypokalemia) were reported less by patients 
receiving orteronel and prednisone in Phase III clinical trials than by patients receiving 
abiraterone and prednisone in the corresponding clinical trial for abiraterone47,56.  Despite 
improvement in radiographic progression-free survival, orteronel failed to improve overall 
survival in Phase III clinical trials and its development was terminated in 2014. 
 The other non-steroidal inhibitor, VT-464, was also identified as a “lyase-selective” 
inhibitor of CYP17A157 and is currently in Phase II clinical trials58.  VT-464 was reported to 
demonstrate 10-fold selectivity for 17,20-lyase inhibition compared to hydroxylase inhibition57, 
but information regarding its in vivo efficacy and side effect profile have yet to be released. 
 Evaluation of the clinically-relevant CYP17A1 inhibitors, including abiraterone, 
orteronel, VT-464, and galeterone (an additional steroidal inhibitor currently in Phase III clinical 
trials) is subject to much variation in experimental conditions.  These inhibitors are evaluated 
based on IC50 values determined under varied conditions, including different systems (whole cell 
vs. microsomal vs. purified proteins), varying substrates for the hydroxylase reaction (Δ4-
progesterone vs. Δ5-pregnenolone), and different substrate concentrations.  All of these factors 
can influence the apparent IC50 value, and there have been no reports of side-by-side evaluations 
for rank order potency of CYP17A1 inhibition and selective inhibition of the 17,20-lyase 
reaction of all four inhibitors that have been assessed in clinical trials.  Chapter 6 focuses on 
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evaluation of these inhibitors side-by-side in a purified system to establish their relative 
potencies and determine whether or not the reported selectivity for 17,20-lyase inhibition by 
some inhibitors is actually mediated by CYP17A1. 
 The use of a steroidal scaffold for CYP17A1 inhibitors such as abiraterone  make them 
susceptible to interaction with other receptors and steroid-metabolizing enzymes.  One such 
enzyme is CYP21A2, which is responsible for corticosteroid biosynthesis.  Abiraterone has been 
shown to bind and inhibit CYP21A2 (Victoria Jasion and Charlie Fehl, unpublished data).  The 
effect of this interaction on the long-term efficacy of CYP17A1 inhibitors and corticosteroid 
levels has yet to be established.  Off-target inhibition of CYP21A2 significantly complicates the 
steroid balance in vivo.  CYP21A2 inhibition likely alters mineralocorticoid and glucocorticoid 
levels involved in the observed corticosteroid-related side effects, and might also increase levels 
of CYP17A1 substrate capable of overwhelming inhibition. Evaluation of the effects of 
CYP21A2 inhibition would be facilitated by the development of CYP17A1 inhibitors that are 
selective against CYP21A2 inhibition.  However, such inhibitors have not been available and the 
structure of CYP21A2 was not known until recently to guide the design of such compounds.  To 
inform the design of inhibitors with higher selectivity for CYP17A1 over CYP21A2, human 
CYP21A2 was crystallized in the presence of abiraterone and its structure was solved at a 
resolution of 2.74 Å.  Despite an inability to model in ligand due to poor ligand density, the 
structure is consistent with the newly published structure of CYP21A2 with progesterone59, as 
will be discussed further in Chapter 7. 
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Conclusion  
 Cytochrome P450 enzymes serve a variety of physiological functions, including the 
biosynthesis of steroid hormones.  These steroid hormones are important for the development of 
secondary sex characteristics and regulating homeostasis, but they can also fuel tumor growth in 
hormone-dependent cancers.  Due to the role of CYP17A1 in the biosynthesis of androgens, on 
which the majority of prostate cancers are dependent, its inhibition is a promising strategy for the 
treatment of prostate cancer.  One of the challenges in using CYP17A1 inhibition to treat 
prostate cancer is effectively preventing androgen biosynthesis (via the 17,20-lyase reaction) 
without compromising its role in the generation of other physiologically-relevant classes of 
steroid hormones (via the 17α-hydroxylase reaction) or inhibiting other steroidogenic enzymes 
such as CYP21A2.  The research described herein employs structural studies, enzymology, and 
inhibitor evaluation to better understand CYP17A1 function and inform the design of more 
potent and selective inhibitors of this enzyme as treatment for prostate cancer. 
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Chapter 2. 
Methods 
INTRODUCTION 
 Since the following chapters all focus on steroidogenic cytochrome P450 enzymes, many 
of the methods used for expression, purification, and analysis of these enzymes are used 
repeatedly as part of this work.  The following chapter will describe methods common for 
CYP17A1, mutants of CYP17A1, and human P450 oxidoreductase as these methods are referred 
to in several different chapters.  Expression and purification of rat cytochrome b5 was performed 
by Natasha DeVore, a former lab member, as reported1 and will not be discussed. 
 Purification of CYP21A2 is only relevant to chapter 7 and will be discussed there in more 
detail. Crystallization of cytochrome P450/ligand complexes vary throughout and will therefore 
be discussed individually in each relevant chapter. 
 
METHODS 
CYP17A1 Mutagenesis 
The gene encoding CYP17A1 bearing an N-terminal truncation of the transmembrane 
helix (residues 2-19), a leading sequence “AKKT” from residues 20-23, and a four histidine tag 
at the C-terminus had previously been inserted into the pCWori+ vector2 containing the β-
lactamase gene to generate the pCW/17A1Δ19H construct used throughout. Site-directed 
mutagenesis to generate CYP17A1 mutants A105L, F114V, D116V, R347H, and R358Q was 
carried out using Quikchange Lightning Site-Directed Mutagenesis Kit (Agilent). 
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Expression of Cytochrome P450 17A12,3 
 E. coli cells (100 µL, JM109 strain) were combined with 1 µL of the pCW17A1Δ19H 
plasmid and incubated at 4 °C for thirty minutes.  Cells were heated to 42 °C for 30 seconds and 
cooled to 4 °C for two minutes.  Newly transformed cells were spread onto lysogeny broth 
agarose plates containing 50 µg/mL ampicillin or 100 µg/mL carbenicillin for plasmid selection.  
Plates were incubated overnight at 37 °C. 
 All media described in the following section contains 50 µg/mL ampicillin or 100 µg/mL 
carbenicillin to select for the pCWori+ vector.  Starter cultures of lysogeny broth (5 mL) were 
inoculated with a single colony from an aforementioned plate and incubated at 37 °C with 220 
rpm shaking for 6-8 hours.  To scale up the culture volume, overnight cultures of lysogeny broth 
(250 mL) were inoculated with 50 µL of the starter culture and incubated overnight at 37 °C with 
220 rpm shaking.  Finally, terrific broth (1 L/ 2.8 L Ferbach flask) was inoculated with 10 mL of 
the latter overnight culture and incubated at 37 °C with 220 rpm shaking until reaching an optical 
density at 600 nm of 0.6-0.8.  Expression of CYP17A1 was induced by addition of β-D-1-
thiogalactopyranoside to a concentration of 0.5 mM.  At the same time, expression media was 
also supplemented with 0.61 mM δ-aminolevulinic acid to augment heme biosynthesis.  Cultures 
were incubated at 28 °C with 140 rpm shaking for an additional 48-72 hours.  Cells were pelleted 
by repeated centrifugation at ~6000 x g and resuspended in 50 mM Tris HCl, pH 7.4, 20% 
glycerol, and 300 mM NaCl and stored at -80 °C until purification.  
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Purification of Cytochrome P450 17A12,3 
All stages of the purification were performed at 4 °C.  CYP17A1 A105L mutant used for 
crystallization with substrates was purified using buffers supplemented with 50 µM of the 
intended substrate.  
Cell pellets were thawed and lysed by sonication on ice (6 x 30 seconds with one minute 
intervals).  Lysate was centrifuged at 9900 x g for 15 minutes to remove cellular debris.  
Membrane proteins were extracted by stirring the supernatant in the presence of 2% Emulgen-
913 (Desert Biologicals) for 60 to 90 minutes followed by ultracentrifugation (100,000 x g) for 
one hour. 
Supernatant was loaded onto a column (~30 mL) of Ni-NTA resin (GE Healthcare) pre-
equilibrated with Ni buffer (50 mM Tris-HCl, pH 7.4, 20% glycerol, 300 mM NaCl, and 0.2% 
Emulgen 913).  The column was subsequently washed with 2 column volumes (CV) of Ni buffer 
followed by 6 CV of Ni buffer supplemented with 100 mM glycine to remove contaminants 
forming non-specific interactions with the resin.  Protein was eluted using 4 CV of Ni buffer 
supplemented with 100 mM glycine and 80 mM histidine.  Elution fractions were pooled based 
on absorbance at a wavelength corresponding to the heme Soret peak (417 nm).   
Pooled fractions were diluted 3 to 5-fold in CM buffer (50 mM Tris-HCl, pH 7.4, 20% 
glycerol, and 100 mM glycine) supplemented with 0.2% of the detergent Emulgen-913 and then 
loaded onto a 5 mL carboxymethyl sepharose fast-flow column (GE Healthcare) pre-equilibrated 
with CM buffer.  The column was washed with 10 CV of CM buffer without detergent prior to 
elution with 5 CV CM buffer without detergent but supplemented with 500 mM NaCl.  Fractions 
were pooled based on absorbance at 417 nm. 
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Pooled fractions were concentrated to ~1 mL and loaded onto a 120 mL Superdex 200 
gel filtration column (GE Healthcare) pre-equilibrated with SEC buffer containing 50 mM Tris-
HCl, pH 7.4, 20% glycerol, 100 mM glycine, and 500 mM NaCl.  Chromatography was 
performed using an isocratic flow of the aforementioned SEC buffer.  Fractions corresponding to 
the major peak absorbing at 417 nm were collected and pooled. 
The concentration of cytochrome P450 used for binding assays and crystallography was 
determined based on heme absorbance in the absolute spectrum of the collected fractions4.  
Baseline absorbance from 700-250 nm was recorded for SEC buffer (800 µL, in both reference 
and sample cuvettes).  A sample of the collected fractions (100 µL) was added to the sample 
cuvette and absorbance was recorded from 700-250 nm.  Concentration of cytochrome P450 was 
determined based on Beer’s Law, c = !!", where A is the absorbance corresponding to the heme 
Soret peak (417 nm for unbound cytochrome P450, 393 or 424 nm for cytochrome P450 bound 
to type I or type II ligands, respectively), ε is the extinction coefficient of the heme Soret peak (a 
value of 0.100 µM -1cm-1 was used in all of the studies described herein) and l is the pathlength 
of the cuvette (1 cm). 
Cytochrome P450 used for assays measuring enzymatic turnover or inhibition was 
quantified by shift in heme absorbance observed in the reduced carbon monoxide difference 
spectrum4.  A sample of the collected fractions (100 µL) was diluted 9-fold in SEC buffer and 
treated with a few grains of sodium dithionite to reduce the enzyme.  Baseline absorbance was 
recorded from 500-400 nm.  The sample was treated with carbon monoxide (~50 bubbles) and 
absorbance measured from 500-400 nm.  Spectra were recorded every minute until no further 
increase in absorbance at 450 nm was observed.  Concentration of cytochrome P450 was 
determined using Beer’s Law, c = !!", where A is the absorbance at 450 nm, ε is the extinction 
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coefficient of reduced, carbon monoxide-bound heme (0.091µM-1cm-1) and l is the pathlength of 
the cuvette (1 cm). 
 
Mutagenesis, Expression, and Purification of Human P450 Oxidoreductase3,5 
The gene for human NADPH-cytochrome P450 reductase bearing an N-terminal 
truncation of residues 2-27 and a C-terminal tag of three glycine residues followed by four 
histidine residues (G3H6) inserted into a pET22 vector was provided by the lab of Dr. Walter 
Miller5.  Mutagenesis of residue 59 from lysine to glutamine to prevent proteolysis frequently 
observed at this site was conducted using Quikchange Lightning site-directed mutagenesis kit 
(Agilent). 
 The resulting pET22 vector with truncated hPORG3H6 K59Q insert (1 µL) was added to 
50 µL of C41(DE3) competent cells and incubated on ice for 30 minutes.  Cells were heat-
shocked at 42 °C for 30 seconds, and returned to ice for 2 minutes.  Transformed cells were 
spread on lysogeny broth agarose plates supplemented with 50 µM ampicillin and incubated 
overnight at 37 °C.   
All expression media in the following was supplemented with 50 µM ampicillin or 100 
µM carbenicillin to select for the pET vector.  A starter culture consisting of lysogeny broth (5 
mL) was inoculated with a single colony from the aforementioned plate and incubated at 37 °C 
for 6-8 hours with 220 rpm shaking.  An overnight culture (250 mL lysogeny broth) was 
inoculated with 50 µL of the starter culture and incubated at 37 °C for ~18 hours. 
Terrific broth (1 L/2.8 L Fernbach Flask) was inoculated with 35 mL overnight culture 
and incubated at 28 °C with 220 rpm shaking to an optical density of 0.4 at 600 nm.  Expression 
was induced by addition of β-D-1-thiogalactopyranoside to a concentration of 0.5 mM.  
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Expression media was also supplemented with riboflavin to a concentration of 100 µM to 
facilitate flavin synthesis.  Cells were incubated at 28 °C with 190 rpm shaking for 48 hours and 
harvested by repeated centrifugation at 6000 x g for 10 minute intervals.  Cells were resuspended 
in buffer containing 20 mM Tris HCl, pH = 8.0, 300 mM NaCl, and 20% glycerol and frozen at -
80 °C until purification. 
All stages of hPORG3H6 K59Q purification were conducted at 4 °C.  Cells were thawed 
and treated with a protease cocktail that included phenylmethylsulfonylfluoride  (1 mM), 
aprotinin (10 µg/mL), leupeptin (10 µM), and pepstatin A (10 µM). Cells were lysed via 
sonication (5 x 1 minute with 1 minute intervals on ice) and centrifuged at 9900 x g for 15 
minutes to remove cellular debris.  Membrane proteins were extracted from the resulting 
supernatant by stirring in the presence of the detergent Triton X-100 (0.1% v/v) for 2.5-3.5 
hours, followed by ultracentrifugation at 100,000 x g for 1 hour. 
The reductase-containing supernatant was loaded onto a 40 mL column of Ni-NTA resin 
(GE Healthcare) that had been pre-equilibrated with reductase purification buffer (20 mM Tris 
HCl, pH 7.4, 300 mM NaCl, 20% glycerol, and 0.1% Triton X-100).  The bound protein was 
washed with 2 CV of reductase purification buffer followed by 6 CV of reductase purification 
buffer supplemented with 100 mM glycine.  The desired reductase protein was eluted by treating 
the column with 4 CV of reductase purification buffer supplemented with 100 mM glycine and 
80 mM histidine.  Fractions were pooled based on absorbance at 453 nm and 375 nm which 
correspond to the absorbance maxima of the enzyme’s flavin cofactors. 
The pooled fractions (30-50 mL) were dialyzed three times against 1 L of buffer 
containing 20 mM KPi, pH 7.4, and 20% glycerol.  Each round of dialysis had a minimum 
duration of 8 hours. 
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The concentration of hPORG3H6 K59Q was determined via cytochrome c reduction 
assay.  One unit of functional reductase is defined as the amount necessary to reduce 1 µmol of 
cytochrome c per minute.  A sample of the dialyzed protein was diluted 50-fold in phosphate 
buffer (300 mM KPi, pH 7.7) and 2 µL of diluted sample added to a cuvette containing 988 µL 
of phosphate buffer with 0.05 mM cytochrome c.  Reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) was added to the cuvette to a concentration of 0.1 mg/mL and the reduction 
of cytochrome c was monitored over 300 seconds as an increase in absorbance at 550 nm. 
 The concentration of hPORG3H6 K59Q was calculated based on rate of cytochrome c 
reduction using the following equation6:   
∆Absorbance/min
21!×!0.002!mL!sample !×!dilution!factor =
x!units/mL
4!units/nmol =
nmol
L !hPORG!H!!K59Q 
 
Spectral Ligand Binding Assay7 
As described in Chapter 1, most cytochrome P450 enzymes are isolated in the resting 
state with a water coordinated to the heme iron.  Addition of ligand that displaces the active site 
water results in a “type I” spectral shift of the heme Soret peak from 417 nm to ~393 nm.  
Addition of ligand that not only displaces the active site water, but also coordinates the heme 
iron itself, results in a “type II” spectral shift of the heme Soret peak from 417 nm to ~424 nm.  
Based on these spectral shifts, the fraction of ligand-bound cytochrome P450 can be monitored 
during titration with a ligand, and can be used to determine a dissociation constant (Kd) for the 
enzyme-ligand complex. 
 Cytochrome P450 17A1 was prepared at a concentration of 0.1 µM in buffer containing 
50 mM Tris-HCl, pH 7.4, 20% glycerol, 100 mM glycine, and 500 mM NaCl.  Five milliliters of 
the protein solution were added to both sample and reference cuvettes with 5 cm pathlength.  The 
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absorbance was baselined from 500 to 300 nm and a spectrum was recorded from 500 to 300 nm 
to ensure the baseline was flat.  The sample cuvette was titrated with ligand, while the reference 
cuvette was titrated with equivalent volumes of solvent.  Following each addition, the solution 
containing CYP17A1 was incubated with ligand for 8 minutes at room temperature prior to 
collecting spectra from 500 – 300 nm.  Iterative ligand titrations were performed and subsequent 
spectra collected until no change in absorbance was observed following several additions.  
Concentration of solvent did not exceed 2% over the course of titration. 
 Dissociation constants (Kd) were determined using Graphpad Prism 5 (Graphpad 
Software).  Ligand concentration was plotted against change in absorbance (Amax-Amin) using the 
nonlinear least-squares regression to the following equation:  
!" = −! ± !
! − 4!"
2!  
! = −1, !! = !!! !+ !!!"!#$ !+ !!!"#, ! = !−1!×!!!"!#$ !×!!!"# 
where [ML] is total binding, Kd is the dissociation constant, Ltotal is the total concentration of 
ligand in solution, and Amax is the maximum absorbance8. 
 
Progesterone Hydroxylation Assay2,3 
 Hydroxylation of progesterone by CYP17A1 and CYP17A1 mutants was monitored by 
HPLC coupled with UV/Vis detection (Shimadzu Scientific Instruments).  The reconstituted 
protein system (50 pmol CYP17A1 with 200 pmol hPORG3H6 K59Q) was added to buffer (50 
mM Tris HCl, pH 7.4, 5 mM magnesium chloride) containing progesterone (0-200 µM) to yield 
a total volume of 480 µL.  Samples were incubated at 37 °C for 3 minutes prior to initiation of 
reactions. Reduced nicotinamide adenine diphosphate (NADPH) was added to samples to a 
concentration of 1 mM to initiate P450 catalysis.  After 10 minutes reactions were quenched by 
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addition of 20% trichloroacetic acid (300 µL) to precipitate all proteins.  Precipitated proteins 
were removed by centrifugation at 4500 x g for 8 minutes.  Standards contained varying 
quantities of 17α-hydroxyprogesterone, 16α-hydroxyprogesterone, or 21-hydroxyprogesterone in 
buffer (50 mM Tris HCl, pH=7.4, 5 mM magnesium chloride) with 1 mM NADPH and 300 µL 
of 20% trichloroacetic acid. 
Thirty-five microliters of standards and samples were injected onto a Luna C18, 5 
micron, 50 x 4.60 mm column (Phenomenex, Torrance, CA) and separated using a mobile phase 
consisting of 40% acetonitrile, 59.99% deionized water and 0.012% acetic acid and a flow rate of 
1 mL/minute.  Metabolites were detected at 248 nm with retention times of ~5.5 minutes, ~4.1 
minutes, and ~2.2 minutes for 17α-hydroxyprogesterone, 21-hydroxyprogesterone, and 16α-
hydroxyprogesterone, respectively. 
To determine steady-state kinetic parameters, enzymatic activity (in pmol 
product/min/pmol P450) was determined using the slope of linear regression generated based on 
standards.  Kinetic parameters were determined by Graphpad Prism 5 (Graphpad Software, San 
Diego, CA) based on the least-squares nonlinear fit of the data to the following equation: 
! = !!"#!×![!]!! + [!]
 
where Vmax is maximal velocity of the reaction, Km is the Michaelis-Menten constant, and [S] is 
the concentration of substrate.9 
 
Pregnenolone Hydroxylation /17α-Hydroxypregnenolone 17,20-Lyase Assay3,10 
Hydroxylation of pregnenolone and the 17,20-lyase reaction of 17α-hydroxypregnenolone by 
CYP17A1 and CYP17A1 mutants were monitored by gas chromatography/mass spectrometry 
using an Agilent 5975 Series GC/MS (Agilent Technologies).  The reconstituted protein system 
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(50 pmol CYP17A1 with 200 pmol hPORG3H6 K59Q for pregnenolone hydroxylation, with 200 
pmol of rat cytochrome b5 added for the 17,20-lyase reaction) was added to buffer (50 mM Tris 
HCl, pH 7.4, 5 mM magnesium chloride) containing pregnenolone (0-7 µM) or 17α-
hydroxypregnenolone (0-20 µM) to yield a total volume of 480 µL.  All samples were incubated 
at 37 °C for 3 minutes prior to initiation of reactions. Reduced nicotinamide adenine diphosphate 
(NADPH) was added to samples to a concentration of 1 mM to initiate P450 catalysis.  After 10 
minutes, reactions were quenched by protein precipitation with the addition of 20% 
trichloroacetic acid (300 µL) supplemented with the internal standard estriol (8.66 µg/mL).  
Standards contained varying quantities of the 17α-hydroxypregnenolone or 
dehydroepiandrosterone (DHEA) metabolites in buffer (50 mM Tris HCl, pH 7.4, 5 mM 
magnesium chloride) with 1 mM NADPH and 300 µL of 20% trichloroacetic acid and were 
supplemented with 8.66 µg/mL estriol as an internal standard. 
Six-hundred and fifty microliters of both samples and standards were loaded onto SPE 
columns (HLB cartridge, 1 mL, 30 mg packing) pre-equilibrated with 2 mL methanol, followed 
by 2 mL H2O.  The columns were washed with 1 mL H2O following sample loading and steroids 
eluted using 1 mL of methanol followed by 3 mL of 1:2 dichloromethane:methanol.  Solvent was 
removed from the elutant, and the resulting  dried material was resuspended in 100 µL 
derivitization reagent (a 4:2:1 mixture of N-methyl-N-(trimethylsilyl)-
trifluoroacetamide/ammonium iodide/dithioerythritol) and heated to 60 °C for 40-60 minutes. 
Following derivatization, silylated metabolites were quantified by GC/MS.  Each sample (3 µL 
for lyase and 5 µL for hydroxylase) was injected onto a capillary column (Agilent DB-5MS, 15 x 
0.25-mm inner diameter with 0.25-micron film) using an injector temperature of 280 °C.  The 
oven temperature (initially 215 °C) was ramped at 1 °C/min for 21.5 minutes.  The electron 
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energy and inlet temperature were 70 eV and 280 °C, respectively.  Selected ion monitoring 
mode was used to analyze ions corresponding to the masses of the silylated products 17α-
hydroxypregnenolone (m/z=548.3, retention time ~16.5 minutes) and dehydroepiandrosterone 
(m/z=432.3, retention time ~7.9 minutes), which were quantified with respect to silylated estriol 
(m/z = 504.3, retention time ~15.7 minutes).    
 Steady state parameters for both pregnenolone hydroxylation and 17α-
hydroxypregnenolone 17,20-lyase were determined using Graphpad Prism 5 (Graphpad 
Software) as described for progesterone hydroxylation. 
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Chapter 3. 
Structures of Human Steroidogenic Cytochrome P450 17A1 (CYP17A1) with 
Substrates 
From publication by Petrunak, E. M.; DeVore, N. M.; Porubsky, P. R.; Scott, E. E. J. Biol. Chem. 
2014, 289, 32952. 
INTRODUCTION 
The cytochrome P450 superfamily of heme monooxygenases performs diverse 
physiological functions, ranging from drug and xenobiotic metabolism to hormone and vitamin 
biosynthesis.  The human cytochrome P450  (P450)2 enzyme 17A1 (CYP17A1) functions 
specifically at a critical juncture in human steroidogenesis1.  Its initial substrates are also 
substrates for mineralocorticoid biosynthesis by other enzymes.  CYP17A1 catalysis leads to 
either steroid precursors of glucocorticoids like cortisol that regulate immune response or 
androgens like testosterone that drive the development and maintenance of male characteristics 
or are converted to estrogens in females2.  In later life, however, androgens drive the 
development of prostate cancer, the cancer of highest incidence and the second leading cause of 
cancer deaths in U.S. men, while estrogens are a long-recognized driver of hormone responsive 
breast cancer3.  Thus this enzyme has garnered substantial interest as a relatively new drug 
target, validated by successful use of the CYP17A1 inhibitor abiraterone in men with castration-
resistant prostate cancer4-6 and its current evaluation in breast cancer patients. 
Abiraterone acetate, the FDA-approved prodrug form of this CYP17A1 inhibitor, 
improves overall survival in men with metastatic castration-resistant prostate cancer, including 
patients for whom the disease has progressed following chemotherapy, with compounds such as 
docetaxel and the androgen receptor blocker enzalutamide5,7. Abiraterone binds with high 
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affinity to the CYP17A1 active site heme iron8 that is essential for catalysis, which effectively 
and systemically prevents androgen production.  However, by doing so, this inhibitor also 
increases the pool of precursors for mineralocorticoid production and halts CYP17A1-mediated 
production of glucocorticoids, which occurs in the same active site and also requires the heme 
iron.  The resulting steroid imbalances in patients treated with abiraterone can frequently lead to 
hypertension, hypokalemia, and adrenocortical insufficiency, which must then be monitored and 
treated with additional drugs9.  Furthermore, there is some evidence that the increase in 
mineralocorticoids associated with complete inhibition of CYP17A1 may facilitate the flow of 
androgen precursors through a “backdoor” androgen biosynthesis pathway10, proposed to 
provide a possible escape route that could permit cancer progression.  Selective inhibition of the 
CYP17A1-mediated androgen biosynthesis proven to increase overall survival, while sparing 
CYP17A1-mediated glucocorticoid biosynthesis to prevent corticosteroid imbalances would 
ameliorate both of these clinically relevant issues for prostate cancer patients.  CYP17A1 
impairment has also been associated with Cushing’s syndrome11, some forms of congenital 
adrenal hyperplasia 12, and polysystic ovary syndrome13-15.  Substantial potential for improving 
prostate cancer treatment and therapies for these other diseases thus lies in an improved 
understanding of the mechanisms whereby CYP17A1 performs catalysis. 
In general, CYP17A1 hydroxylates the mineralocorticoid precursor steroids 
pregnenolone and progesterone to yield 17 α-hydroxypregnenolone and 17α-
hydroxyprogesterone, respectively (Figure 3.1).  These resulting C17-hydroxylated steroids can 
serve as substrates for glucocorticoid biosynthesis or for the subsequent CYP17A1-mediated 
17,20 lyase reaction to yield the androgens dehydroepiandrosterone or androstenedione (Figure 
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3.1).  Functional variations on this general pathway for different substrates provide clues to key 
protein/small molecule interactions that direct catalysis.   
 
Figure 3.1: Summary of human cytochrome P450 17A1 reactions.  Progesterone is hydroxylated 
at either C16 (minor, red) or C17 (major, blue) via Groves hydrogen abstraction and rebound 
mediated by the typical P450 iron (IV)-oxo intermediate 16.  The resulting 17α-
hydroxyprogesterone metabolite undergoes the 17,20 lyase reaction to androstenedione (pink) 
with very low efficiency.  Conversely, pregnenolone is hydroxylated only at C17 (blue).  The 
resulting 17α-hydroxypregnenolone metabolite efficiently undergoes the 17,20 lyase reaction to 
form the 19-carbon androgen dehydroepiandrosterone (pink), proposed to occur via an iron-
peroxy intermediate 17.  The latter reaction is facilitated as much as 10-fold by the presence of 
cytochrome b5 18.  CYP17A1 hydroxylase substrates progesterone and pregnenolone are also 
converted to mineralocorticoids and 17α-hydroxy products to glucocorticoids, largely by other 
cytochrome P450 enzymes. 
 
First, while human CYP17A1 hydroxylates pregnenolone (a Δ5,3-ol steroid) only at 
carbon 17, progesterone (the corresponding Δ4,3-keto steroid) is hydroxylated at C17 as the 
major product, but also at C16 to generate an additional minor product (Figure 3.1) 19,20.  It is 
known that in other species CYP17A1 with Leu at position 105 generates much less 16α-
hydroxyprogesterone20 and that an A105L mutation in the human CYP17A1 enzyme decreases 
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progesterone 16α-hydroxylation and increases its 17α-hydroxylation21.  Suggested to somehow 
alter substrate position in the CYP17A1 active site or alter protein flexibility, the structural basis 
for the effects of the A105L mutation wild type substrate and regio-selectivity of hydroxylation 
have not been elucidated experimentally. 
Second, CYP17A1 also performs a carbon-carbon bond cleavage, which is unusual for 
cytochrome P450 enzymes22.  For human CYP17A1 this 17,20-lyase reaction proceeds far less 
efficiently for the Δ4,3-keto 17α-hydroxyprogesterone substrate than for its counterpart, the 
Δ5,3-ol hydroxylated steroid 17α-hydroxypregnenolone (Figure 3.1).  As a result, the Δ5,3-ol 
17α-hydroxypregnenolone 17,20-lyase product dehydroepiandrosterone (Figure 3.1) is the 
physiologically-relevant intermediate in the formation of all human androgens and estrogens23.  
Although hydroxylation is well established to occur by the Groves hydrogen abstraction/oxygen 
rebound mechanism mediated by an Fe(IV)-oxo catalytic intermediate called Compound I16,24 
(Figure 3.1), a mechanism for cleavage of the bond between carbons 17 and 20 has been an 
ongoing debate in the literature.  Recent data, however, favors a ferric peroxy anion intermediate 
(Figure 3.1)17,25 and spectroscopic evidence has suggested that the two 17α-hydroxy steroids 
might interact differentially with the peroxy intermediate26. 
Third, while the presence of cytochrome b5 has relatively little effect on the 
hydroxylation reactions, the presence of this small heme protein18,27-29 substantially and 
selectively facilitates the 17,20-lyase reaction.  Compartmentalization of b5 and developmental 
changes in b5 levels control the tissue specificity and timing of androgen production in humans.  
Individuals with nonfunctional b5 are unable to perform the lyase reaction and produce sex 
steroids, though the hydroxylase reaction required for glucocorticoid synthesis is operational30,31. 
Facilitation of the lyase reaction by b5 occurs without electron delivery18.  Thus it has been 
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suggested that b5 might selectively stabilize the intermediate in the lyase reaction or cause 
substrates to assume orientations in the CYP17A1 active site more favorable for the lyase 
chemistry, but the mechanism remains unresolved32. 
The structural basis for each of these effects—hydroxylase substrate regioselectivity, 
lyase reaction selectivity for the Δ4,3-keto vs. Δ5,3-ol 17-hydroxylated substrate, and 
cytochrome b5 facilitation of the lyase vs. hydroxylase reaction—is unknown.  Homology 
models and docking studies have suggested that substrates were likely to orient essentially 
parallel to the plane of the heme33 and proposed a “bi-lobed” active site to carry out the separate 
hydroxylase and lyase reactions of CYP17A134-37.  The only known structures of CYP17A1, in 
the presence of the steroidal inhibitors abiraterone or TOK-001, were published recently8.  These 
steroidal inhibitors both orient more nearly perpendicular to the heme, evoking the prediction of 
a similar binding mode for substrates8, but the actual binding of CYP17A1 substrates is 
unknown. 
To probe the binding orientations of the physiologically-relevant substrates and the 
structural basis of CYP17A1 function, a series of experimental X-ray structures were generated 
for CYP17A1 in complexes with both hydroxylase and both lyase substrates with the mutation 
A105L.  Comparisons among these structures identify steric and hydrogen bonding interactions 
between CYP17A1 and distal portions of the substrate that play key roles in modulating spatial 
relationships between sites of metabolism on the opposite end of substrates and the catalytic 
heme iron.  A steric rationale is provided for hydroxylase regioselectivity, while differences 
observed for hydrogen bonding and substrate positioning may form the basis for substrate 
selectivity of the lyase reaction.  This new information informs a working hypothesis for how 
cytochrome b5 might selectively facilitate the lyase reaction. 
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METHODS 
Mutagenesis 
The A105L mutant was generated via site-directed mutagenesis as described in Chapter 2. 
Protein Expression and Purification 
CYP17A1, CYP17A1 A105L mutant, and human NADPH-cytochrome P450 reductase were 
expressed and purified as described in Chapter 2.  Cytochrome b5 was produced by Natasha 
DeVore. 
 
Assays 
Spectral ligand binding assays were performed as described in Chapter 2.  Progesterone 
hydroxylation, pregnenolone hydroxylation, and 17α-pregnenolone 17,20-lyase activity were all 
evaluated as described in Chapter 2. 
 
Protein Crystallization, Data Collection, and Structure Determination 
CYP17A1 A105L was crystallized by hanging drop vapor diffusion. Purified protein 
(~29 mg/mL) containing either 50 µM of one of the substrates or 10 µM abiraterone and 0.5% 
Emulgen-913 was mixed 1:1 to form 2 µl drops that were equilibrated against precipitant 
solution at 20 °C.  The precipitant solution used to crystallize CYP17A1 A105L with 
progesterone, pregnenolone, 17α-hydroxypregnenolone, and abiraterone consisted of 100 mM 
Tris-HCl, pH 8.5, 25% PEG 4000 (Hampton Research), 150 mM magnesium chloride 
hexahydrate, and 4-6% glycerol.  The precipitant solution used to crystallize CYP17A1 A105L 
with 17α-hydroxyprogesterone contained 175 mM Tris-HCl, pH 8.5, 30% PEG 3350 (Hampton 
Research), 250 mM lithium sulfate and 3% glycerol.  Crystals were cryoprotected in a 7:3 
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mixture of mother liquor and 80% glycerol and flash cooled in liquid nitrogen.  Diffraction data 
were collected on beamlines 14-1 and 12-2 of the Stanford Synchrotron Radiation Lightsource 
and processed using XDS38.  Data collection and refinement statistics and deposition IDs in the 
Protein Data Bank are given in Table 3.1.  Structures were solved by molecular replacement 
using Phaser39 and the structure of wild type CYP17A1 (PDB 3RUK or 3SWZ8) as a search 
model using data to the respective resolution cutoff for the different structures (2.5-3.0 Å), 
yielding log likelihoods of 9,094-13,090. Model-building and refinement were performed 
iteratively with Coot40 and PHENIX41, respectively using data to a cutoff of <I/σ(I)> of 1.5 or 
higher in the outer shell.  Hydrogens were modeled in the riding positions for protein and 
substrates.  Reference model restraints were incorporated only for the 3.0 Å 17α-
hydroxypregnenolone data set, in order to avoid overfitting.  After the protein structures were 
essentially completed, ligands were added.  The ligand-omit 2Fo-Fc maps shown were calculated 
in PHENIX.  Ligand models were obtained from the Hetero-compound Information Center at 
Uppsala (HIC-Up) or constructed using the PRODRG2 server.  Superpositions between 
CYP17A1 molecules were generated using the secondary structure matching algorithm in 
COOT40.  Superposition between P450cam and CYP17A1 was generated by the same process, 
then optimized using least squares fit for the hemes, also in COOT40.  Probe-occupied active site 
volumes were generated using VOIDOO42 (probe radius = 1.4 Å; grid spacing = 0.33).  Figures 
were prepared in PyMOL43.  
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Table 3.1.  Statistics for X-ray data collection and refinement of CYP17A1 A105L structures 
with abiraterone and substrates. 
 CYP17A1 
A105L 
abiraterone 
CYP17A1 
A105L 
pregnenolone 
CYP17A1 
A105L 
progesterone 
CYP17A1 
A105L 
17α-hydroxy-
progesterone 
CYP17A1 
A105L 
17α-hydroxy-
pregnenolone 
PDB ID 4NKV 4NKW 4NKX 4NKY 4NKZ 
Data Collection      
Beamline SSRL 12-2 SSRL14-1 SSRL 12-2 SSRL 12-2 SSRL 12-2 
Space group P212121 P212121 P212121 P212121 P212121 
Cell dimensions      
   a,b,c, (Å) 90.7, 153.3, 
167.7 
86.1, 152.6, 
173.8 
85.9, 153.0, 
173.2 
91.3, 151.8, 
168.0 
85.8, 151.1, 170.3 
Molecules/a.u. 4 4 4 4 4 
Resolution (Å)* 39.31–2.65 
(2.79–2.65) 
39.11-2.50 
(2.63-2.50) 
39.13-2.79 
(2.94-2.79) 
39.15-2.55 
(2.69-2.55) 
38.70-3.00 
(3.17-3.00) 
Total reflections* 450,626 
(62,230) 
557,941 
(64,186) 
380,303 
(52,751) 
511,008 
(71,923) 
287,854 (36,646) 
Unique reflections* 68,380 
(9,523) 
79,365 
(11,000) 
56,987 (7,891) 76,008 
(10,667) 
44,496 (6,106) 
Redundancy* 6.6 (6.5) 7.0 (5.8) 6.7 (6.7) 6.7 (6.7) 6.5 (6.0) 
Rpim* 0.044 (0.556) 0.060 (0.717) 0.074 (0.579) 0.060 (0.666) 0.080 (0.650) 
<I/σ(I)>* 6.8 (1.5) 11.0 (2.1) 9.7 (1.5) 12.3 (1.5) 8.9 (1.5) 
Completeness (%)* 99.3 (96.1) 99.3 (95.6) 99.2 (95.5) 99.1 (96.3) 98.9 (94.3) 
Refinement      
Resolution (Å) 38.59-2.65 39.11-2.50 39.13-2.80 39.15-2.55 38.70-3.00 
No. reflections 68,166 79,236 56,820 75,825 43,862 
R/Rfree (%) 19.1 / 24.3 18.9 / 24.5 18.4 / 25.7 17.8 / 24.4 19.1 / 26.1 
Ramachandran (%)      
   Favored 96.44 95.50 95.63 96.46 96.78 
   Allowed 3.45 4.39 4.26 3.54 3.06 
   Outliers 0.11 0.11 0.11 0 0.16 
Wilson B factor (Å2) 61.4 52.8 56.9 51.4 68.6 
No. atoms/B factors (Å2)      
   Protein 14913 / 71.6 14852 / 71.8 14925 / 59.3 14832 / 56.8 14806 / 80.1 
   Ligand     104 / 36.7      92 / 61.1       92 / 46.3       96 / 52.3       96 / 65.7 
   Heme     172 / 50.5    172 / 50.4     172 / 41.9     172 / 44.1     172 / 63.8 
   Water     139 / 50.4      87 / 52.6       46 / 37.4     161 / 44.5         8 / 65.9 
RMSD bond (Å) 0.011 0.008 0.008 0.007 0.010 
RMSD angle (°) 1.2 1.2 1.1 1.2 1.3 
Coordinate error 
(maximum-likelihood 
based) (Å) 
0.41 0.34 0.41 0.33 0.39  
Key bond distances and angles** 
N/ON202–O3 (Å) 2.7 ± 0.1 2.8 ± 0.1 2.7 ± 0.3 2.9 ± 0.05 2.8, 2.5, 3.8, 3.0 
∠C3–O3–N/ON202 (°) ((°) 102 ± 3 121 ± 5 121 ± 7 137 ± 4 144, 132, 135, 136 
C16 – Fe (Å) 5.9 ± 0.2 4.9 ± 0.2 4.8 ± 0.2 4.7 ± 0.1 5.1, 5.1, 4.6, 4.7 
C17 – Fe (Å) 5.7 ± 0.1 4.8 ± 0.1 4.8 ± 0.1 5.0 ± 0.1 4.8, 4.8, 4.4, 4.6 
C20 – Fe (Å) 4.6 ± 0.2 4.6 ± 0.1 4.6 ± 0.1 4.6 ± 0.2 4.6, 4.6, 4.4, 4.4 
            *Statistics corresponding to the highest resolution shell are in parentheses. 
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RESULTS 
Characterization of CYP17A1 ligand binding and substrate metabolism 
In order to compare the interactions of CYP17A1 with its various substrates and products, upon 
A105L mutation, and with structural findings, both dissociation constants and steady-state 
kinetic parameters were measured (Table 3.2). CYP17A1 affinities for steroid substrates and 
products were evaluated by monitoring the spectral shift associated with displacement of an 
active site water from the heme iron that occurs as ligands bind adjacent to the heme. Steady-
state kinetic parameters were determined for all three substrates with appreciable product 
formation (progesterone and pregnenolone 17-hydroxylation reactions and the 17α-
hydroxypregnenolone 17,20 lyase reaction).   
Table 3.2.  Substrate binding, progesterone hydroxylase activity, and steady state kinetic 
parameters for progesterone C17 hydroxylation by CYP17A1 wild type vs. A105L mutant. 
 
 
 
 Wild Type A105L 
Steroid substrate and product Kd values (nM)   
   Pregnenolone <1008 <100 
   Progesterone   230 ± 108 <100 
  17α-hydroxypregnenolone   210 ± 7 <100 
  17α-hydroxyprogesterone   330 ± 20   390 ± 90 
  16α-hydroxyprogesterone 8700 ± 600 8900 ± 600 
       
Progesterone 17α-Hydroxylation kinetics   
  kcat (min-1) 1.01 ± 0.05 1.16 ± 0.01 
  Km (µM) 10 ± 2 2.0 ± 0.1 
   
Pregnenolone 17α-Hydroxylation kinetics   
  kcat (min-1) 0.39 ± 0.03 0.39 ± 0.03 
  Km (µM) 0.9 ± 0.2 0.38 ± 0.09 
   
17,20-Lyase kinetics   
  kcat (min-1) 0.24 ± 0.02 1.21 ± 0.08 
  Km (µM) 1.2 ± 0.3 1.2 ± 0.3 
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 Progesterone binds more tightly to wild type CYP17A1 than either its major (17α-) or 
minor (16α-) hydroxylation products, with the 16α-hydroxyl conferring a notable >80-fold 
decrease in affinity (Table 3.2). Similarly, pregnenolone binds wild type CYP17A1 more tightly 
than its 17α-hydroxylated product.  Higher affinities are observed for all pregnenolone-based 
(Δ5,3-ol) ligands than for the corresponding progesterone (Δ4,3-keto) compounds.  The effect of 
the A105L mutation is to increase progesterone affinity at least 2-fold, but has little effect on the 
already lower affinity for either progesterone hydroxylation product.  Pregenenolone binds with 
such high affinity to both wild type and A105L that any changes in affinity due to mutation are 
not apparent, but the decrease in affinity that the 17α-hydroxy substituent confers on 
pregnenolone is offset by the A105L mutation. 
 Significant catalytic differences are also observed for different substrates and upon 
mutation (Table 3.2).  The wild type CYP17A1 17-hydroxylates pregnenolone with a Km that is 
10-fold lower than for progesterone 17-hydroxylation, consistent with the rank order of the 
dissociation constants.  Although the kcat is ~3-fold lower for pregnenolone 17-hydroxylation 
than for progesterone 17-hydroxylation, the overall catalytic efficiency (kcat/Km) is still 4.4 higher 
for pregnenolone 17-hydroxylation.  The A105L mutation does not alter kcat for the 17-
hydroxylation of either substrate, but does substantially decrease the Km for both reactions, 
consistent with general increases abserved in the dissociation constants reported above. 
 While pregnenolone is only hydroxylated at C17, human CYP17A1 is reported to also 
convert progesterone to the minor 16α-hydroxylated metabolite (Figure 3.1), which can compose 
10-30% of total hydroxylated metabolites depending on the system under study21,44.  For wild 
type CYP17A1 in the current purified enzyme system at saturating progesterone concentrations, 
16α-hydroxyprogesterone comprised 12% of the total progesterone hydroxylase activity, with 
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17α-hydroxyprogesterone accounting for the remainder.  The A105L mutation was reported to 
increase 17-hydroxylation and decrease 16-hydroxylation in a cell-based system21.  In 
agreement, under the same conditions used to evaluate the wild type enzyme herein, CYP17A1 
A105L yielded only ~5% of the total hydroxy metabolites as the 16α-hydroxyprogesterone 
minor product, with 95% being the 17α-hydroxyprogesterone metabolite.  Thus, these functional 
results agree that the A105L mutation increases the affinity of CYP17A1 for progesterone and 
that it does so by preferentially orienting progesterone for hydrogen abstraction at C17 over C16. 
 Human CYP17A1 has also been noted to produce very small amounts of 21-
hydroxyprogesterone, also called 11-deoxycorticosterone, which is increased with the A105L 
mutation44.  Although the current purified system yielded no detectable 21-hydroxyprogesterone 
at the highest substrate concentrations used for determining steady-state kinetic parameters (70 
µM), at much higher progesterone concentrations (200 µM) trace amounts of 21-
hydroxyprogesterone were inconsistently detected for the A105L mutant, but never for the wild 
type enzyme.  Thus the A105L mutation appears to slightly increase the production of 21-
hydroxyprogesterone. 
In contrast to hydroxylation reactions, where the A105L mutation altered only the Km, in 
the 17,20-lyase reaction the mutation had no effect on the Km.  Instead the mutation resulted in a 
5-fold increase in kcat, suggesting that the A105L mutation contributes to interactions that more 
readily permit the lyase reaction while having little affect on affinity. 
 
Global overview of CYP17A1/A105L structures 
 Introduction of the A105L mutation increased general CYP17A1 stability during 
purification (and likely during expression as well), as evaluated by overall protein yield.  This 
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consistently higher yield, perhaps in combination with an increased affinity for at least two of the 
steroid substrates, facilitated determination of a series of CYP17A1 A105L ligand complexes for 
side-by-side comparison.  All crystallized in the same space group with the same packing.  
Comparison of the four molecules composing the asymmetric unit for one substrate complex 
with any of the other substrate complexes or for the inhibitor abiraterone reveals they are all very 
similar to each other (average root mean square deviation (RMSD) over all Cα of 0.42 ± 0.10) 
and to previous structures of wild type CYP17A1 bound to abiraterone and another steroidal 
inhibitor (average RMSD over all Cα 0.41 ± 0.10)8.  However, for all CYP17A1 structures to 
date, two of the four molecules in the asymmetric unit (molecules A and B) differ slightly from 
the other two (molecules C and D), resulting in a higher Cα RMSD of 1.29 ± 0.06.  Structural 
differences between these two conformations are observed at the backbone level for the N-
terminus, a loop between β1 strands, and the F-G region (Figure 3.2).  These regions all lie on 
one face of the molecule, that is proposed to be involved in membrane binding.  As is true for 
almost all membrane P450 structures, this surface also constitutes a packing interaction with 
neighboring molecules in the crystalline lattice and is known to be relatively flexible.  Therefore 
it is difficult to determine whether these differences between molecules are functionally 
significant.  In all structures, a short loop region between helices H and I was not modeled 
(Figure 3.2) due to poor density, suggesting that this region is disordered.  In two molecules of 
the structure with 17α-hydroxyprogesterone and three molecules of the structure with 17α-
hydroxypregnenolone, several residues between the C and D helices were also not modeled due 
to ambiguous electron density. 
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Figure 3.2: The overall structure of CYP17A1 A105L molecules A/B (shown in rainbow) and 
C/D (gray) have small variations in the backbone structure on one face of the enzyme, including 
the N-terminus, the residues between the F and G helices, and a small portion of the adjacent β1 
sheet.  Dashed line, HI turn residues not modeled due to weak density. 
 
Structure of CYP17A1/A105L with Abiraterone 
In order to determine the effects of the A105L mutation alone on enzyme structure, the 
CYP17A1/A105L structure was determined in complex with the steroidal inhibitor abiraterone 
and compared to that of the wild type enzyme containing this same ligand (PDB 3RUK8).  The 
2.65 Å structure of the mutant enzyme (Table 3.1) is essentially identical to the wild type 
enzyme at the backbone level and in all other respects, save in the local region of the single site 
mutation.  The major difference between wild type CYP17A1 and the A105L mutant abiraterone 
structures is that the additional bulk due to substitution of leucine for alanine projects directly 
into what is part of the active site for the wild type enzyme (Figure 3.3).  Reduction in overall 
active site volume from 677 Å for the wild type enzyme to 642 Å for the A105L mutant is due 
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almost entirely to this substitution.  This reduction in active site volume does not alter the 
orientation of abiraterone or any of its interactions with the CYP17A1 active site.  The steroid 
still lies with the unsubstituted α face against the I helix with the steroid plane forming a 60° 
angle from the plane of the heme.  The only intermolecular hydrogen bond, between the 3β-
hydroxyl group of abiraterone and Asn202, is present in both structures.  Thus in this structure 
the impact of the A105L mutation appears to be only steric in nature  
 
Figure 3.3: Active site of wild type CYP17A1 (orange) bound to abiraterone (PDB 3RUK)8 
overlaid with the active site of CYP17A1 A105L (green) bound to abiraterone.  Mutation of 
residue 105 does not affect the orientation of the abiraterone inhibitor (shown in gray sticks), but 
reduces the active site volume specifically in the local region of the substituted side chain (wild 
type and A105L active site voids in orange and green mesh, respectively). 
 
Structure of CYP17A1 A105L with Hydroxylase Substrates 
Structures of the CYP17A1 A105L mutant with the 17α-hydroxylase substrates 
progesterone and pregnenolone were determined at resolutions of 2.80 Å and 2.50 Å, 
respectively (Table 3.1).  In all four molecules of the asymmetric unit of both hydroxylase 
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substrate complexes, the ligand steroids assume the same orientation (Figure 3.4A vs. 3.4B).  
This general orientation is also almost identical to that previously observed for abiraterone 
(Figure 3.4C), with the α-face of the steroid packed against the I helix and the 
cyclopentanophenanthrene steroid nucleus forming a ~60° angle from the heme plane.  
Abiraterone forms a hydrogen bond to the side chain of Asn202 in the F helix in both the wild 
type structure8 and in the A105L mutant (Figure 3.4C).  Abiraterone and pregnenolone are both 
Δ5,3-ol steroids.  Thus it is not surprising that the C3-OH of pregnenolone is also oriented to 
form a 2.8±0.1 Å (average) hydrogen bond to the Asn202 side chain (Figure 3.4A).  The 
corresponding C3-keto substituent of progesterone is located to form a hydrogen bond of similar 
length (2.7±0.3 Å average) to Asn202 (Figure 3.4B).  While progesterone must be the hydrogen 
bond acceptor and the amide nitrogen of Asn202 the hydrogen bond donor, the donor/acceptor 
relationship is less clear for pregnenolone.  The pregnenolone C3 hydroxyl could be donor or 
acceptor, and the side chain nitrogen/oxygen could be donor/acceptor respectively depending on 
the side chain torsion.  As a result of their similar hydrogen bonding interactions with Asn202 
(distances and angles, Table 3.2) and similar packing against the I helix, the distances from C17 
that is hydroxylated to the iron that would compose the catalytic iron (IV) oxo intermediate is 
essentially identical (4.8 ± 0.1 Å, Table 3.2) between the two hydroxylase substrates. Similarly, 
C16 (hydroxylated when progesterone is the substrate, but not when pregnenolone is the 
substrate) is also essentially same distance from the heme iron for both substrates (Table 3.2), 
but is located less directly over the iron than C17 (Figure 3.4A and 3.4B). 
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Figure 3.4: X-ray structures of CYP17A1 A105L with all four physiological substrates 
demonstrate overall similar orientations, with the steroid nucleus at an ~60° angle with respect to 
the heme plane and the steroid α-face flat against a peptide bond in the I helix.  Hydroxylase 
substrates pregnenolone (A, green) and progesterone (B, orange) form hydrogen bonds between 
their respective C3 alcohol and keto substituents and the side chain amide of Asn202, an 
orientation termed position 1 and similar to that observed for the steroidal inhibitor abiraterone 
(C).  The poor 17,20-lyase substrate 17α-hydroxyprogesterone (D, magenta) and is oriented 
similar to the hydroxylase substrates in position 1 with its C3 keto group also hydrogen bonding 
to Asn202.  However in different molecules of the structure with the efficient lyase substrate 
17α-hydroxypregnenolone, this substrate is found either in position 1 with its C3 hydroxyl 
hydrogen bonding to Asn202 (E, purple) or in a position closer to the heme which is too distant 
from Asn202 to allow hydrogen bonding (F, purple, position 2).  For clarity, in panels A-F the 
brackets only indicate the distances between C17 and Fe.  Other distances and angles are 
provided in Table 3.1.  Electron density is shown as a 2Fo-Fc ligand omit map contoured at 1.0 
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sigma.  In G, overlays of hydroxylase substrates pregnenolone (green) and progesterone (orange) 
demonstrate the similarity of their binding modes, while an overlay of 17α-
hydroxypregnenolone in its two observed positions illustrates important differences in hydrogen 
bonding (H). 
 
Structure of CYP17A1 A105L with 17,20-Lyase Substrates 
Structures of CYP17A1/A105L co-crystallized with the efficient lyase substrate 17α-
hydroxypregnenolone and the poor lyase substrate 17α-hydroxyprogesterone were determined to 
resolutions of 3.0 Å and 2.55 Å, respectively (Table 3.1).  In the 17α-hydroxyprogesterone 
complex, the ligand binds very similarly in all four molecules of the crystal and very similar to 
the orientation observed for the hydroxylase substrates (Figure 3.4D).  The hydrogen bond 
between the C3-keto and side chain amide of Asn202 is maintained with similar distances and 
angles (Table 3.1).  The substrate position with respect to the I helix and heme iron (e.g. C17-Fe 
5.0±0.1 Å, Table 3.1) is also consistent with the hydroxylase substrates, a state that will be 
referred to as position 1.  In the 17α-hydroxypregnenolone structure, the general substrate 
position relative to the I helix is maintained, but the substrate is observed to occupy distinct 
positions that vary by their relative position between Asn202 and the heme.  For two of the 
molecules of this structure, 17α-hydroxypregnenolone is in position 1 as observed for 17α-
hydroxyprogesterone (Figure 3.4E), with its C3 alcohol forming a hydrogen bond to Asn202 
(Table 3.1).  However in the other two molecules of this structure, 17α-hydroxypregnenolone is 
found farther from Asn202 and closer to the heme iron.  In its closest approach to the iron, a state 
referred to as position 2 (Figure 3.4F), the substrate C3 alcohol is much too far removed from 
Asn202 to participate in even a weak hydrogen bond (3.8 Å) and C17-Fe distance is reduced to 
4.3 Å.  The fourth molecule shows 17α-hydroxypregnenolone in an intermediate position.  The 
differences in position are perhaps better illustrated by comparing the electron density associated 
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with ligand and heme for these various complexes.  For 17α-hydroxypregnenolone in position 1 
and all other CYP17A1 substrates the substrate electron density is distinct from that of the heme 
(Figure 3.4A, 3.4B, 3.4D, 3.4E), while for 17α-hydroxypregnenolone in position 2, closer to the 
heme, the substrate electron density is continuous with the heme (Figure 3.4F), more similar to 
that of abiraterone (Figure 3.4C).  Thus overlays of the progesterone and pregnenolone 
complexes illustrate the high degree of similarity in their binding (Figure 3.4G) in a position and 
orientation also shared with 17α-hydroxyprogesterone (not shown).  However an overlay of the 
two binding positions observed for 17α-hydroxypregnenolone illustrates differences in the 
hydrogen binding to N202, and a shift toward the heme. 
 
Further variation in active site activity topography 
The amino acid side chains surrounding the active site, the observable waters, and the hydrogen 
bonding of the I helix that the steroids pack against are not significantly different between 
complexes (even when 17α-hydroxypregnenolone is positioned nearer to the heme) or between 
molecules in each structure.  Very minor differences reflect small changes in torsion angles or 
slightly favored rotamers to best fit the density in each structure.  However in two regions these 
small differences result in substantial variation in active site size and topography (Figure 3.5).  
Rather than being correlated with a particular substrate, this appears to result primarily from the 
relatively small differences in the backbone for molecules A and B vs. molecules C and D.  Like 
the wild type/abiraterone structure, the active site cavity extends beyond the C3 substituent and 
this varies somewhat in size, even between molecules of a particular substrate complex, due to 
slight differences in side chain torsions.  Additionally, several molecules have extensions from 
the main active site extending from the region of the ligand C19 substituent, which can consist of 
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substantial extra volume as a result of the slight differences in the F-G' loop backbone and very 
slight side chain torsions. In a very few molecules one or both of these active site extensions 
reach the protein surface, at the intersection of the F/G' loop, β4-1, and the first turn of the A helix 
or between the bases of the F and G helices, respectively.  If expanded by breathing motions or 
conformational changes in the protein, these channels could play a role in ligand entry/exit.  The 
cavity over the I helix, exiting at the base of the F and G helices would be exposed to solvent, 
while the cavity extension exiting in the region of the F/G' loop would be expected to be buried 
in the membrane. 
 
Figure 3.5: Probe-occupied cavities for the active sites of CYP17A1/A105L bound to 
progesterone (molecule B and D, yellow and blue, respectively) exemplify the range of volumes 
among the present structures.  While abiraterone always exhibits a minimal active site volume 
similar to that shown in blue mesh, for substrates slight modifications of backbone and side chain 
torsions in the F-G' region and/or at the base of the F and G helices can result in a significant 
extension near C19 and/or enlargement of the extension off C3.  In a few cases these cavities 
extend to the protein surface.  
 
DISCUSSION 
The reactions catalyzed by CYP17A1 have long been of substantial interest as they occur 
at a key juncture in human steroidogenesis, controlling the biosynthesis of mineralocorticoids, 
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glucocorticoids, and sex steroid androgens and estrogens.  Originally thought to be performed by 
two different enzymes, a steroid 17α-hydroxylase and a 17,20-lyase or –desmolase, both 
catalytic functions were later shown to be accomplished by CYP17A145.  In part to explain how 
both reactions might occur in the single CYP17A1 active site, the concept of a “bi-lobed” active 
site was advanced37, in which the different lobes would carry out the separate hydroxylase and 
lyase reactions.  Homology models and docking studies suggested that substrates were likely to 
orient essentially parallel to the plane of the heme33-35.  In contrast, the first available structures 
of CYP17A1, which were complexes of steroidal inhibitor analogs of pregnenolone, did not 
support a bi-lobed cavity and demonstrated ligand orientation more nearly perpendicular to the 
heme than parallel8.  However both of these inhibitors contained nitrogen heterocycles as 
substituents to the steroid scaffold at C17 and coordinated to the heme iron.  In the absence of 
further data subsequent work has been interpreted with differing models of steroid substrate 
orientation either parallel44 or more perpendicular to the heme8,26 within the CYP17A1 active 
site.  Herein experimental structures of CYP17A1 with each of the four substrates clearly 
demonstrate that steroid substrates adopt a binding orientation generally consistent with that of 
the steroidal inhibitors in the original X-ray structures (Figure 3.4). 
One possible caveat might be that all of the current structures were obtained in the 
presence of the A105L mutation.  However the only structural difference between the wild type 
and A105L structures with the common ligand abiraterone was a steric difference in active site 
volume as the larger leucine filled active site space unoccupied by abiraterone (Figure 3.3).  The 
mutation did not alter the orientation of the steroidal inhibitor in the CYP17A1 active site.  The 
reduction in the excess width of the active site engendered by the alanine to leucine substitution 
is consistent with decreases in Kd for most substrates and decreases in hydroxylation Km values 
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(Table 3.2).  This evidence in accordance with functional evidence discussed below suggests that 
the A105L mutation does not significantly alter the primary orientation of substrate steroids 
important for C17 hydroxylation. 
Thus, the structural results herein are first integrated with the functional hydroxylase data 
to propose an internally consistent hypothesis for CYP17A1 hydroxylase selectivities.  The 
orientations observed for CYP17A1 with progesterone or pregnenolone in the current structures 
are consistent with production of the major 17α-hydroxy metabolites observed.   In both cases 
C17 is oriented toward the heme iron.  The C17 alpha hydrogens of both hydroxylase substrates 
are located such that they would be clearly most susceptible to abstraction by the iron (IV) oxo 
intermediate in the hydroxylase reaction.  The C17 hydrogen is not located directly over the 
heme iron, but a few degrees off center, consistent with the moderate reported kinetic isotope 
effect for progesterone 17α-hydroxylation, interpreted as a bent transition state 44.  Wild type and 
the A105L mutant have essentially the same kinetic isotope effect for 17α-hydroxylation, 4.1 
and 3.8, respectively44, further supporting the idea that ligand orientation for 17α-hydroxylation 
is unperturbed by the mutation.   
Combination of the current structural and functional data suggests a mechanism 
underlying the generation of minor progesterone metabolites. Depending on the system under 
study, wild type CYP17A1 also hydroxylates progesterone to yield 10-30%21,44 of the total 
product as 16α-hydroxyprogesterone and has also been reported to produce trace amounts of 21-
hydroxyprogesterone44.  The C16 and C21 hydrogens flank the C17 hydrogen and the current 
structure positions them such that they would be the next most susceptible for hydrogen 
abstraction by the iron oxo intermediate (Figure 3.6A, experimental ligand position in grey 
sticks). In the purified system wild type CYP17A1 produced 88% of the total progesterone 
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metabolites with hydroxylation at C17 while the remaining 12% was the minor C16-
hydroxylated product and 21-hydroxyprogesterone was not detected. Consistent with previous 
reports21,44, the A105L mutation decreased the percentage of 16-hydroxylated product, increased 
17-hydroxylated product, and could produce trace amounts of the 21-hydroxylated metabolite 
11-deoxycorticosterone.  Thus the A105L mutation, whose nearest atom is some 8-11 Å away 
from the site of metabolism substantially reduces 16-hydroxylation on one side of C17 and 
slightly increases C21 hydroxylation on the opposite side of C17, suggesting a rotation of the 
substrate in the active site (Figure 3.6A, proposed minor orientation in pink sticks). 
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Figure 3.6: Combination of structural and functional data supports the following models for 
CYP17A1 catalysis. (A) Regioselectivity and substrate selectivity of hydroxylation.  While the 
major binding modes for progesterone and pregnenolone are oriented with C17 directed toward 
the iron for 17α-hydroxylation (grey sticks, orientation observed in structures), the steroid core 
of progesterone may also adopt an alternate plane that facilitates C16 hydroxylation (salmon 
sticks, proposed orientation).  The A105L mutation suppresses this alternate orientation, 
decreasing C16 hydroxylation, increasing C17 hydroxylation, and slightly increasing 
hydroxylation of C21 on the opposite side of the substrate.  Pregnenolone may not adopt this 
alternate orientation favoring C16 hydroxylation because its C3 hydroxyl is restrained by a 
stronger hydrogen bond with Asn202. Grey mesh is CYP17A1 wild type active site cavity.  B) In 
the current model for substrate selectivity of the lyase reaction, 17α-hydroxyprogesterone may 
be a poor 17,20-lyase substrate due to its positioning in the active site.  This substrate is only 
observed hydrogen bonding to N202 such that it is farther away from the iron, and its C17 
hydroxyl is predicted to hydrogen bond with the distal oxygen of the peroxy intermediate, an 
interaction that is not conducive to the lyase reaction.  C) In contrast, 17α-hydroxypregnenolone 
may be a more efficient substrate for the lyase reaction because it is observed to move closer to 
the iron, where studies suggest the C17 hydroxy may hydrogen bond with the proximal oxygen 
of the catalytic peroxy intermediate.  This position would facilitate nucleophilic attack of the 
distal oxygen on C20 to perform the lyase reaction.  The well established facilitation of the lyase 
reaction by b5 is consistent with an allosteric interaction favoring 17α-hydroxypregnenolone in 
position 2 vs. position 1. 
 
The present structural information demonstrates that A105L occludes part of the active 
site volume adjacent to the B' helix (Figure 3.3).  This volume is not utilized by progesterone 
binding in a mode consistent with 17-hydroxylation.  However, the functional data suggests that 
the availability of active site volume near Ala105 correlates with the production of 16α-
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hydroxyprogesterone.  In the wild type enzyme progesterone might take advantage of the cavity 
space near Ala105 to adopt a variation of the observed progesterone orientation that 
preferentially exposes C16 for hydroxylation (Figure 3.6A, pink).  Since the steroid nucleus is a 
relatively rigid body, reduction of volume near Ala105 would be structurally consistent with the 
proposition that the A105L active site topography disallows such alternative positioning of 
progesterone in the CYP17A1 active site, reducing production of the minor 16α-
hydroxyprogesterone metabolite, increasing the catalytic efficiency of 17α-hydroxylation, and 
slightly increasing C21 access to the iron for hydroxylation as observed experimentally.   
Thus it is proposed that in the wild type enzyme the progesterone long axis can adopt at 
least two orientations in the wild type active site (Figure 3.6A).  The major one would pack 
directly against the I helix and hydrogen bond to Asn202 as observed in the crystal structure, 
resulting in the major 17α-hydroxy metabolite.  The minor orientation would be most consistent 
with a shift of the long axis of the steroidal core, pivoting about C17 to move the C3 substituent 
into the space adjacent to Ala105 near the B' helix where it perhaps cannot hydrogen bond with 
Asn202. This proposed position for progesterone would move C16 towards the iron, increasing 
the likelihood of abstraction of one of the C16 hydrogens and subsequent hydroxylation to yield 
the minor product.  This model is consistent with intramolecular kinetic isotope effect studies 
demonstrating that the A105L mutation affects the transition state for hydrogen abstraction at 
C16, with negligible effects on progesterone C17 hydroxylation44.  It is therefore likely that the 
proposed alternative positioning is a very modest rotation of the steroid about C17 that affects 
the proximity of C16 to the oxygen of compound I without substantial effects on C17.  Detection 
of the proposed progesterone minor orientation would not be likely by X-ray crystallography, 
especially within the context of the A105L mutation background.  In summary, the contribution 
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of the A105L mutation to more efficient 17α-hydroxylation appears to be related to the binding 
of substrates and doing so in an optimal position for hydrogen abstraction at the appropriate 
carbon. 
The current structural and functional data also suggest a potential mechanism for 
differential regiospecificity between hydroxylase substrates.  Though the wild type active site 
cavity topography might suggest that pregnenolone could adopt a similar minor orientation 
resulting in the generation of 16α-hydroxypregnenolone, no such product is observed 
experimentally 19.  This could be due to a stronger hydrogen bonding interaction with Asn202 for 
pregnenolone compared to progesterone.  Pregnenolone (and 17α-hydroxypregnenolone) have a 
C3 hydroxyl substituent with the ability to serve as either hydrogen bond donor or acceptor to the 
Asn202 side chain amide, which can also serve as donor or acceptor depending on the 
orientation.  These substrates bind more tightly than either of the corresponding Δ4,3-keto 
progesterone-based substrates (Table 3.2), as reflected by at least a 2-fold decrease in the Kd and 
perhaps even more by the 17-hydroxylase Km, which is a full order of magnitude lower for 
pregnenolone than its Δ4,3-keto counterpart progesterone.  This stronger interaction with Asn202 
could inhibit pregnenolone from adopting the minor orientation proposed for progesterone and 
prevent pregnenolone 16-hydroxylation. 
A second debate in the field of steroidogenesis centers on the mechanism and substrate 
selectivity of the lyase reaction.  Human CYP17A1 performs the 17,20-lyase reaction much 
more efficiently on 17α-hydroxypregnenolone to form the physiologically-relevant androgen 
dehydroepiandrosterone, with 50-fold lower metabolism of 17 α-hydroxyprogesterone to the 
corresponding 17,20-lyase product androstenedione18,19, despite similar Kd values (Table 3.2).  
However the current structural results suggest a basis for this selectivity.  Although both lyase 
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substrates can hydrogen bond to Asn202 similar to the hydroxylase substrates, the poor lyase 
substrate 17α-hydroxyprogesterone was only observed in this position (called position 1).  In 
contrast, the favored lyase substrate 17α-hydroxypregnenolone is also observed closer to the 
heme and far enough from Asn202 that this hydrogen bond is no longer present (termed position 
2). The potential significance of this substrate repositioning was investigated by modeling the 
proposed intermediate for the lyase reaction into both substrate complexes.  The peroxy state17,25 
was modeled by incorporating the heme-bound oxygenated state observed in P450cam46, 
wherein the proximal oxygen is bound to the iron and the distal oxygen is oriented toward a 
portion of the adjacent I helix with non-canonical hydrogen bonding.  The CYP17A1 I helix 
shows similar non-cononical hydrogen bonding interactions at this position, though a water 
molecule observed in this groove for P450cam is not apparent for CYP17A1. With the iron 
peroxy modeled in this manner, the distance between the distal oxygen of the peroxo thought to 
perform nucleophilic attack on the substrate C20 position is similar for both substrate positions 
(~3.2 Å), but the distance between C17 and the proximal oxygen goes from 3.6 Å in position 1 to 
3.0 Å in position 2.  As a result, in position 1 (the only position observed for 17α-
hydroxyprogesterone) the C17 hydroxyl is positioned to best interact with the distal oxygen of 
the peroxy intermediate (Figure 3.6B).  In contrast, position 2 (observed only for 17α-
hydroxypregnenolone) brings the C17 hydroxyl within a similar distance to the proximal oxygen 
of the peroxy intermediate (Figure 3.6C).  Hydrogen bonding of the C17 hydroxyl to the distal 
oxygen as suggested by position 1 would tend to promote breakage of the oxygen-oxygen bond, 
leading to compound I and depressing the lyase reaction 26.  Hydrogen bonding of the C17 
hydroxyl to the proximal oxygen, as suggested by 17α-hydroxypregnenolone in position 2, 
would tend to preferentially stabilize the peroxy intermediate and leave the distal oxygen 
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available to perform nucleophilic attack on C20 of the substrate, thereby facilitating the lyase 
reaction. Thus subtle positioning of the substrate over the heme-peroxy intermediate, as mediated 
by the distant interaction with Asn202, is proposed to modulate substrate selectivity for the lyase 
reaction.  This hypothesis is consistent with several orthogonal lines of evidence.  First, although 
the residue at N202 may not be the only factor, the identity of this residue appears to largely 
correlate with lyase specificity in various species. In human, sheep, cow, and pig, the residue at 
position 202 is an asparagine and these proteins preferentially perform the lyase reaction on the 
17α-hydroxypregnenolone substrate to produce dehydroepiandrosterone. Conversely hamster, 
mouse, rat, and guinea pig have a threonine at position 202 and preferentially perform the lyase 
reaction on 17α-hydroxyprogesterone, yielding androstendione.  Second, resonance Raman 
spectroscopy supports differential hydrogen bonding of the efficient and poor lyase substrates to 
the proximal or distal oxygens, respectively, for the ferrous dioxygen state immediately 
preceding the peroxy state in the P450 catalytic cycle26.  Third, resonance Raman studies with 
CYP17A1 bound to CO demonstrate two distinct Fe-C-O vibrational modes exist for 17α-
hydroxypregnenolone and only a single mode in the presence of hydroxylase substrates and the 
poor lyase substrate, 17α-hydroxyprogesterone47.  Thus the recent functional and current 
structural evidence converge to strongly support two binding modes for 17α-
hydroxypregnenolone, one of which is oriented appropriately to stabilize the peroxo intermediate 
and undergo the lyase reaction.  Finally, repositioning of 17α-hydroxypregnenolone lower in the 
active site to promote the lyase reaction is consistent with the effects of the A105L mutation, 
where filling space in the distal part of the active site cavity results in a 5-fold increase in kcat 
with no change in Km. 
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 A third major conundrum with respect to CYP17A1 biochemistry is how the presence of 
cytochrome b5 promotes the 17,20-lyase reaction to increase androgen production in specific 
tissues and during human development.  Cytochrome b5 binding is not associated with electron 
delivery to CYP17A1, but nonetheless increases the 17,20-lyase reaction as much as 10-fold18.  
One might suggest that stabilization of the lyase iron-oxo intermediate might be accomplished if 
b5 binding inhibited protonation of the iron-peroxo intermediate.  The peroxo intermediate 
operative in the lyase reaction must first be protonated on the distal oxygen, followed by a 
second protonation and loss of water to yield the iron-oxo compound I intermediate required for 
hydroxylation. However this is incompatible with the observation that b5 does not reduce the 
hydroxylation reaction.  Alternatively, b5 binding has been suggested to allosterically alter 
CYP17A1 conformation and/or substrate orientation to promote the lyase activity18, but a 
mechanism for this has not been previously elucidated48.  The current structural results suggest 
that this might occur by altering the distribution of 17α-hydroxypregnenolone in position 1 (not 
conducive to the lyase reaction) vs. position 2 (compatible with productive lyase chemistry).  
The anionic E48 and E49 residues of cytochrome b5 are known to interact with the cationic 
R347, R358, and R449 CYP17A1 residues based on both mutagenesis and recent solution NMR 
binding studies32,49.  This means that the b5 binding site is on the opposite side of the heme and 
11-21 Å away from the buried active site. Recently, however, solution NMR results established 
that b5 binds differentially to CYP17A1 depending on whether the hydroxylase substrate 
pregnenolone or the lyase substrate 17α-hydroxypregnenolone is present in the buried CYP17A1 
active site49.  Cytochrome b5 binding on the proximal side of CYP17A1 has been demonstrated 
to change the backbone conformations for F helix residues I205 and I206 adjacent to N20250, 
although information on N202 itself is not yet available.  The functional and structural data 
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suggest that communication between the b5 binding site and the active site could allosterically 
favor 17α-hydroxypregnenolone binding in position 2.  Optimized positioning of 17α-
hydroxypregnenolone for the lyase reaction would be consistent with the observed decrease in 
the amount of uncoupling for the lyase reaction when b5 is present51, increasing the lyase product 
generated without substantially altering CYP17A1 hydroxylase activity, which is already ~97% 
coupled51.  Although we have been unable to replicate these results, phosphorylation of 
CYP17A1 is also reported to facilitate the lyase reaction52,53 and could similarly promote a 
conformation of CYP17A1 that increases 17α-hydroxypregnenolone in position 2 closer to the 
heme. 
In summary, the balance of human mineralocorticoids, glucocorticoids, androgens and 
estrogens depends on the interactions of CYP17A1 with its four different steroidal substrates.  
While structural information has previously been lacking, the current set of X-ray structures 
establishes that each of these substrates binds in the CYP17A1 active site with the site(s) of 
metabolism oriented toward the heme, the α face packed against the I helix, and with the C3 keto 
or alcohol substitutent hydrogen bonding to Asn202 in the F helix.  Complexes with the 
hydroxylase substrates progesterone and pregnenolone demonstrate primary binding modes 
consistent with production of the observed 17α-hydroxy major metabolites, while the structural 
and functional effects of the A105L mutation suggest a minor alternate orientation not seen in 
the current structure, but that would be consistent with the 16α-hydroxylation observed for 
progesterone but not pregnenolone.  Comparison of complexes between the poor lyase substrate 
17α-hydroxyprogesterone and the efficient lyase substrate 17α-hydroxypregnenolone reveal that 
only 17α-hydroxypregnenolone is also observed positioned closer to the heme without hydrogen 
bonding to Asn202.  This latter position, termed position 2, is consistent with spectroscopic 
 66 
evidence suggesting that 17α-hydroxypregnenolone hydrogen bonds differently to the proposed 
peroxy catalytic intermediate compared to its Δ4-3keto counterpart, resulting in C-C bond 
cleavage only for 17α-hydroxypregnenolone.  Finally, cytochrome b5 binding to CYP17A1 is 
known to have an allosteric effect on the active site, which would be consistent with favoring 
17α-hydroxypregnenolone localization nearer the heme in position 2 and potentially decreasing 
nonproductive uncoupling of the catalytic cycle.  In aggregate, the set of structures herein 
provide a structural basis for the regioselectivity and substrate specificity of the hydroxylation 
reaction and the substrate specificity of the lyase reaction, as well as providing potential 
mechanism for the allosteric effects of cytochrome b5 on the lyase reaction.  Providing such a 
structural basis for understanding key reactions at the crossroads of human steroidogenesis 
should improve our ability to modulate physiological status in diseases ranging from sexual 
development, fertility and hormone-responsive breast and prostate cancer, to immune and stress 
responses and blood pressure. 
 
ACKNOWLEDGEMENTS 
Initial pregnenolone hydroxylase and 17,20-lyase assay development was performed by 
Patrick Porubsky.  Unpublished CYP17A1 wild type binding data was provided by Dr. Natasha 
DeVore.
 67 
REFERENCES 
 
(1) Miller, W. L.; Auchus, R. J. Endocr. Rev. 2011, 32, 81. 
(2) Gilep, A. A.; Sushko, T. A.; Usanov, S. A. Biochim. Biophys. Acta 2011, 1814, 
200. 
(3) Edwards, B. K.; Noone, A. M.; Mariotto, A. B.; Simard, E. P.; Boscoe, F. P.; 
Henley, S. J.; Jemal, A.; Cho, H.; Anderson, R. N.; Kohler, B. A.; Eheman, C. R.; 
Ward, E. M. Cancer 2013. 
(4) Ferraldeschi, R.; de Bono, J. Cancer J 2013, 19, 34. 
(5) de Bono, J. S.; Logothetis, C. J.; Molina, A.; Fizazi, K.; North, S.; Chu, L.; Chi, 
K. N.; Jones, R. J.; Goodman, O. B., Jr.; Saad, F.; Staffurth, J. N.; Mainwaring, 
P.; Harland, S.; Flaig, T. W.; Hutson, T. E.; Cheng, T.; Patterson, H.; Hainsworth, 
J. D.; Ryan, C. J.; Sternberg, C. N.; Ellard, S. L.; Flechon, A.; Saleh, M.; Scholz, 
M.; Efstathiou, E.; Zivi, A.; Bianchini, D.; Loriot, Y.; Chieffo, N.; Kheoh, T.; 
Haqq, C. M.; Scher, H. I. N. Engl. J. Med. 2011, 364, 1995. 
(6) Auchus, M. L.; Auchus, R. J. J. Investig. Med. 2012, 60, 495. 
(7) Loriot, Y.; Bianchini, D.; Ileana, E.; Sandhu, S.; Patrikidou, A.; Pezaro, C.; 
Albiges, L.; Attard, G.; Fizazi, K.; De Bono, J. S.; Massard, C. Ann. Oncol. 2013, 
24, 1807. 
(8) DeVore, N. M.; Scott, E. E. Nature 2012, 482, 116. 
(9) Pia, A.; Vignani, F.; Attard, G.; Tucci, M.; Bironzo, P.; Scagliotti, G.; Arlt, W.; 
Terzolo, M.; Berruti, A. Cancer Treat. Rev. 2013, 39, 966. 
(10) Attard, G.; Reid, A. H.; Auchus, R. J.; Hughes, B. A.; Cassidy, A. M.; Thompson, 
E.; Oommen, N. B.; Folkerd, E.; Dowsett, M.; Arlt, W.; de Bono, J. S. J. Clin. 
Endocrinol. Metab. 2012, 97, 507. 
(11) Ogo, A.; Haji, M.; Ohashi, M.; Nawata, H. Mol. Cell. Endocrinol. 1991, 80, 83. 
(12) Maitra, A.; Shirwalkar, H. Indian J Exp Biol 2003, 41, 701. 
(13) Qin, K. N.; Rosenfield, R. L. Mol Cell Endocrinol 1998, 145, 111. 
(14) Miller, W. L. Mol. Cell. Endocrinol. 2002, 198, 7. 
(15) Strauss, J. F., 3rd Ann. N. Y. Acad. Sci. 2003, 997, 42. 
(16) Groves, J. T.; McClusky, G. A.; White, R. E.; Coon, M. J. Biochem. Biophys. Res. 
Commun. 1978, 81, 154. 
(17) Akhtar, M.; Corina, D.; Miller, S.; Shyadehi, A. Z.; Wright, J. N. Biochemistry 
1994, 33, 4410. 
(18) Auchus, R. J.; Lee, T. C.; Miller, W. L. J. Biol. Chem. 1998, 273, 3158. 
(19) Swart, P.; Swart, A. C.; Waterman, M. R.; Estabrook, R. W.; Mason, J. I. J. Clin. 
Endocrinol. Metab. 1993, 77, 98. 
(20) Arlt, W.; Martens, J. W.; Song, M.; Wang, J. T.; Auchus, R. J.; Miller, W. L. 
Endocrinology 2002, 143, 4665. 
(21) Swart, A. C.; Storbeck, K. H.; Swart, P. J. Steroid Biochem. Mol. Biol. 2010, 119, 
112. 
(22) Sohl, C. D.; Guengerich, F. P. J. Biol. Chem. 2010, 285, 17734. 
(23) Fluck, C. E.; Miller, W. L.; Auchus, R. J. J. Clin. Endocrinol. Metab. 2003, 88, 
3762. 
 (24) Guengerich, F. P. J Biochem. Mol. Toxicol. 2007, 21, 163. 
 68 
 (25) Gregory, M. C.; Denisov, I. G.; Grinkova, Y. V.; Khatri, Y.; Sligar, S. G. 
J. Am. Chem. Soc. 2013, 135, 16245. 
(26) Gregory, M.; Mak, P. J.; Sligar, S. G.; Kincaid, J. R. Angew. Chem. Int. Ed. Engl. 
2013, 52, 5342. 
(27) Katagiri, M.; Kagawa, N.; Waterman, M. R. Arch. Biochem. Biophys. 1995, 317, 
343. 
(28) Lee-Robichaud, P.; Wright, J. N.; Akhtar, M. E.; Akhtar, M. Biochem. J 1995, 
308 ( Pt 3), 901. 
(29) Onoda, M.; Hall, P. F. Biochem. Biophys. Res. Commun. 1982, 108, 454. 
(30) Idkowiak, J.; Randell, T.; Dhir, V.; Patel, P.; Shackleton, C. H.; Taylor, N. F.; 
Krone, N.; Arlt, W. J. Clin. Endocrinol. Metab. 2012, 97, E465. 
(31) Kok, R. C.; Timmerman, M. A.; Wolffenbuttel, K. P.; Drop, S. L.; de Jong, F. H. 
J. Clin. Endocrinol. Metab. 2010, 95, 994. 
(32) Naffin-Olivos, J. L.; Auchus, R. J. Biochemistry 2006, 45, 755. 
(33) Auchus, R. J.; Miller, W. L. Mol Endocrinol 1999, 13, 1169. 
(34) Schappach, A.; Holtje, H. D. Pharmazie 2001, 56, 435. 
(35) Haider, S. M.; Patel, J. S.; Poojari, C. S.; Neidle, S. J. Mol. Biol. 2010, 400, 1078. 
(36) Lin, D.; Zhang, L. H.; Chiao, E.; Miller, W. L. Mol. Endocrinol. 1994, 8, 392. 
(37) Laughton, C. A.; Neidle, S.; Zvelebil, M. J.; Sternberg, M. J. Biochem. Biophys. 
Res. Commun. 1990, 171, 1160. 
(38) Kabsch, W. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 125. 
(39) McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. 
C.; Read, R. J. J. Appl. Crystallogr. 2007, 40, 658. 
(40) Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Acta Crystallogr., Sect. D: 
Biol. Crystallogr. 2010, 66, 486. 
(41) Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis, I. W.; Echols, 
N.; Headd, J. J.; Hung, L. W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. 
J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; 
Terwilliger, T. C.; Zwart, P. H. Acta Crystallogr., Sect. D: Biol. Crystallogr. 
2010, 66, 213. 
(42) Kleywegt, G. J.; Jones, T. A. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 
50, 178. 
(43) Schrodinger, LLC  2010. 
(44) Yoshimoto, F. K.; Zhou, Y.; Peng, H. M.; Stidd, D.; Yoshimoto, J. A.; Sharma, K. 
K.; Matthew, S.; Auchus, R. J. Biochemistry 2012, 51, 7064. 
(45) Nakajin, S.; Hall, P. F. J. Biol. Chem. 1981, 256, 3871. 
(46) Schlichting, I.; Berendzen, J.; Chu, K.; Stock, A. M.; Maves, S. A.; Benson, D. 
E.; Sweet, R. M.; Ringe, D.; Petsko, G. A.; Sligar, S. G. Science 2000, 287, 1615. 
(47) Mak, P. J.; Gregory, M. C.; Sligar, S. G.; Kincaid, J. R. Biochemistry 2013. 
(48) Akhtar, M. K.; Kelly, S. L.; Kaderbhai, M. A. J. Endocrinol. 2005, 187, 267. 
(49) Estrada, D. F.; Laurence, J. S.; Scott, E. E. J. Biol. Chem. 2013, 288, 17008. 
(50) Estrada, D. F.; Skinner, A. L.; Laurence, J. S.; Scott, E. E. J. Biol. Chem. 2014. 
(51) Khatri, Y.; Gregory, M. C.; Grinkova, Y. V.; Denisov, I. G.; Sligar, S. G. 
Biochem. Biophys. Res. Commun. 2014, 443, 179. 
(52) Zhang, L. H.; Rodriguez, H.; Ohno, S.; Miller, W. L. Proc. Natl. Acad. Sci. U. S. 
A. 1995, 92, 10619. 
 69 
(53) Tee, M. K.; Miller, W. L. J. Biol. Chem. 2013, 288, 23903. 
 
 70 
Chapter 4. 
Structures of Cytochrome P450 17A1 with A Ring-Modified Steroidal 
Inhibitors 
INTRODUCTION 
 The first compounds designed to inhibit CYP17A1, a required enzyme in androgen 
biosynthesis and therefore a target for the treatment of prostate cancer, were logically based on 
the pregnenolone substrate of this enzyme.  Effective inhibitors were developed by incorporation 
of nitrogen heterocycle substituents at carbon 17 of the steroidal scaffold, which is now known to 
coordinate the heme iron of CYP17A11. The FDA-approved abiraterone incorporates a pyridine 
ring at this position.  Galeterone, currently in Phase III clinical trials, substitutes a 
benzimidazole.  The design of these inhibitors was guided by structure activity relationships to 
optimize the type of heterocycle2, the configuration of the heterocycle2,3, and the oxidation state 
of the D ring4.  Although these early efforts were more focused on the heterocycles that interact 
with the heme iron directly, more recent studies have explored structure activity relationships on 
other parts of the steroidal scaffold. 
 Variations in the configurations of A and B rings are of particular interest because the 
natural substrates of CYP17A1 vary in these rings.  Abiraterone and galeterone share the 3β-OH, 
Δ5 configuration with pregnenolone.  However, human CYP17A1 also turns over progestagens 
with different A ring configurations, and A ring configuration can strongly influence the 
efficiency of the reactions performed on the other end of the steroid (as discussed more 
thoroughly in Chapter 3).  Progesterone (a 3-keto, Δ4 progestagen) is a comparable substrate to 
pregnenolone for the CYP17A1-mediated hydroxylase reaction.  However, the 17-hydroxylated 
progesterone product is a much poorer substrate for the subsequent 17,20 lyase reaction of 
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human CYP17A1 compared to its 3β-OH, Δ5 analog, 17α-hydroxypregnenolone5.  Reduction of 
pregnenolone’s Δ5 double bond and projection of the hydroxyl group on carbon 3 toward the α-
face of the steroid results in allopregnanolone.  Allopregnenolone is an endogenous  progestagen 
that is also a substrate for 17α-hydroxylation by CYP17A1. Additionally, the 17α-
hydroxyallopregnanolone product has been reported to subsequently undergo the 17,20 lyase 
reaction more efficiently than 17α-hydroxypregnenolone6.  CYP17A1-mediated hydroxylation 
and lyase reactions on allopregnanalone and 17α-hydroxyallopregnanolone are components of 
the so-called “backdoor” route to androgen biosynthesis described in Chapter 1. 
 Several different A ring configurations have been explored in the context of CYP17A1 
inhibition by steroidal compounds. Reduction of the Δ5 double bond in galeterone (while 
maintaining the 3β stereochemistry of the hydroxyl group) is reported to result in a significantly 
less potent inhibitor of CYP17A1-mediated 17,20-lyase activity7, but there are currently no 
reports of analogs with A configurations that more closely resemble that of progesterone (3-keto, 
Δ4) or allopregnanolone (3α-OH, 5α).  Recently, however, analogs of abiraterone with various A 
ring configurations (Table 4.1) were examined for CYP17A1 binding affinity and inhibition of 
progesterone hydroxylation in the Auchus lab, including the 3-keto, Δ4 analog (1), the 3-keto, 5α 
analog (2), and the 3α-OH, 5α analog (3)8. Notably, compounds (1) and (3) have A-ring 
configurations based on CYP17A1 substrates progesterone and allopregnanolone, respectively.  
All three compounds demonstrated binding affinity and potency for progesterone hydroxylation 
comparable to abiraterone8. Moreover, compound (1) was recently identified as a metabolite of 
abiraterone in human patients receiving abiraterone as treatment for prostate cancer9.  In vivo, 
patients convert small amounts of abiraterone to (1) via 3β-hydroxysteroid dehydrogenase9.  
Importantly, (1) was shown to inhibit not only CYP17A1, but two other enzymes required for 
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androgen biosynthesis, 3β-hydroxysteroid dehydrogenase and 5α-reductase.  Finally, (1) also 
acts as a very effective androgen receptor antagonist, equipotent to a specific androgen receptor 
antagonist used clinically, enzalutamide9.  This four-way inhibition of androgen biosynthesis 
potentially represents a significantly improved multi-target approach for treatment of prostate 
cancer.  Long-term inhibition of CYP17A1, or any single target approach, can result in resistance 
to treatment10. Therefore an agent such as (1) that interferes with androgen biosynthesis at 
multiple steps in the pathway could minimize resistance and improve overall survival, especially 
if undesirable off-target effects on enzymes such as CYP21A2 can be simultaneously avoided. 
Table 4.1: Analogs of abiraterone with A-ring modifications with reported affinities for 
CYP17A1 and Ki values for inhibition of progesterone hydroxylation.
 
 
 
 Although inhibitors (1), (2), and (3) are reported to bind and effectively inhibit 
CYP17A1, there have been no reported structures of CYP17A1 in complex with any of them.  
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All three inhibitors share substantial structural similarity with abiraterone, and therefore were 
proposed to adopt the same orientation and engage in the same interactions with the CYP17A1 
active site as abiraterone, for which a structure has previously been reported1.  To examine this 
hypothesis, CYP17A1 was crystallized in complex with compounds (1), (2), and (3) and the X-
ray crystal structures solved at resolutions of 2.7, 2.0, and 2.4 Å, respectively.  The structures do 
indeed indicate that compounds (1), (2), and (3) bind to CYP17A1 in the same orientation as 
abiraterone, and make similar contacts with the active site of CYP17A1.  Such findings support 
previous studies comparing the affinity and potency of CYP17A1 inhibition for these inhibitors 
compared to abiraterone.  Furthermore, the 2.0 Å structure of CYP17A1 with inhibitor (2) is the 
highest resolution structure of the enzyme to date, and supports a peripheral ligand binding site 
that had not been clearly defined in previous CYP17A1 structures. 
 
METHODS 
Protein Expression and Purification 
 CYP17A1 was expressed and purified without ligand as described in Chapter 2. 
Crystallization, Data Collection, and Structure Determination 
 CYP17A1 was co-crystallized with inhibitors (1), (2), and (3) via hanging drop vapor 
diffusion.  CYP17A1 (30 mg/mL) in buffer containing 50 mM Tris-HCl, pH 7.4, 20% glycerol, 
100 mM glycine, 500 mM NaCl, 0.5% (v/v) Emulgen-913, with 10 µM inhibitor (1) or (3), or 20 
µM (2) was set up in a 1:1 ratio with precipiant to form 2 µL drops.  Drops were equilibrated 
against 750 µL precipitant containing 175 mM Tris HCl, pH 8.5, 30% PEG-3350, 300 mM 
LiSO4, and 3% glycerol.  Crystals were cryoprotected in a 7:3 mixture of mother liquor to 80% 
glycerol and flash cooled in liquid nitrogen. 
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 Data were collected on beamline 14-1 and 12-2 at the Stanford Synchrotron Radiation 
Lightsource.  All crystallographic data were processed using XDS11.  Statistics for data 
collection and refinement are shown in Table 4.2.  Structures were solved by molecular 
replacement in Phaser12 at the corresponding resolution cutoff for each structure (see Table 4.2) 
and using a previous structure of CYP17A1 with heme cofactor (PDB ID: 3SWZ1) as a search 
model.  Model building and iterative refinement were performed using COOT13 and PHENIX14, 
respectively.  Ligand coordinates were generated using eLBOW in PHENIX14.  Simulated-
annealing composite omit maps were calculated in PHENIX14.  Probe-occupied active site void 
volumes were calculated using VOIDOO15 (Probe radius of 1.4 Å, grid spacing of 0.33).  
Overlays between CYP17A1 structures were generated in COOT13 using the secondary structure 
matching algorithm.  Overlays between CYP17A1 and CYP3A4 or CYP21A2 were generated in 
COOT13 using the least squares fit to overlay hemes.  Figures were created using PyMOL16. 
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Table 4.2: Crystallographic data collection and refinement statistics for CYP17A1 with 
abiraterone A-ring analogs. 
 CYP17A1/(1) CYP17A1/(2) CYP17A1/(3) 
Data Collection    
Beamline SSRL 12-2 SSRL 12-2 SSRL 14-1 
Space group P212121 P212121 P212121 
Cell dimensions:  
a, b, c (Å) 
90.35,152.98,168.50 85.72, 151.18, 169.94 89.76, 153.18, 168.88 
Molecules/a.u. 4 4 4 
Resolution (Å)* 39.81-2.70 (2.85 – 
2.75) 
38.68 – 2.00 (2.11-
2.00 ) 
39.29 - 2.39 (2.52-
2.39) 
Total reflections* 432,291 (58,652) 1,503,586 (191,079) 683,522 (97,537) 
Unique reflections* 64,672 (9,236) 146,679 (20,040) 92,392 (13,193) 
Redundancy* 6.7 (6.4) 10.3 (9.5) 7.4 (7.4) 
Rpim* 0.062 (0.554) 0.066 (0.717) 0.067 (0.629) 
<I/σ(I)>* 12.9 (1.7) 8.5 (1.5) 11.5 (1.5) 
Completeness* 99.7 (98.4) 98.8 (93.5) 99.8 (97.7) 
Refinement    
Resolution (Å) 39.81-2.70 38.68-2.00 39.29-2.40 
No. reflections 64,546 144,568 92,110 
R/Rfree (%) 18.82/24.88 18.46/24.23 18.95/24.51 
Ramachandran (%)    
    Favored 96.50 97.41 96.32 
    Allowed 3.28 2.43 3.57 
    Outliers 0.22 0.16 0.11 
Wilson B Factor (Å2) 52.76 27.91 41.13 
No. Atoms/B Factors 
(Å2) 
   
    Protein 14,905 / 63.09 14,872 / 39.27 15,015 / 47.13 
    Ligand      104 / 42.07      156 / 45.87      104 / 34.20 
    Heme      172 / 46.20      172 / 26.75      172 / 31.51 
    Water        91 / 43.47      778 / 37.62      339 / 35.97 
RMSD bonds (Å) 0.009 0.008 0.007 
RMSD angles (°) 1.251 1.130 1.130 
Coordinate error 
(maximum-likelihood 
based) (Å) 
0.39 0.27 0.34 
Average bond 
angles/distances 
   
N/ON202-O3 (Å) 2.70 ± 0.10 2.86 ± 0.08 2.67 ± 0.04 
∠C3-O3-N/ON202 (°) 130 ± 20 130 ± 3 95 ± 7 
*Statistics for highest resolution shell are shown in parentheses. 
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RESULTS 
 The crystal structures of CYP17A1 co-crystallized with each of the three compounds 
were determined in the same space group (P212121) as previous structures of CYP17A11,17.  The 
four molecules occupying the asymmetric unit also had conformations consistent with previous 
structures of CYP17A1, with two sets of similar copies of the enzyme.  Molecules A and B 
demonstrate high similarity to one another (RMSD over all Cα ranges from 0.18 to 0.62 Å), 
while molecules C and D are also similar to each other (RMSD over all Cα ranges from 0.27 to 
0.9 Å), but there are some greater disparities between the conformations of molecules A and B 
compared to molecules C and D (average RMSD over all Cα = 1.26 ± 0.06 Å).  These 
differences in protein backbone are very similar to those of all other CYP17A1 structures 
described to date regardless of the ligand17. 
 For all three complexes, clearly defined electron density was apparent in the active sites 
of all four copies of the protein, and was consistent between copies of the protein.  Inhibitors (1), 
(2), and (3) share a similar orientation within the CYP17A1 active site compared to one another 
and abiraterone1 (Figure 4.1).  The α-face of the steroid lies flat against the I helix at ~60° angle 
from the plane of the heme.  Consistent with Type II spectral shifts observed during binding 
studies,8 the heteroatom of the pyridine ring incorporated into inhibitors (1), (2), and (3) 
coordinates the heme iron, as also observed previously with abiraterone1. 
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Figure 4.1:  Electron density for inhibitors (1) in panel A, (2) in panel B, and (3) in panel C 
support a binding mode similar to abiraterone for all three.  Direct contacts between C3 
substituents to N202, as well as between the pyridine nitrogen and the heme iron are conserved.  
Distances shown are average distances among the all four molecules of CYP17A1 in each 
structure.  Maps shown are simulated annealing composite omit maps contoured to 1.0 σ.   
  
On the steroid A ring, C3 substituent hydrogen bonding to asparagine 202 (N202) in the 
F helix is conserved among the three inhibitors and abiraterone.  For inhibitors (1) and (2), which 
have a ketone as a C3 substituent, N202 is implied to act as a hydrogen bond donor. In contrast, 
N202 may either be the hydrogen bond donor or acceptor to inhibitor (3), which has a C3 
hydroxyl substituent.  The average distance between C3 substituent and N202 among the four 
molecules of CYP17A1 is relatively consistent between ligands (2.6 ± 0.1 Å, 2.86 ± 0.08 Å, and 
2.66 ± 0.04 Å for inhibitors (1), (2), and (3), respectively). The angle between the C3 substituent 
and the participating carbon or nitrogen of N202 varies depending on the conformation adopted 
by the A ring.  The A rings of abiraterone and inhibitor (3) are completely saturated and both 
inhibitors are sp3 hybridized at carbon 3.  The A ring adopts the chair conformation as a result.  
In both axial and equatorial positions, the C3 alcohol adopts a ~95° bond angle from the 
heteroatom of N202 participating in a hydrogen bond.  For inhibitors (1) and (2) with sp2 
hybridization at C3, the A ring takes on a conformation closer to that of a half-chair.  
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Consequently, the C3 substituent is projected more directly at N202 and forms an ~130° degree 
angle with the nitrogen of that residue. 
Although direct contacts with the protein are largely conserved among the three 
inhibitors, substantial differences in the A ring configuration affect indirect interactions of these 
inhibitors with active site waters (Figure 4.2).  Projection of the hydroxyl substituent from the α-
face of the saturated A ring of inhibitor (3) allows this hydroxyl to interact with water molecule 
A, which is in turn engaged in hydrogen bonds with the side chain of residue arginine 239 
(R239) on the G helix and the backbone carbonyl of glycine 297 (G297) in the I helix (Figure 
4.2A).  This water is also hydrogen bonded to an additional water (water B), which is hydrogen 
bonded to tyrosine 201 (Y201) on the F helix, forming a hydrogen bond network.  The ketone 
substituent of the 3-keto, Δ4 inhibitor (1) also participates in a hydrogen bond with this water 
(Figure 4.3A) in some copies of this complex, although in others the water molecule lies outside 
hydrogen bonding distance or is not observed.  It is important to note that structures of 
CYP17A1 with A-ring modified inhibitors span a range of resolutions from 2.0-2.7 Å, which can 
affect visualization of water molecules between structures.  This is especially apparent in 
comparisons with the lowest resolution structure, the complex of CYP17A1 with inhibitor (1). 
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Figure 4.2: Analogs of abiraterone with various modifications to the A ring participate in 
different hydrogen bond networks.  A) The hydrogen bond network surrounding compound (1, 
3-keto,Δ4 analog) (shown in cyan sticks) is similar to that of (3, 3α-OH analog) (shown in 
magenta sticks).  B) The hydrogen bond network of inhibitor (2, 3-keto analog) (green sticks) is 
most similar to that of abiraterone (light blue sticks).  C) Differences in the A ring configuration 
affect whether the C3 substituent interacts with water A or B. 
 
In contrast, the 3-keto group of inhibitor (2), with the A and B rings saturated, does not 
participate in a direct hydrogen bond with water A.  Instead, the 3-keto substituent of inhibitor 
(2) lies within weak hydrogen bonding distance (average bond length among four molecules of 
CYP17A1 = 3.5 ± 0.3 Å) of water B, which itself participates in a larger network that includes 
N202 directly, as well as other residues (side chains of Y201 and R239 and the backbone 
carbonyl of G297).  This hydrogen bonding network is most similar to that observed in the 
structure of CYP17A1 with abiraterone (Figure 4.2B).  Projection of the C3 substitutent above 
the plane of the ring by abiraterone and inhibitor (2) seems to favor hydrogen bonding to water 
B, whereas projection of the C3 substituent below the plane of the ring by inhibitors (1) and (3) 
facilitates interaction with water A (Figure 4.2C). 
The structure of CYP17A1 with inhibitor (2) is the highest resolution structure of this 
enzyme to date, which allows us to observe less-ordered elements and lower occupancy 
components of this complex than previous structures of ligand-bound CYP17A1.  Most 
structures of CYP17A1 to date include unmodeled electron density in two of the four molecules 
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of the structure in a lipophilic region near the N-terminal β strands and the F/G loop (Figure 
4.3A).  There are no apparent hydrogen-bonding contacts with polypeptide to facilitate modeling 
a chain of waters, and the density was not clear enough to model any of the known components 
of the crystallization solution.  This density is best defined in the 2.0 Å structure of CYP17A1 
with inhibitor (2), and is consistent in length and planarity to the steroidal scaffold of the 
inhibitor (Figure 4.3B).  Inhibitor (2) was modeled with the pyridine ring oriented either toward 
the interior of the protein or toward the solvent exposed surface (Figure 4.3C). The electron 
density maps and a 0.32% decrease in Rfree following refinement suggested that the pyridine 
ring is better modeled with the pyridine ring projected toward the interior of the protein.  An 
alternate scenario in which both orientations are simultaneously present at partial occupancy was 
explored, but was a poor fit to the maps following a round of refinement.  Thus, the final model 
of inhibitor (2) in the peripheral binding site has the pyridine ring oriented toward the interior of 
the binding pocket (Figure 4.3B) 
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Figure 4.3: Peripheral steroid binding site observed in structure of CYP17A1 with inhibitor (2). 
A) Locations of inhibitor (2) (shown in green sticks) binding sites in CYP17A1 with respect to 
heme (shown in black sticks).  B) Inhibitor (2) (green sticks) modeled into electron density 
(shown as blue mesh) at peripheral site..  C) Inhibitor (2) modeled into the peripheral binding site 
in the orientation modeled in the final structure (green sticks) as well as the alternate orientation 
projecting the pyridine ring into bulk solvent (magenta sticks).  Map shown in panels B and C is 
composite omit map with simulated annealing contoured to 0.8 σ. 
 
DISCUSSION 
 Analogs of abiraterone with modifications to the A ring of the steroid nucleus have 
previously been demonstrated to have similar affinity for CYP17A1 as abiraterone and are 
reported to be equipotent inhibitors of progesterone hydroxylation8.  In the current work, the X-
ray crystal structures of three such analogs in complex with CYP17A1 demonstrate that these 
inhibitors bind within CYP17A1 active site very similarly to abiraterone.   
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 Direct contacts with the enzyme, specifically coordination of the pyridine nitrogen to the 
heme iron and the hydrogen bond between the C3 substituent and N202, were maintained among 
the three inhibitors.  The most substantial differences among the structures of CYP17A1 with A-
ring modified analogs were different interactions between the active site water network and the 
inhibitors.   
 In the structure of CYP17A1 with 3-hydroxy, Δ5 inhibitor abiraterone, the 3-hydroxy 
substituent of the inhibitor interacts with an active site water A, which in turn hydrogen bonds to 
water B, a participant in hydrogen bonds with R239 and the backbone of G297.  Inhibitor (2), for 
which the A ring can also adopt the chair conformation, also participates in a weak hydrogen 
bond with the same water.  In contrast, the 3α-hydroxy substituent of inhibitor (3) lies in an axial 
position where it can no longer interact with water molecule A, but is placed within hydrogen 
bonding distance of water molecule B.  The Δ4 double bond of inhibitor (2) leads to a flattening 
of the A-ring, and consequently the 3-keto-substituent interacts with water molecule B in some 
copies of the structure.  
 Interaction of C3 substituents with different water molecules demonstrates the role of A 
ring configuration on where in the active site the oxygen on C3 is projected.  Since this oxygen is 
part of one of the few functional groups available for modification on the steroid, the direction in 
which it is projected could be crucial in designing inhibitors to access particular active site 
features.  For example, the CYP17A1 active site features a pocket that extends over the I helix 
(Figure 4.4), which is not observed in other steroidogenic cytochrome P450s such as CYP21A2 
(as described in more detail in Chapter 7).  Design of inhibitors that extend over the I helix may 
therefore demonstrate more selectivity for CYP17A1 compared to CYP21A2.  Building upon the 
3α-hydroxyl group of inhibitor (3), which runs parallel to and is projected over the I helix, might 
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be more effective in accessing this pocket than building upon the corresponding 3β-hydroxyl 
group in abiraterone, which is projected toward the F helix. 
 
Figure 4.4: The C3 hydroxyl substituent of inhibitor (3) shown in magenta points toward an 
extension of the CYP17A1 active site, whereas the C3 hydroxyl substituent of abiraterone (cyan) 
is projected into the F helix.  Further functionalization of the C3 hydroxyl group of inhibitor (3) 
may therefore be a strategy for accessing this active site pocket. 
 
Differences in A ring configuration and therefore hydrogen-bonding to the active site 
water network do not appear to affect the potency of progesterone 17α-hydroxyase inhibition8, 
though all three A-ring modified inhibitors have yet to be compared for inhibition of the 17,20-
lyase reaction.  However, changes to the A ring configuration of abiraterone do appear to have a 
significant effect on the compound’s potency toward other prostate cancer targets.  This was 
recently demonstrated by studies that identified inhibitor (1) as an effective inhibitor of 3β-
hydroxysteroid dehydrogenase and 5α-reductase, both of which are necessary to generate 
dihydrotestosterone, and a much more potent androgen receptor antagonist than abiraterone9.  
The structure of CYP17A1 with inhibitor (1), as well as the two other analogs of abiraterone, 
support binding and inhibition data that suggest changes to the A-ring do not substantially affect 
interactions of these inhibitors with CYP17A1.  Besides inhibitor (1), inhibitors (2) and (3) 
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should also be evaluated against other prostate cancer targets, as these compounds could also 
demonstrate improved capabilities as multi-targeting agents for the treatment of advanced stage 
prostate cancer. 
In addition to revealing interactions of A-ring modified inhibitors with the active site of 
CYP17A1, the high resolution structure of CYP17A1 with inhibitor (2), solved to 2.0 Å, 
provides insight into a potential peripheral ligand binding site.  Electron density near the N-
terminal beta sheet region, A helix, and F/G loop has been observed in some molecules of 
previous CYP17A1 crystal structures, but was too ambiguous to permit the modeling of an 
additional ligand.  At 2.0 Å resolution, the map more strongly suggests this density is actually a 
steroid at partial occupancy.  Although additional steroid binding sites had not been previously 
reported for CYP17A1, crystal structures of other cytochrome P450 enzymes have shown 
steroids interacting with similar regions of the enzyme.  One of the first structures of CYP3A4 
revealed that progesterone, the intended ligand, was not located in the active site, but instead 
bound to a shallow pocket formed in the F/G loop (Figure 4.5A)18.  This site has also been 
identified through fluorescence energy resonance transfer, and is hypothesized to participate in 
cooperative ligand binding by inducing a conformational change in CYP3A419.  The structure of 
the steroidogenic bovine CYP21A2 revealed a second copy of the substrate 17α-
hydroxyprogesterone in a site near the N-terminal β strands and the F! helix20 (Figure 4.5B).  
This site lies between the active site of the enzyme and bulk solvent, suggesting that this channel 
may be a route for substrate access.  The peripheral ligand in the structure of CYP17A1 with 
inhibitor (2) interacts with very similar structural elements of the enzyme.  However, the 
conformation of the F/G region in bovine CYP21A2 is so dissimilar from that of human 
CYP17A1 (Figure 4.5C), that the peripheral copy of ligand is nearly 20 Å from the active site 
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ligand compared to ~10 Å in the bovine CYP21A2 structure.  A more recent structure of human 
CYP21A2 with progesterone also identified a second binding site in the the same region of the 
human form of the enzyme, albeit at lower occupancy21.  Whether or not this second, partially-
occupied binding site is an artifact of crystallization or functionally relevant is unknown, as the 
role of a peripheral binding site in CYP17A1 function has yet to be explored.  It is tempting to 
suggest that binding interactions at this secondary site, near elements suggested to be responsible 
for enzyme opening and closing, might affect the processivity of CYP17A1 and thus provide 
opportunities for lyase-selective inhibition.  Cytochrome b5, which binds to a site on the 
proximal face of the enzyme, is known to allosterically and selectively augment the CYP17A1-
mediated 17,20-lyase reaction but not 17α-hydroxylation and has been shown to modulate the 
conformation of residues in the F and G helices22.  Thus allosteric influences on CYP17A1 
function are not only possible, but may suggest a new strategy for selective inhibition of the 
17,20-lyase reaction.  Retrospective analysis of this peripheral binding site may be particularly 
informative for CYP17A1 with R-orteronel, which demonstrates the most selectivity toward 
17,20-lyase inhibition in our studies (vide infra, Chapter 6). 
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Figure 4.5: Steroids (all shown in black sticks) bind in different peripheral sites in cytochrome 
P450 enzymes A) human CYP3A4 with progesterone B) bovine CYP21A2 with 17α-
hydroxyprogesterone, and C) human CYP17A1 with inhibitor 2. 
 
In conclusion, the crystal structure of CYP17A1 with A-ring modified analogs of 
abiraterone demonstrate that these inhibitors make similar direct interactions with CYP17A1.  
Changes in the conformation of the A ring do affect indirect interactions with the active site by 
changing which active site waters participate in hydrogen bonds with an inhibitor.  Additionally, 
the high resolution structure of CYP17A1 with inhibitor (2) demonstrates a likely peripheral 
ligand binding site, which may be relevant to the function of CYP17A1, a crucial target in the 
treatment of advanced prostate cancer. 
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Chapter 5. 
Evaluation of Cytochrome P450 17A1 (CYP17A1) Function with Clinically 
Observed Mutations 
INTRODUCTION 
Cytochrome P450 17A1 (CYP17A1) is necessary for the biosynthesis of both androgens 
and corticosteroids.  Impairment of CYP17A1 function is desirable for patients with hormone-
dependent prostate cancer since inhibition of androgen biosynthesis can halt tumor growth and 
progression. For otherwise healthy individuals, however, suppression of CYP17A1 function as a 
consequence of missense mutations in the enzyme prevents production of sex steroids required 
for normal development1. In both populations, impaired CYP17A1 function can manifest as high 
blood pressure and fluid retention, as a consequence of secondary mineralocorticoid excess1-3.  
Unlike androgen deprivation, which is useful for the treatment of prostate cancer, the 
corticosteroid-related symptoms of CYP17A1 impairment are generally detrimental.  Ideally, 
therapeutic inhibition of CYP17A1 to treat prostate cancer would affect only androgen 
production, but have minimal effects on the production of corticosteroids. 
More than 50 mutations of CYP17A1 have been observed in human patients with varying 
effects on steroid biosynthesis, altering levels of circulating androgens and estrogens, as well as 
17-hydroxysteroids and glucocorticoids4,5.  Most patients in which CYP17A1 mutations are 
identified present with symptoms such as ambiguous genitalia or lack of secondary sexual 
development as a consequence of low levels of circulating androgens and estrogens1,4.  
Hypertension as a result of low cortisol production and the resulting secondary mineralocorticoid 
excess is often also observed1. 
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Inhibitors of CYP17A1 approved to treat prostate cancer have not yet been able to 
selectively disrupt androgen production without interfering with corticosteroid biosynthesis.  
However, there is precedent in the literature for selective disruption of androgen production in 
humans with CYP17A1 deficiency due to missense mutations in the CYP17A1 gene5.  Two 
types of CYP17A1 mutations have been observed clinically.  The first type of mutations disrupt 
both androgen production and glucocorticoid production, while the second type appear to only 
affect the production of androgens.  Biochemically, this is the consequence of inhibiting the 
different reactions performed by CYP17A1, which result in different steroid hormone 
metabolites.  Mutations of CYP17A1 that prevent both androgen production and glucocorticoid 
production block both 17α-hydroxylation necessary to generate both androgens and 
glucocorticoids, as well as the 17,20-lyase reaction necessary for biosynthesis of androgens.  In 
contrast, mutations of CYP17A1 that affect androgen production without interrupting 
glucocorticoid production selectively disrupt the 17,20-lyase reaction while allowing CYP17A1-
mediated 17α-hydroxylation to proceed normally.  Understanding how some mutations 
selectively disrupt the 17,20-lyase reaction but allow the 17α-hydroxylase reaction to proceed 
may be useful to inform strategies for selective inhibition of androgen production by small 
molecule inhibitors.  
 Mutations of CYP17A1 that disrupt both hydroxylase and 17,20-lyase reactions are the 
most widely reported, and may affect crucial aspects of the enzyme including the formation of 
key secondary structural elements and heme incorporation.  Two such examples are D116V and 
F114V mutations5. The D116V mutation was identified in a female patient that presented with 
lack of sexual development due to insufficient androgen production and low levels of cortisol, 
indicating both hydroxylase and lyase deficiency5.  Following identification, the D116V 
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mutation was demonstrated to indeed result in a loss of both hydroxylase and l7,20-lyase 
function (38% and ~11% wild type activity, respectively)5.  The side chain of D116, a solvent 
exposed residue in the loop between the B! and C helices, hydrogen bonds to the backbone of 
residue R96, which in turn interacts with the heme cofactor proprionates (Figure 5.1).  Mutation 
of D116 to a valine would not support such hydrogen bonding to R96 and may therefore 
indirectly affect heme incorporation, which would prevent all CYP17A1 catalysis6.  However, 
the proximity of D116 to the B! helix could also make mutation of this residue deleterious to 
formation of this crucial element of the CYP17A1 structure.  Some mutations that affect both 
hydroxylase and 17,20-lyase turnover line the CYP17A1 active site directly. Originally 
identified in a 17 year-old female patient that presented with lack of secondary sexual 
development and hypertension5, mutation of active site residue F114 to a valine is reported to 
demonstrate less than 10% of the progesterone hydroxylase activity of the wild type enzyme5,7.  
Also located in the B!/C loop, the side chain of F114 is directed toward the protein interior and 
lies only ~4 Å from steroidal substrates and inhibitors in previous structures of CYP17A16,8. 
Mutation to the smaller hydrophobic valine would certainly affect active site topography and 
potentially the binding of hydroxylase and lyase substrates.  Alternatively, as proposed for the 
D116V mutation, dual hydroxylase/17,20-lyase deficiency observed for F114V could be the 
result of substitution of a substitution at this position which disrupts the formation of adjacent 
secondary structural elements such as the B! helix (Figure 5.1). 
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Figure 5.1: Location of CYP17A1 residues whose mutation is reported to affect 17α-hydroxylase 
and 17,20-lyase activity (green) or only 17,20-lyase activity (magenta). 
 
 Mutations of CYP17A1 that disrupt the 17,20-lyase reaction more substantially than the 
hydroxylase reaction are rarer than those which impact both reactions equally.  Of these 
mutations, only one is known to occur in the active site.  Mutation of a glutamate residue in the I 
helix (E305) to a glycine was identified in a male patient with a lack of secondary sexual 
development but with high levels of 17α-hydroxylated metabolites, suggesting selective 17,20-
lyases deficiency9.  Follow-up studies substantiated 17α-hydroxylase activity for both 
progesterone and pregnenolone.  Additionally, although human CYP17A1 enzyme is very 
inefficient at converting the Δ4 17α-hydroxyprogesterone to its 19-carbon counterpart 
androstenedione via 17,20-lyase activity10, this reaction was not further compromised in the 
E305G variant9.  However, this mutant failed to produce the major 17,20-lyase product, 
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dehydroepiandrosterone, at detectable levels9.  Despite production of small quantities of the Δ4 
17,20-lyase product androstenedione, the male patient with E305G mutation presented with a 
micropenis and gynecomastia9. This indicated that the 17α-hydroxyprogesterone turnover by 
E305G was not sufficient to support normal sexual development9.  CYP17A1 E305G was 
expressed in E. coli and purified by Dr. Natasha DeVore, a previous lab member, but this mutant 
enzyme failed to catalyze progesterone hydroxylation in our typical system of reconstituted, 
purified proteins. 
 Other mutations reported to selectively disrupt the 17,20-lyase function are located on the 
proximal face of CYP17A1.  This region of the protein is known to generally interact with 
partner proteins NADPH-cytochrome P450 reductase (CPR) and cytochrome b511,12.  Electron 
delivery by CPR is necessary for both CYP17A1-mediated reactions.  In contrast, cytochrome b5 
augments the 17,20-lyase reaction 10-fold, but has little effect on the 17-hydroxylase reaction13.  
Mutation of basic residues on this face of CYP17A1 had been proposed to interrupt binding to 
the anionic surface of cytochrome b5 and therefore selectively disrupt the CYP17A1-mediated 
17,20-lyase reaction14,15. 
 Mutation of residues R347 and R358 (Figure 5.1) to histidine and glutamine, respectively 
were identified in patients with severe 17,20-lyase deficiency but normal or elevated levels of 
17α-hydroxylated metabolites16.  Further studies demonstrated that these single site mutations 
result in only 5% 17,20-lyase activity compared to wild type16.  However, these mutants retain 
65% of wild type 17α-hydroxylase activity.  Unlike wild type enzyme, addition of cytochrome b5 
does not appear to augment the 17,20-lyase reaction, which suggests that impairment of the 
17,20-lyase reaction by these mutants could be mediated by interrupting the 
CYP17A1/cytochrome b5 interaction14,15.  Moreover, mutation of these residues to conserve 
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cationic charge results in a partial recovery of 17,20-lyase activity14, which also implicates 
binding of anionic partner proteins as the basis for loss in 17,20-lyase activity. 
 Most studies examining the effect of these mutations have been performed using 
CYP17A1 in COS-1 cells or yeast microsomes which can contain other enzymes capable of 
steroid metabolism or electron delivery to cytochromes P450 and varying amounts of redox 
partner proteins5,9,15.  Very few studies have kinetically characterized both 17α-hydroxylase or 
17,20-lyase reactions for wild type CYP17A1 and relevant mutants.  Additionally, most studies 
have only focused on a single CYP17A1 mutant or a small panel of mutants with similar 
functional impairment, evaluating either mutants that exhibit no CYP17A1 activity or mutants 
with selective 17,20-lyase impairment.   
 The aim of the study described herein was to use purified cytochrome P450 and partner 
proteins to evaluate the function of a small panel of clinically-observed CYP17A1 mutants that 
exhibit either 1) both hydroxylase and lyase impairment or 2) selective 17,20-lyase impairment.  
Kinetic analysis of relevant reactions could help determine a basis for hindered enzymatic 
activity by CYP17A1 mutants F114V and D116V, confirm the role of cytochrome b5 in l7,20-
lyase-deficient mutants R347H and R358Q, and perhaps even help elucidate whether cytochrome 
b5 augments 17,20-lyase activity via electron transfer or allosteric effects on CYP17A1 
conformation.   
The mutants reported with combined hydroxylase/17,20-lyase deficiencies, F114V and 
D116V, were expressed in E. coli, but were not stable enough to permit isolation.  This 
suggested that the native residues at these positions are necessary for protein stability.  In 
contrast, the R347H and R358Q mutants, reported to be selectively lyase-deficient, were 
successfully purified from E. coli.  Both enzymes were subsequently evaluated for conversion of 
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progesterone to 17α-hydroxyprogesterone.  R347H did not bind or turn over progesterone, while 
R358Q was substantially less active than the wild type enzyme,.  R358Q was also evaluated for 
17,20-lyase turnover, and produced levels of DHEA at lower levels compared to wild type 
enzyme in the presence of cytochrome b5, suggesting that lyase deficiency resulting from 
mutation of this residue is the result of decreased interactions between CYP17A1 and redox 
partner proteins.  However, both of the latter mutants demonstrated substantial deficiencies in 
progesterone hydroxylation compared to wild type, suggesting that R358Q and R347H are not 
selectively lyase-deficient as reported previously15,16. 
 
METHODS 
Mutagenesis 
Site-directed mutagenesis was performed using the pCW/CYP17A1Δ19H plasmid to 
generate CYP17A1 mutants F114V, D116V, R347H, and R358Q as described in Chapter 2. 
 
Expression and Purification of Wild Type CYP17A1 and CYP17A1 Mutants 
 CYP17A1 wild type enzyme and all four mutants were expressed in the absence of ligand 
as described in Chapter 2.  In addition to expression in the absence of ligand, the unstable F114V 
mutant was also expressed at a separate time in the presence of 50 µM progesterone since the 
presence of ligand can aid in the stabilization of these enzymes. 
 CYP17A1 wild type enzyme was purified as described in Chapter 2.  CYP17A1 R347H 
and R358Q mutant enzymes were purified in the absence of ligand through CM sepharose 
chromatography as described in Chapter 2.  Purification was performed for CYP17A1 F114V 
and D116V mutant enzymes expressed in the absence of ligand through Ni-NTA affinity 
 96 
chromatography as described in Chapter 2.  CYP17A1 F114V expressed in the presence of 50 
µM progesterone was purified through Ni-NTA affinity chromatography as described in Chapter 
2, but with 50 µM progesterone in all purification buffers in an effort to enhance protein 
stability. 
 CYP17A1 R358Q was quantified via carbon monoxide spectral shift as described in 
Chapter 2, but since the reduced form of this mutant was unstable in the absence of ligand 
resulting in a spectral shift to 420 nm, the enzyme was also quantified in the presence of 50 µM 
progesterone. 
 
Assays 
The progesterone hydroxylation assay was performed as described in Chapter 2 at 
substrate concentrations varying from 0-200 µM. 
The 17,20-lyase assay was performed as described in Chapter 2 using a substrate 
concentration of 25 µM.  One modification is that the reconstituted protein system for reactions 
run in the absence of cytochrome b5 contained a 1:4:0 ratio of cytochrome P450 to CPR to 
cytochrome b5. 
Spectral ligand binding assays were performed as described in Chapter 2 with the 
progesterone concentration varied from 0 – 11 µM. 
 
RESULTS 
Protein Expression and Purification of CYP17A1 Mutants 
 CYP17A1 mutants were all expressed in E. coli and purification attempted according to 
the same protocol used to express wild type enzyme. However, the yield and stability of these 
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mutant proteins varied substantially between CYP17A1 mutants.  The combined 17α-
hydroxylase/17,20-lyase deficient mutants CYP17A1 F114V and D116V demonstrated a small 
amount cytochrome P450 immediately following detergent extraction as revealed by the reduced 
carbon monoxide difference spectrum (Figure 5.2), albeit much less than wild type at the same 
stage in purification.  Following affinity chromatography, the elution fractions for CYP17A1 
D116V demonstrated little absorbance based on the absolute spectrum of the protein, indicating 
the presence of very little heme-containing protein.  The heme Soret peak λmax was observed at 
405-407 nm, which is more consistent with free heme cofactor than heme coordinated to thiolate.  
Following seven-fold concentration, the reduced carbon monoxide difference spectrum of these 
elution fractions demonstrated a very small amount of the inactive P420 form (Figure 5.3A).  
Although the nature of the protein absorbing at 420 nm, commonly referred to as “P420”, is not 
fully understood, this species is generally considered to be a form of the enzyme unstable under 
reducing conditions. The difference spectrum was also recorded in the presence of 50 µM 
progesterone as a potential stabilizing ligand, but still did not result in significant absorbance at 
450 nm (Figure 5.3B).   
Affinity chromatography of CYP17A1 F114V yielded similar results with the heme Soret 
peak λmax at 408-413 nm in the initial absolute spectrum and very little absorbance demonstrated 
by any of the affinity chromatography elution fractions.  The carbon monoxide difference 
spectrum of the affinity chromatography elution fractions exhibited only a small peak at 420 nm, 
also similar to that of the D116V mutant. 
 98 
 
Figure 5.2:  Reduced carbon monoxide difference spectra of F114V (magenta) and D116V (gray) 
mutants following detergent extraction demonstrate a small absorbance peak at 450 nm.  
Reduced carbon monoxide spectrum of wild type enzyme (green) at the same stage of 
purification shown for comparison. 
 
 
Figure 5.3: Carbon monoxide difference spectra of D116V in the absence of ligand (panel A) and 
presence of 50 µM progesterone (panel B) mainly demonstrate a shift to 420 nm. 
 
 CYP17A1 F114V had previously been successfully expressed and purified in the same 
strain of E. coli by another lab member, Dr. D. Fernando Estrada, when the tight-binding 
CYP17A1 inhibitor abiraterone was present in both expression media and purification buffers. 
This suggests that the presence of this ligand improves the stability of the protein.  Since the 
presence of abiraterone precludes functional studies of the mutant, expression and purification of 
CYP17A1 F114V was attempted in the presence of 50 µM progesterone substrate instead.  The 
outcome of this expression and attempted isolation of the mutant was similar to that in the 
absence of ligand.  The affinity chromatography elution demonstrated no significant absorbance 
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at 417 nm and the reduced carbon monoxide difference spectrum revealed only a peak at 420 nm 
very similar to D116V. 
Purification of CYP17A1 R358Q through CM sepharose chromatography yielded ~5 
mg/L expression culture based on the absolute spectrum of the purified protein, which is similar 
to the amount of wild type enzyme usually isolated at this stage, an average of 7 ± 2 mg/L.  The 
reduced carbon monoxide spectrum of CYP17A1 R358Q featured very little protein with a λmax 
at 450 nm approximately one minute after treatment with carbon monoxide, and instead resulted 
in absorbance at 420 nm (Figure 5.4A, light blue).  After eight minutes, essentially all available 
protein had shifted to a λmax at 420 nm, leaving no absorbance at 450 nm (Figure 5.24, dark 
blue).  In an effort to better stabilize the CYP17A1 R358Q under reducing conditions, a reduced 
carbon monoxide spectrum was obtained in the presence of substrate progesterone (50 µM).  The 
resulting difference spectrum yielded only a λmax of 450 nm (Figure 5.4A, red), similar to wild 
type CYP17A1, indicating that the R358Q mutant can be stabilized in the presence of substrate. 
 
Figure 5.4: Carbon monoxide difference spectra of CYP17A1 mutants reported to be selectively 
17,20-lyase deficient.  A) In the absence of ligand, the spectrum of R358Q exhibits some 
absorbance at 450 nm at ~1 minute (light blue), but after 8 minutes is entirely shifted to 420 nm 
(dark blue).  However, when this spectrum is collected in the presence of 50 µM progesterone, 
the λmax is observed at 450 nm after 10 minutes (red) similar to wild type CYP17A1.  B) The λmax 
of R347H is shifted to 450 nm even in the absence of ligand, consistent with active cytochrome 
P450 protein. 
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 CYP17A1 R347H, which features a modification to a similar region of the enzyme as 
R358Q, was isolated at about 1/10th the quantity seen for wild type enzyme.  Following cation 
exchange chromatography, CYP17A1 R347H yielded only 0.42 mg / L expression media.  The 
protein that was isolated, however, demonstrated a carbon monoxide difference spectrum with a 
λmax of 450 nm (Figure 5.4B).  This indicated that the purified protein was stable similar to wild 
type enzyme under reducing conditions, even in the absence of ligand. 
  
Progesterone Hydroxylation by Reported Lyase-Deficient Mutants 
 Both mutants CYP17A1 R347H and R358Q, reported to be selectively lyase deficient, 
were evaluated for progesterone hydroxylation.  The R347H mutant demonstrated no production 
of the major CYP17A1 metabolite 17α-hydroxyprogesterone at substrate concentrations as high 
as 200 µM.  To determine whether the lack of progesterone hydroxylase activity by R347H 
resulted from a failure to bind substrate or an inability to perform catalysis, binding of 
progesterone to R347H was monitored via spectral shift binding assay as described in Chapter 2.  
At a progesterone concentration of 11 µM, no shift in spectrum was observed for the R347H 
mutant.  This indicated impaired binding of the substrate compared to wild type CYP17A1, 
which is saturated with the same ligand at 1 µM under the same conditions. 
 In contrast, the R358Q mutant protein demonstrated turnover of progesterone to 17α-
hydroxyprogesterone.  The R358Q mutant demonstrated a two-fold increase in Km compared to 
wild type enzyme, which may not be significant when considering the error of measurement.  In 
contrast, its kcat was over 25-fold lower than that of wild type CYP17A1, resulting in a 
significant drop in catalytic efficiency (Table 5.1).   
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Table 5.1: Kinetic constants for progesterone 17α-hydroxylation by CYP17A1 wild type and 
R358Q mutant. 
Enzyme Km (µM) kcat (min-1) kcat/Km (µM-1 min-1) 
Wild type 10 ± 2 1.01 ± 0.05 0.0960 
R358Q 20 ± 5 0.039 ± 0.003 0.0195 
 
17,20-Lyase Catalysis by R358Q 
 Since the 17,20-lyase activity of CYP17A1 of R358Q is reported to be extremely low16, 
full kinetic analysis of the enzyme was not performed.  Instead, 17,20-lyase activity of the 
R358Q mutant was evaluated alongside wild type CYP17A1 at 25 µM 17α-
hydroxypregnenolone, which corresponds to saturation of wild type enzyme.  Measurements 
were made in both the presence and absence of cytochrome b5 (Table 5.2) to validate whether or 
not the R358Q mutant performs the 17,20-lyase reaction14,16.  The rate of 17,20-lyase turnover 
by R358Q in the absence of cytochrome b5 (0.011 ± 0.001 pmol product/min/pmol cytochrome 
P450) was 2-fold lower than wild type CYP17A1 under the same conditions (0.023 ± 0.003 pmol 
product/min/pmol cytochrome P450).  A slight increase in 17,20-lyase turnover by the R358Q 
mutant was observed in the presence of cytochrome b5 (0.019 ± 0.002 pmol product/min/pmol 
cytochrome P450).  By comparison, wild-type CYP17A1 demonstrated the expected eight-fold 
increase in 17,20-lyase turnover in the presence of cytochrome b5.  The net result is that in the 
presence of cytochrome b5, the lyase activity of R358Q is ten-fold lower than wild type 
evaluated under the same conditions.  Thus, compared to wild type enzyme, the R358Q mutant 
exhibits substantial deficiency in both hydroxylase and 17,20-lyase catalysis. 
Table 5.2: 17α-hydroxypregnenolone 17,20-lyase turnover by CYP17A1 wild type and R358Q 
mutant in the presence and absence of cytochrome b5. 
Enzyme 17,20-Lyase turnover (min-1) 
- cytochrome b5 + cytochrome b5 
Wild type 0.023 ± 0.009 0.19 ± 0.03 
R358Q 0.011 ± 0.001 0.019 ± 0.003 
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DISCUSSION 
Different mutations of CYP17A1 have been reported in the literature to either disrupt 
both 17α-hydroxylase and 17,20-lyase reactions performed by the enzyme5 or to selectively 
prevent 17,20-lyase turnover while retaining the ability to perform the 17α-hydroxylase 
reaction9,16.  Although the structure of CYP17A1 has been determined in the presence of both 
inhibitors and substrates, the inability of such studies to capture the dynamics of the enzyme or 
its interactions with essential partner proteins does not necessarily inform the basis for loss in 
activity associated with mutation of these residues.  An understanding of how such mutations 
affect CYP17A1 structure, function, and interaction with partner proteins can be useful in 
designing inhibitors of the enzyme intended to halt androgen production and treat hormone-
dependent prostate cancer.  This is especially true of mutations that selectively disrupt 17,20-
lyase activity and androgen biosynthesis, but allow the production of 17α-hydroxylated products 
that act as glucocorticoid precursors. Selective 17,20-lyase inhibition is expected to achieve the 
desired androgen ablation effects in prostate cancer patients with reduced corticosteroid-
mediated side effects. The aim of the study described herein was to functionally characterize 
clinical mutants of CYP17A1 in vitro.  
Two of the mutations evaluated, F114V and D116V, are located in the loop region 
between B! and C helices and are reported to result in loss of both 17α-hydroxylase and 17,20-
lyase activity5.  Although both proteins seemed to express at low levels in E. coli, the F114V and 
D116V mutants appeared to be much less stable than wild type enzyme purified under the same 
conditions.  Purification of the F114V and D116V mutants by affinity chromatography, which 
yields substantial wild type enzyme, resulted in very little heme-containing protein.  The protein 
that was isolated did not produce the characteristic cytochrome P450 spectrum with λmax at 450 
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nm when bound to carbon monoxide in the reduced state (Table 5.3).  This suggests that the 
F114V and D116V mutations may both affect the folding and/or stability of catalytically active 
CYP17A1.  As discussed in the introduction, the side chain of residue D116 participates in a 
hydrogen bond with R96, which in turn interacts with the heme cofactor.  Therefore mutation of 
this residue to valine could affect incorporation or retention of the heme necessary for catalysis 
and/or destabilize adjacent structural elements, such as the B! helix. The B! helix comprises part 
of the active site and is known to be a relatively dynamic region of cytochrome P450 enzymes17.  
The heme Soret peak λmax of 405-407 nm is consistent with the presence of some free heme 
cofactor, suggesting poor heme incorporation or retention, but poor yields of D116V prevented 
us from further characterizing the loss in enzymatic activity due to this substitution. 
Table 5.3: Summary of CYP17A1 mutant evaluation. 
Mutation Purification Function Compared to Wild Type 
Yield (mg / 
L culture) 
Absolute 
Spectrum 
λmax (nm)* 
Reduced CO 
difference 
spectrum 
Hydroxylase Lyase 
Wild Type 7 ± 2 416-419 Mostly P450 -- -- 
F114V Very low 408-413 Mostly P420 ND§ ND§ 
D116V Very low 405-407 Mostly P420 ND§ ND§ 
R347H 0.42** 420 P450 No product 
detected⌘ 
ND§ 
R358Q 5** 416 P450 in 
presence of 
substrate 
2x ! Km,  
 
25x" kcat 
2x " activity –b5 
10x  " activity +b5 
*Range indicates values from multiple purifications 
**Standard error not determined as values reflect yield from a single expression and purification 
§Not determined 
⌘Titration with substrate did not produce spectral shift 
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As with D116V, very little heme protein was purified from E. coli transformed with 
plasmid containing the F114V mutation, and the protein that was isolated did not demonstrate a 
spectrum with a peak at 450 nm in the reduced, carbon-monoxide bound state (Table 5.3).  Also 
similar to D116V, the Soret peak λmax for isolated F114V (408-413) was lower than wild type, 
potentially indicating the presence of free heme.  This similarly suggests disruption of protein 
folding and stability and/or a problem with heme incorporation.  The lack of stable protein 
prevented further investigation into the loss of function associated with the F114V mutation.  
While the presence of progesterone in expression media and purification buffers to improve 
stabilization did not permit the isolation of this mutant protein in higher yields, addition of 
abiraterone in previous studies did permit isolation of inhibitor-bound F114V in significant 
quantities.  Abiraterone interacts with the CYP17A1 active site by simultaneously coordinating 
to the heme iron and hydrogen bonding residue asparagine 202, whereas progesterone only 
interacts with asparagine 202.  Consequently, abiraterone binds wild type CYP17A1 with a 
reported Kd < 100 nM and therefore much higher affinity than progesterone (Kd = 230 ± 10 
nM)6. This suggests that a heme-coordinating, and therefore tight-binding ligand in the 
CYP17A1 active site overcomes the destabilizing effects of a smaller residue substituted for 
phenylalanine in this position.  Residue F114 is only separated from D116 by a single residue, 
but instead of being projected toward the exterior of the protein, the side chain of F114 faces 
inward, comprising a part of the CYP17A1 active site.  The ζ-carbon of phenylalanine side chain 
is only ~4 Å from the β-face of steroidal substrates and inhibitors in the X-ray crystal structure 
with wild type enzyme6.  Inability to generate significant quantities of the F114V mutant under 
standard conditions for wild type enzyme suggests that destabilization of this enzyme may be the 
consequence of packing defects.  In summary, the inability to generate stable F114V and D116V 
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for further analysis is consistent with impaired hydroxylase and lyase turnover resulting from 
misfolded protein in patients harboring these mutations5. 
 In contrast, the R347H and R358Q mutant proteins reported to be selectively deficient in 
17,20-lyase turnover demonstrated normal spectral properties for P450 enzymes and could be 
purified in quantities sufficient to evaluate enzyme catalysis (Table 5.3).  Substantial differences 
in ligand binding and catalytic activity compared to wild type enzyme were observed for both 
mutants. Mutation of residue R347 to histidine was proposed to selectively prevent 17,20-lyase 
turnover by interfering with the CYP17A1/cytochrome b5 interaction14,15 that significantly 
augments 17,20-lyase catalysis but does not significantly affect the hydroxylase reaction.  
However, in our system the R347H mutant did not demonstrate a spectral shift upon titration 
with progesterone or produce detectable amounts of the 17α-hydroxyprogesterone when 
evaluated catalytically (Table 5.3).  Consequently, R347H did not appear to bind or turn over 
progesterone.  This contrasts with previous reports that R347H retains some pregnenolone 
hydroxylase activity, albeit with a 3.5-7.5-fold loss in Vmax compared to wild type enzyme5,15.  
The Km value for R347H has also been consistently reported as lower than that of wild type 
enzyme, which suggests higher affinity for the substrate than wild type5,16.  The aforementioned 
comparison studies of R347H were performed in COS-1 cells and using a different hydroxylase 
substrate, making it difficult to determine which experimental parameter leads to such different 
results. Although the inability of R347H to bind steroidal substrate described herein contradicts 
previous studies that demonstrate 17α-hydroxylase turnover, the effects of this residue on 
substrate binding does suggest that changes on the surface of the proximal face of the enzyme 
can have a significant effect on either the conformation of the active site itself, or on substrate 
access to the buried active site.   
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 In contrast to the R347H mutant, CYP17A1 R358Q was isolated in quantities similar to 
wild-type enzyme, and did metabolize the hydroxylase substrate progesterone.  However, the 
17α-hydroxyprogesterone metabolite was generated with a five-fold loss in catalytic efficiency 
compared to wild type enzyme (Table 5.3).  R358Q had a Km value within two-fold of the wild 
type enzyme, but the kcat was 25-fold lower.  Positive residues on the proximal face of the 
enzyme may interact with anionic residues of both cytochrome b5 and CPR.  The binding sites of 
these partner proteins are not well defined, but are reported to overlap12.  Since cytochrome b5 is 
not present in hydroxylation assays, the simplest explanation for deficient hydroxylase catalysis 
is that mutation of residue R358 hinders electron transfer by CPR and consequently reduces 17α-
hydroxylase activity.  The 17,20-lyase activity of the R358Q mutant was lower than that of wild 
type CYP17A1, even in the presence of cytochrome b5.  Addition of cytochrome b5 to R358Q in 
a 4:1 ratio resulted in a very small increase in activity, but not enough to result in substantial 
17,20-lyase turnover.  Therefore, although deficient 17,20-lyase turnover in the R358Q mutant 
may be partially the result of reduced cytochrome b5 binding, this residue likely plays a role in 
electron transfer by CPR as well.  At a minimum, it is clear that the R358Q mutation 
substantially impacts both hydroxylase and 17,20-lyase activities, and not just hydroxylation as 
previously reported15,16.   
In the past, in vitro follow-up studies have revealed that several other mutations initially 
reported to selectively block 17,20-lyase activity actually caused combined hydroxylase/17,20-
lyase deficiencies18,19 or were actually the result of functional deficiency of CYP17A1 redox 
partners20.  17α-hydroxylase deficiencies demonstrated by R347H and R358Q as a part of this 
study similarly reflect less selective 17,20-lyase impairment than previously reported.  Such 
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discrepancies make evaluation of mutant proteins in a controlled setting very important for 
determining their molecular basis. 
 The analysis of purified CYP17A1 R347H and R358Q proteins in this study supports 
important roles for these residues in catalysis.  Cationic residues on the proximal face of the 
enzyme appear to play a substantial and complex role in ligand binding and electron transfer, as 
well as binding of cytochrome b5 in the case of R358Q. In contrast, CYP17A1 with mutations of 
residues on the loop between the B! and C helices demonstrated decreased stability, likely the 
consequence of improper folding, poor stability, and/or impaired heme incorporation.  Overall, 
these studies highlight the necessity of evaluating mutant proteins in a controlled system to better 
understand the functional basis of deficiencies reportedly related to mutations identified in 
patients. 
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Chapter 6. 
Evaluation and Comparison of Clinically-Relevant Inhibitors of Cytochrome 
P450 17A1 (CYP17A1) 
INTRODUCTION 
 The role of cytochrome P450 17A1 (CYP17A1) in human androgen biosynthesis makes 
inhibition of this enzyme an emerging strategy for the treatment of castration-resistant prostate 
cancer in contrast to traditional androgen-deprivation therapy.  As discussed in previous 
chapters, CYP17A1 mediates two successive reactions relevant to steroid biosynthesis, the 
hydroxylation of 21-carbon progestagens followed by a carbon-carbon bond cleavage reaction to 
generate 19-carbon androgens.  The 17-hydroxylase reaction is necessary for both androgen and 
glucocorticoid synthesis, whereas the second carbon-carbon bond cleavage (17,20-lyase) 
reaction is only required for androgen biosynthesis. 
 Although the clinical success of abiraterone in treating prostate cancer has validated 
CYP17A1 as a target for this disease state, a variety of corticosteroid-related side effects 
including hypertension and peripheral edema have been attributed to off-target inhibition of the 
17-hydroxylase reaction.  Consequently, there has been a growing interest in developing 
CYP17A1 inhibitors that selectively inhibit the 17,20-lyase reaction while allowing CYP17A1-
mediated 17-hydroxylation to proceed with minimal interference.  A number of CYP17A1 
inhibitors have entered clinical trials since the discovery of abiraterone, some reportedly showing 
selectivity for inhibition of the 17,20-lyase reaction (Table 5.1). 
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Table 6.1: Reported IC50 values for inhibitors of CYP17A1 that have undergone clinical trials. 
Inhibitor FDA 
Approval 
Status 
Reported 
17,20-Lyase 
IC50 (nM) 
Reported 17α-
Hydroxylase 
IC50 (nM) 
Reported 
17,20-Lyase 
Selectivity 
 
Abiraterone 
Approved 2.9 - 8001-4 1.5 - 721,3-6 0.1 to 1.4-
fold1,3,4 
 
Galeterone 
Phase III 
Clinical Trials 
47-3002,7 N/R* N/R* 
 
(S)-Orteronel 
Discontinued 
after Phase III 
Clinical Trials 
19-1403,8 7603 5-fold3 
 
(S)-VT-464 
Phase II 
Clinical Trials 
694 6904 10-fold4 
*Value not reported in literature. 
CYP17A1 inhibition is typically evaluated as the half-maximal inhibitory concentration 
(IC50), or the concentration at which the inhibitor reduces a CYP17A1-mediated reaction to half 
of its maximal activity. This value is useful for comparing potency between inhibitors, and in the 
case of CYP17A1 is also used to compare potency of inhibition for a single inhibitor between 
different reactions (17α-hydroxylase vs. lyase).  The apparent IC50 value can vary widely 
depending on experimental conditions, as demonstrated by the reports of abiraterone’s IC50 for 
the 17,20-lyase reaction, which ranges over three orders of magnitude (Table 6.1).   
There are multiple factors that contribute to such variability. Included among them are 
the concentration of substrate and the mode of inhibition (competitive, non-competitive, or 
uncompetitive).  For example, low concentrations of substrate bias inhibition studies toward 
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competitive inhibitors, whereas high concentrations of substrate are associated with a bias 
toward uncompetitive inhibitors9.  Bias related to inhibitor modality can be reduced by using a 
substrate concentration equivalent the Michaelis-Menten constant for a particular reaction9. 
Unfortunately, such kinetic considerations have often not been taken into account when 
evaluating CYP17A1 inhibitors. 
To complicate matters further, CYP17A1 requires the partner proteins NADPH-
cytochrome P450 reductase and cytochrome b5 for catalysis, and the system in which these 
partner proteins are produced and incorporated with CYP17A1 vary.  Almost all inhibitor 
evaluations use human CYP17A1 and partner proteins produced recombinantly in E. coli or 
yeast, but the preparation and purity of such enzyme system components vary.  Some studies use 
CYP17A1 and redox partners in whole cells, in which case IC50 values reflect not only inhibition 
of a reaction but also membrane permeability.  The majority of in vitro inhibitor evaluation are 
performed using CYP17A1 and partner proteins in microsomes, the fraction of cell lysate that 
includes cell membrane and membrane-bound components including associated proteins.  In 
whole cell and microsomal systems, it is difficult to accurately measure or control the amount of 
available CYP17A1 enzyme or the relative amounts of co-expressed partner proteins required for 
catalysis. A few in vitro studies have used purified CYP17A1 and redox partners.  Under these 
conditions, it is easier to control relative amounts of enzyme system components.  However, 
experiments performed with purified proteins may or may not be conducted in the presence of 
lipid, an essential component for full-length enzyme in microsomal and whole cell systems.  The 
presence of lipid has been known to affect cytochrome P450 turnover, and previous studies have 
even demonstrated that the type of lipid used can affect catalysis by CYP17A110.  Finally, the 
source (human or rat) of redox partners CRP and cytochrome b5 can vary between experimental 
 112 
conditions, which can influence catalytic turnover.  In summary, different systems used to 
measure cytochrome P450 catalysis produce substantial variation in the resultant kinetics.  
Therefore direct comparisons of CYP450 IC50 values evaluated under different conditions are 
problematic.  
In the interest of developing lyase-selective inhibitors of CYP17A1, it has become 
increasingly common to evaluate candidates for their ability to inhibit the 17α-hydroxylase 
reactions that contribute to secondary mineralocorticoid excess, in addition to the targeted 17,20-
lyase reaction.  As discussed earlier, studies comparing inhibition between different reactions are 
not always performed using kinetically comparable substrate concentrations.  It is also often 
neglected that CYP17A1 has two physiologically relevant substrates for the 17α-hydroxylase 
reaction, and when evaluating candidates for inhibition of this reaction, usually only one 
substrate (progesterone or pregnenolone) is evaluated.  Although the structure of these substrates 
differs only in the A-ring of the steroid on the opposite end of the steroid that is catalytically 
modified by CYP17A1, progesterone and pregnenolone have different affinities for CYP17A1 
and are hydroxylated at different rates11.   
Evaluation of compounds for selective inhibition of the 17,20-lyase reaction has focused 
on two clinical candidates, orteronel and VT-464.  Both inhibitors are nonsteroidal, in contrast to 
abiraterone and galeterone, but still include a nitrogen-containing heterocycle capable of 
coordinating the heme iron.  Such coordination is seemingly at odds with the reported selectivity 
profiles for these inhibitors.  It is logical to expect that coordination of the heme iron should 
prevent all catalysis by CYP17A1 equally, but in the absence of structural information about 
interactions between reported lyase-selective non-steroidal inhibitors and CYP17A1, the 
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mechanism for selective inhibition of the 17,20-lyase versus either 17α-hydroxylase reaction 
remains unclear.   
One possible mechanism for selective inhibition of the 17,20-lyase reaction over 17α-
hydroxylation is interference with CYP17A1 processivity, the capacity of CYP17A1 to perform 
the 17,20-lyase reaction following the 17α-hydroxylase reaction without releasing the 
intermediate product from the active site.  Studies with zebra fish CYP17A112 have demonstrated 
that the Δ4 17α-hydroxyprogesterone is more likely than its Δ5 counterpart 17α-
hydroxypregnenolone to dissociate from the active site prior to 17,20-lyase turnover.  
Differences in IC50 values between hydroxylase and lyase reactions are not observed with Δ5 
steroids in which the hydroxylase product is less likely to leave the active site (Figure 6.1A). In 
contrast, a 10-fold difference is observed between progesterone hydroxylase and 17α-
hydroxyprogesterone 17,20-lyase IC50 values (Figure 6.1B).  This information seems to suggest 
that the selective inhibition of the 17,20-lyase reaction demonstrated by orteronel may be related 
to the processivity of CYP17A1.  However, processivity studies have not yet been reported on 
human CYP17A1, and the relationship between CYP17A1 and selective 17,20-lyase inhibition 
by orteronel remains unclear. 
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Figure 6.1: Processivity in zebra fish CYP17A1 affects apparent selectivity of S-orteronel for 
17,20-lyase inhibition over 17α-hydroxylase inhibition.  A) Δ5 steroids are less likely to leave 
the active site after hydroxylation and prior to the 17,20-lyase reaction (more processive) 
compared to B) Δ4 steroids which are more likely to dissociate from the active site following 
hydroxylation and prior to 17,20-lyase reaction. 
 
 The following study consists of direct comparisons between 17,20-lyase inhibition and 
17α-hydroxylase inhibition using purified CYP17A1 and partner proteins in controlled ratios and 
using concentrations of substrates equivalent to previously determined Michaelis-Menten 
constants.  This allowed us to determine whether reports of selective 17,20-lyase inhibition 
versus 17α-hydroxylase inhibition are justified, and moreover, whether or not CYP17A1 
inhibitors that coordinate the heme iron can even inhibit one reaction over another selectively.  
The X-ray crystal structures of CYP17A1 were determined with non-steroidal inhibitors S-
orteronel, R-orteronel and VT-464 to determine the potential structural bases for any observed 
17,20-lyase selectivity. 
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METHODS 
Protein Expression and Purification  
CYP17A1 and human NADPH-cytochrome P450 reductase were expressed and purified as 
described in Chapter 2.  Rat cytochrome b5 was produced by Dr. Natasha DeVore. 
Assays 
Spectral ligand binding assays were performed as described in Chapter 2.  IC50 values for 
progesterone 17α-hydroxylase, pregnenolone 17α-hydroxylase, and 17α-hydroxypregnenolone 
17,20-lyase reactions were determined by performing reactions and sample preparations as 
described in Chapter 2 for each individual assay, with the following modifications.  First, the 
substrate concentration was constant between samples and equal to the previously determined Km 
for the monitored reaction (10 µM, 1 µM, and 1.2 µM for progesterone 17α-hydroxylation, 
pregnenolone 17α-hydroxylation and 17α-hydroxypregnenolone 17,20-lyase, respectively). 
Inhibitor concentrations were in the range of 0-30 µM. 
  Graphpad Prism 5 (Graphpad Software, San Diego, CA) was used to determine the IC50 
value.  The percent enzymatic activity (in pmol product/min/pmol CYP17A1) for each sample 
containing inhibitor was normalized to enzymatic activity in the absence of inhibitor and plotted 
as a function of log [inhibitor].  Data were fit to the equation for log [inhibitor] vs. normalized 
response, Y = 100/ (1+10^((LogIC50-X)*HillSlope))). 
 
Crystallization, Data Collection, and Structure Determination 
CYP17A1 was co-crystallized with either racemic orteronel or VT-464 via hanging drop 
vapor diffusion.  CYP17A1 (29 mg/mL) in 50 mM Tris-HCl, pH 7.4, 20% glycerol, 100 mM 
glycine, 500 mM NaCl, 0.5% (v/v) Emulgen-913, and 100 µM racemic orteronel or 500 µM VT-
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464 was mixed in a 1:1 ratio with precipitant to form 2 µL drops.  The 2 µL drop used to 
generate VT-464 crystals was seeded with microcrystals generated in a 1 µL drop via sitting drop 
vapor diffusion in a 1:1 ratio with precipitant. Drops were equilibrated against 750 µL precipitant 
at 20°C.  The precipitant solution used to crystallize CYP17A1 with orteronel was 175 mM Tris 
HCl, pH 8.0, 30% (w/v) PEG-3350, 200 mM Li2SO4, and 12% glycerol.  The precipitant solution 
used to crystallize CYP17A1 with VT-464 was 100 mM sodium cacodylate trihydrate, pH 6.5, 
200 mM ammonium sulfate, and 30% (w/v) PEG-8000.  Crystals were cryoprotected using a 7:3 
mixture of mother liquor to 80% glycerol and were flash cooled in liquid nitrogen. 
Data were collected on beamline 12-2 or 7-1 at the Stanford Synchrotron Radiation 
Lightsource, and processed using XDS13.  Parameters for data collection and refinement statistics 
are described in Table 6.2.  Structures were solved by molecular replacement in Phaser14 using a 
previous structure of CYP17A1 with heme cofactor (PDB ID: 3SWZ15) as a search model and 
data to the corresponding resolution cutoff (2.2 Å for CYP17A1 with orteronel and 3.15 Å for 
CYP17A1 with VT-464).  Model-building and iterative refinement were performed using 
COOT16 and PHENIX17, respectively.  Ligand models were generated using eLBOW in 
PHENIX17.  Simulated-annealing composite omit maps were calculated in PHENIX17.  Figures 
were generated using PyMOL18. 
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Table 6.2: Crystallographic data collection and refinement statistics for CYP17A1 with 
nonsteroidal inhibitors orteronel and VT-464. 
 CYP17A1/orteronel CYP17A1/VT-464 
Data Collection   
Beamline SSRL 7-1 SSRL 12-2 
Space Group P212121 P212121 
Cell Dimensions   
a,b,c (Å) 90.17, 153.20, 168.12 90.95, 153.50, 169.04 
Molecules/a.u. 4 4 
Resolution (Å)* 39.28-2.20 (2.32-2.20) 39.44-3.10 (3.27-3.10) 
Total reflections* 871,993 (125,334) 142,288 (20,014) 
Unique reflections* 118,993 (16,928) 43,069 (6,096) 
Redundancy* 7.4 (7.4) 3.3 (3.3) 
Rpim* 0.053 (0.608) 0.087 (0.579) 
<I/σ(I)>* 14.0 (1.6) 8.4 (1.6) 
Completeness (%)* 99.8 (99.0) 98.5 (96.5) 
Refinement   
Resolution (Å) 39.29-2.20 39.44-3.10 
No. reflections 117,964 42,930 
R/Rfree (%) 19.76/24.94 18.27/24.88 
Ramachandran (%)   
    Favored 95.26 94.28 
    Allowed 4.09 5.40 
    Outliers 0.65 0.32 
No. atoms/B factors (Å2)   
    Protein 14901 / 44.1 15013 / 67.9 
    Ligand       92 / 43.8     112 / 45.0 
    Heme     172 / 32.0     172 / 53.4 
    Water     648 / 45.3         0 / NA§ 
RMSD bond (Å) 0.009 0.011 
RMSD angle (°) 1.157 1.356 
Coordinate error (maximum-
likelihood based) (Å) 
0.29 0.44 
*Statistics for highest resolution shell are shown in parentheses. 
§Not Applicable 
 
RESULTS 
Binding of Non-steroidal Inhibitors to CYP17A1 
 CYP17A1 was titrated with the non-steroidal inhibitors S-orteronel, R-orteronel, VT-464, 
and VT-463 and the observed spectral shift was used to determine the dissociation constant (Kd) 
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for the enzyme-inhibitor complex.  All inhibitors exhibited a type II shift over the course of 
titration typified by an increase in absorbance at 424 nm and a decrease in absorbance at 393-410 
nm (Figure 6.2).  Such changes indicate direct coordination of the heteroaromatic ring in each 
structure to the heme iron of the P450.   Of the four non-steroidal inhibitors tested, VT-463 
demonstrated the lowest affinity for the enzyme by far, with an estimated Kd of 290 ± 10 nM 
(Figure 6.3A).  VT-464 and both enantiomers of orteronel exhibited significantly higher affinity.  
For these three highest affinity nonsteroidal inhibitors, fits to the tight-binding equation yielded 
Kd values of 31 ± 7 nM for VT-464; (Figure 6.3B), 40 ± 7 nM for S-orteronel (Figure 6.2C), and 
56 ± 8 nM  for R-orteronel (Figure 6.3D). However, the changes in absorbance as a function of 
inhibitor concentration deviate substantially from a hyperbolic curve for the tight-binding 
equation (Figure 6.3 B-D), as all available ligand is tightly engaged in a complex with the 
enzyme and there is little free inhibitor in solution. This behavior has previously been observed 
for extremely tight binding ligands for CYP17A1 and is especially pronounced for the steroidal 
inhibitors abiraterone (Figure 6.3E) and galeterone (Figure 6.23).  In each case, though 
correlation coefficients range from 0.94 to 0.99 for both steroidal and tight-binding non-steroidal 
inhibitors, the residuals are not random and the data is better described as a linear increase 
followed by a plateau as CYP17A1 is saturated.  In such cases, one would typically further 
reduce the concentration of enzyme, but herein the concentration of enzyme (100 nM) is already 
as low as experimentally feasible to maintain a good signal-to-noise ratio. The net outcome is 
that for these tight-binding inhibitors the determined Kd values are, at best, upper limits and do 
not fully reflect the high affinity of these ligands for CYP17A1. 
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Figure 6.2: Type II spectral shifts were observed upon titration of CYP17A1 with non-steroidal 
inhibitors A) VT-463, B) VT-464, C) S-orteronel, and D) R-orteronel.  Increasing concentrations 
of inhibitors are shown from low concentrations (red/orange) to intermediate concentrations 
(yellow/green) to high concentrations (blue/violet).  The difference in absorbance between the 
resulting peak and trough (ΔAbsorbance) were used to monitor binding of ligand to enzyme 
(Figure 6.3). 
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Figure 6.3: Binding of non-steroidal CYP17A1 inhibitors A) VT-463, B) VT-464, C) S-
orteronel, and D) R-orteronel monitored as change in absorbance with increasing concentrations 
of inhibitor.  Binding of steroidal CYP17A1 inhibitors E) abiraterone and F) galeterone (data 
generated by Dr. Natasha DeVore) are shown for comparison. 
 
Based on such observations however, steroidal and non-steroidal inhibitors can be 
roughly rank-ordered according to their affinity for the CYP17A1 active site.  Steroidal 
inhibitors abiraterone and galeterone show higher affinity than any of the non-steroidal inhibitors 
evaluated. VT-464 demonstrates the highest affinity non-steroidal inhibitor, followed by S-
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orteronel and R-orteronel.  Of all inhibitors evaluated, VT-463 clearly demonstrated the lowest 
affinity for CYP17A1. 
 
Inhibition of Targeted 17,20-Lyase Reaction 
 Steroidal inhibitors (abiraterone and galeterone) as well as non-steroidal inhibitors that 
had entered clinical trials (S-orteronel and VT-464) and their corresponding enantiomers (R-
orteronel and VT-463) were evaluated for desired inhibition of the 17,20-lyase reaction using the 
primary physiological substrate 17α-hydroxypregnenolone.  IC50 determination was conducted at 
a substrate concentration corresponding to the previously determined Km of this reaction (1.2 
µM; see Chapter 4) and in the presence of cytochrome b5.  Product formation was plotted as a 
function of log [inhibitor] concentration to determine IC50 values for each inhibitor (Figure 6.4). 
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Figure 6.4: Inhibition of CYP17A1 17,20-lyase activity by steroidal inhibitors (top panel), 
orteronel (S- and R- enantiomers, middle panel) and VT-464 analogs (S- and R- enantiomers, 
bottom panel). 
 
The FDA-approved first-in-class CYP17A1 inhibitor abiraterone demonstrated the 
highest potency with an IC50 value of 36 ± 2 nM.  The other steroidal inhibitor, galeterone, was 
~3-fold less potent than abiraterone (IC50 = 100 ± 10 nM), but still showed higher potency than 
any of the non-steroidal inhibitors. Of the non-steroidal inhibitors, S-orteronel exhibited only 6-
fold lower potency than abiraterone for inhibition of the 17,20-lyase reaction (IC50 = 210 ± 20 
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nM), while R-orteronel (IC50 = 460 ± 90 nM) exhibited nearly 13-fold lower potency compared 
to abiraterone.  Finally, VT-464 and VT-463 were 12-fold and nearly 140-fold less potent than 
abiraterone (IC50 values of 430 ± 40 and 5000 ± 1000 nM), respectively. 
 
Inhibition of Off-Target Progesterone Hydroxylation Reaction   
 Each inhibitor was also evaluated for inhibition of progesterone hydroxylation.  
Consistent with the 17,20-lyase inhibition assay, these reactions were also performed using 
purified human CYP17A1 and P450 oxidoreductase and a substrate concentration equal to the 
previously determined Km of this reaction (10 µM; Chapter 4).  Since the hydroxylase reaction 
does not appear to require cytochrome b5 physiologically, this protein was not included in the in 
vitro enzyme system to prevent subsequent conversion of the hydroxylase product to 
androstenedione via the subsequent 17,20-lyase reaction. 
 The rank order potency for inhibition of this off-target reaction was identical to that of 
17,20-lyase inhibition (Figure 6.5). Abiraterone displayed the greatest potency (IC50 = 76 ± 5 
nM), followed by the other steroidal inhibitor, galeterone (IC50 = 130 ± 10 nM).  All four non-
steroidal inhibitors demonstrated less potency than abiraterone and galeterone.  Of the non-
steroidal inhibitors evaluated, S-orteronel was the most potent inhibitor of the progesterone 
hydroxylase reaction (IC50 = 950 ± 70 nM), but was still 13-fold less potent than abiraterone.  
The other non-steroidal inhibitor, VT-464, was the second most potent non-steroidal inhibitor of 
this reaction (IC50 = 1170 ± 90 nM), followed by R-orteronel (IC50 = 4000 ± 300 nM).  
Consistent with inhibition of the 17,20-lyase reaction and binding data, VT-463 exhibited the 
lowest potency (IC50 = 11.3 ± 0.9 µM).  
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Figure 6.5: Inhibition of progesterone hydroxylation by CYP17A1 inhibitors (shown as open 
symbols) and resulting nonlinear fits used to estimate the progesterone hydroxylase IC50 (shown 
as dotted lines).  These data are compared with 17,20-lyase inhibition data (closed symbols, solid 
lines) to illustrate selectivity for the targeted 17,20-lyase reaction. 
 
 Comparison of IC50 values for 17,20-lyase inhibition and progesterone hydroxylation 
(Figure 6.5) can be used to evaluate inhibitor selectivity for the targeted reaction (17,20-lyase) 
over the non-targeted reaction (progesterone hydroxylase).  The most selective inhibitors exhibit 
high IC50 values for the off-target hydroxylase reaction and low IC50 values for the targeted 
17,20-lyase reaction.   Selectivity factors in this section and following sections is determined 
using the following ratio: 17-hydroxylase IC50 / 17,20-lyase IC50.  A selectivity factor of 1 
therefore indicates no selectivity for 17,20-lyase reaction, while higher selectivity factors 
indicate more selectivity toward inhibition of the 17,20 lyase reaction.   
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All inhibitors evaluated were more effective in suppressing the 17,20-lyase reaction than 
the 17-hydroxylase reaction, and therefore all have selectivity factors greater than 1.  The 
steroidal inhibitors abiraterone and galeterone demonstrate 2.1-fold and 1.3-fold selectivity for 
17,20-lyase inhibition over progesterone hydroxylase inhibition, respectively.  The S-enantiomer 
of non-steroidal orteronel showed 4.5-fold selectivity, while R-orteronel exhibited greater (8-
fold) selectivity for inhibition of the targeted 17,20-lyase reaction over progesterone 
hydroxylation.  In contrast, the non-steroidal inhibitor VT-464 demonstrated only 2.7-fold 
selectivity for inhibition of the 17,20-lyase reaction over inhibition of progesterone 
hydroxylation, very similar to the 2.3-fold selectivity observed for its R-enantiomer, VT-463. 
 
Inhibition of Off-Target Pregnenolone Hydroxylation Reaction 
 Since both progesterone and pregnenolone are physiologically relevant substrates for the 
17α-hydroxylase reaction, inhibitors were also evaluated for inhibition of 17α-hydroxylation of 
pregnenolone as a substrate (Figure 6.6).  As with progesterone hydroxylase and 17,20-lyase 
inhibition, these studies were also conducted at a concentration of substrate corresponding to the 
previously determined Km of this reaction (1 µM; Chapter 4). 
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Figure 6.6: Inhibition of pregnenolone hydroxylation by CYP17A1 inhibitors (shown as open 
symbols) and resulting nonlinear fits used to estimate the pregnenolone hydroxylase IC50 (shown 
as dotted lines).  These data are compared with 17,20-lyase inhibition data (closed symbols, solid 
lines) to determine selectivity for the targeted 17,20-lyase reaction. 
 
 Similar to inhibition of the other reactions performed by CYP17A1, abiraterone was the 
most potent inhibitor of pregnenolone hydroxylation (IC50 = 121 ± 7 nM), followed by the other 
steroidal inhibitor, galeterone (IC50 = 150 ± 20 nM).  Non-steroidal inhibitors S-orteronel and 
VT-464 were the most potent non-steroidal inhibitors of pregnenolone hydroxylation, both 
exhibiting an IC50 value of 700 ± 100 nM.  R-orteronel was significantly less potent than its S-
enantiomer, demonstrating an IC50 value of 6000 ± 1000.  Due to its low affinity for CYP17A1 
and general lack of both potency and selectivity toward inhibition of the 17,20-lyase reaction, 
inhibition of pregnenolone hydroxylation by VT-463 was not evaluated. 
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Selectivity for 17,20-lyase inhibition was evaluated against pregnenolone hydroxylation 
in the same way it was evaluated against progesterone hydroxylation, as the pregnenolone 
hydroxylase IC50 value / 17,20-lyase IC50 value (Figure 6.6).  In general, selectivity for 17,20-
lyase inhibition versus pregnenolone hydroxylase inhibition was similar to selectivity of 17,20-
lyase inhibition versus progesterone hydroxylase inhibition.  Steroidal inhibitors abiraterone and 
galeterone demonstrated 3.3-fold and 1.5-fold selectivity for inhibition of the 17,20-lyase 
reaction compared to inhibition of pregnenolone hydroxylation.  S-orteronel exhibited 3-fold 
selectivity for the 17,20-lyase reaction compared to pregnenolone hydroxylation. Selectivity for 
the R- enantiomer of orteronel for inhibition of the 17,20-lyase reaction compared to 
pregnenolone hydroxylation was again estimated to be higher than that of S-orteronel (11-fold 
selectivity). VT-464 exhibited only 2-fold selectivity for 17,20-lyase inhibition compared to 
pregnenolone hydroxylation, consistent with its poor selectivity for inhibition of the 17,20-lyase 
reaction against progesterone hydroxylation. 
In most cases, each inhibitor’s selectivity for 17,20-lyase inhibition versus pregnenolone 
hydroxylase inhibition was similar to selectivity of 17,20-lyase inhibition versus progesterone 
hydroxylase inhibition (Table 6.3).  This is the case for galeterone (1.3 and 1.5-fold selectivity) 
and VT-464 (2.1 and 2.7-fold selectivity).  Slight differences in the selectivity were observed for 
abiraterone, S-orteronel, R-orteronel.  For example, S-orteronel 17,20-lyase selectivity appears 
slightly higher against progesterone hydroxylation (progesterone hydroxylase IC50 / 17,20-lyase 
IC50 = 4.5) than against pregnenolone hydroxylation (pregnenolone hydroxylase IC50 / 17,20-
lyase IC50 = 3.3).  Given the higher IC50 values for progesterone and pregnenolone hydroxylation 
overall and higher error associated with the values, differences between progesterone and 
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pregnenolone hydroxylase IC50 values and therefore differences in 17,20-lyase selectivity versus 
these reactions likely are not significant. 
Table 6.3: Summary of IC50 values for 17α-hydroxypregnenolone 17,20-lyase inhibition 
(targeted reaction), progesterone and pregnenolone hydroxylation (off-target reactions), and 
resulting selectivity ratios. 
Inhibitor Lyase IC50 
(nM) 
Progesterone 
Hydroxylase 
IC50 (nM) 
Progesterone 
Hydroxylase 
IC50/ Lyase 
IC50  
Pregnenolone 
Hydroxylase 
IC50 (nM) 
Pregnenolone 
Hydroxylase 
IC50 / Lyase 
IC50 
Abiraterone 36 ± 2 76 ± 5 2.1 ± 0.2 121 ± 7 3.3 ± 0.3 
Galeterone 100 ± 10 130 ± 10 1.3 ± 0.2 150 ± 20 1.5 ± 0.3 
S-Orteronel 210 ± 20 950 ± 70 4.5 ± 0.5 700 ± 100 3.3 ± 0.6 
R-Orteronel 460 ± 90 4000 ± 300 8 ± 2 5000 ± 1000 11 ± 3 
VT-464 430 ± 40 1170 ± 90 2.7 ± 0.3 700 ± 100 2.1 ± 0.4 
VT-463 5000 ± 1000 11300 ± 900 2.3 ± 0.5 N/D N/D 
 
 
Crystal Structure of CYP17A1 with Orteronel 
 Steroidal inhibitors of CYP17A1 show very little selectivity (1.3 to 3.3-fold) for 17,20-
lyase inhibition over 17α-hydroxylase inhibition.  This is consistent with the X-ray crystal 
structure of CYP17A1 abiraterone and galeterone in which the nitrogen of the inhibitor pyridine 
ring coordinates to the heme iron, an interaction that should non-selectively prevent all turnover 
by the enzyme.  Of the inhibitors evaluated as part of this study, only two inhibitors 
demonstrated greater selectivity for 17,20-lyase inhibition compared to abiraterone. S- and R- 
orteronel exhibit 3 to 5-fold and 8 to 11-fold selectivity for inhibition of the targeted 17,20-lyase 
reaction over off-target hydroxylation reactions.  However, the mechanism by which these 
inhibitors do so is not understood.  There is no published structural information on any 
CYP17A1 complexes with non-steroidal inhibitors to guide our understanding in this area.   
To elucidate a structural basis for selective inhibition of the 17,20-lyase reactions over 
hydroxylase reactions, purified CYP17A1 was co-crystallized with commercial material 
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purchased as S-orteronel (Selleckchem).  The resulting structure of CYP17A1 was determined at 
2.2 Å resolution in the space group (P212121).  This is the same space group as previous 
CYP17A1 structures with both inhibitors and substrates11,15. The overall structure was consistent 
with the aforementioned structures, with four molecules comprising the asymmetric unit. Also in 
agreement with previous structures of CYP17A1, there is high symmetry between molecules A 
and B (RMSD over all Cα = 0.28 Å), and between molecules C and D of (RMSD over all Cα = 
0.42 Å), but greater deviation is observed when comparing molecules A/B against C/D (average 
RMSD over all Cα = 1.20 ± 0.02 Å).  This is the result of some conformational changes to the 
protein backbone, localized in the N-terminus and the region between F-G helices, as described 
for previous structures of CYP17A111.  
 Although density was observed for ligand in the active sites of all four molecules, the 
density observed in the active site of molecules A and B was significantly different compared to 
that observed in molecules C and D.  In all cases, electron density clearly indicates that the 
ligand is coordinated to the heme iron (Figure 6.7), consistent with the Type II spectral shifts 
observed upon ligand binding (Figure 6.2).  Ligand density in molecules C and D was very 
identifiably S-orteronel (Figure 6.7A), however, this ligand was a poor fit for the density 
observed in the active sites of molecules A and B.    The inconsistent ligand density observed in 
the active site of molecules A and B led to an in-house characterization of the commercially-
purchased S-orteronel, which actually contained both enantiomers of orteronel, along with an 
unidentified impurity. R-orteronel provides a reasonable fit for the ligand density in molecules A 
and B (Figure 6.7B) and is fairly consistent with the 2Fo-Fc map.  However, the Fo-Fc maps are 
not completely satisfied by inclusion of this ligand in a single orientation.  Some negative Fo-Fc 
density is observed around the fused imidazole group interacting with the heme iron and some 
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positive density on one face of the naphthalene ring opposite the I helix, as well as between the 
heme iron and coordinating heterocycle.  
 
Figure 6.7: The contrasting ligand density in molecules C/D (panel A) compared to molecules 
A/B (panel B) in the 2.2 Å structure of CYP17A1 with orteronel suggests binding of different 
enantiomers of orteronel in different molecules of the structure (S-orteronel in panel A, R-
orteronel in panel B).  Simulated annealing composite omit map (contoured to 1.0 σ) is shown as 
blue mesh. R- orteronel, modeled into molecules A/B of the structure (panel B), does not fully 
satisfy electron density as demonstrated by Fo-Fc map for molecule A (negative density shown 
in red mesh and positive density shown in green mesh, contoured to 3.0 σ), but is the best 
solution. 
  
R-Orteronel modeled into the ligand density of molecules A/B is oriented similar to 
steroidal substrates and inhibitors, at a 60° angle from the plane of the heme, with one face of the 
naphthalene ring positioned flat against the I helix and the oxygen of the amide substituent 
oriented toward a residue on the F helix, asparagine 202 (N202).  This residue has been shown to 
hydrogen bond with the C3 substituent of steroidal inhibitors and substrates, and appears to 
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participate in a weak hydrogen bond (distances of 3.4 and 3.0 Å for molecules A and B, 
respectively) with R-orteronel (Figure 6.8A). 
 
Figure 6.8: Interaction of A) R-orteronel and B) S-orteronel with CYP17A1 active site residues.  
All distances shown are averages for molecules A and B (in panel A) or C and D (in panel B). 
 
The orientation of S-orteronel in the active site of molecules C/D shares some 
characteristics with R-orteronel as well as steroidal inhibitors and substrates.  The ligand also 
forms an approximate 60° angle from the plane of the heme, with one face of the naphthalene 
core positioned flat against the I helix.  However, in contrast to R-orteronel and steroidal 
inhibitors, S-orteronel is oriented toward the G helix (Figure 6.8B).  The amide substituent 
hydrogen bonds with arginine 239 (R239; H-bonding distance of 2.7 and 3.0 Å for molecules C 
and D, respectively) and aspartic acid 298 (D298; H-bonding distance of 2.7 and 2.8 Å for 
molecules C and D respectively) on the I helix. 
  
Crystal Structure of CYP17A1 with VT-464 
 Of the two non-steroidal CYP17A1 inhibitors to enter clinical trials, only S-orteronel 
demonstrated better selectivity than abiraterone for 17,20-lyase inhibition over 17α-hydroxylase 
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inhibition in the current study.  VT-464, reportedly 10-fold selective for 17,20-lyase inhibition4, 
only demonstrated 2-3-fold selectivity using purified CYP17A1 and partner proteins.  
Nonetheless, structural information for this inhibitor in complex with CYP17A1 is useful for 
comparison to the CYP17A1/orteronel complex, as such comparisons can be useful in 
establishing the structural basis for orteronel’s selectivity. 
 The crystal structure of CYP17A1 bound to VT-464 was determined at 3.1 Å in the space 
group P212121.  The asymmetric unit was comprised of four copies of CYP17A1, which were 
similar to previous structures of CYP17A1 with substrates and inhibitors, including that of 
CYP17A1 with orteronel.  As previously described for the CYP17A1/orteronel structure, 
molecules A and B demonstrated very similar overall structure, as did molecules C and D.  Less 
similarity was observed between molecules A/B and C/D as a consequence of the same 
conformational changes to the N-terminus and F/G loop observed in the CYP17A1/orteronel 
structure. 
 Density corresponding to the ligand is present in all four copies of CYP17A1 (Figure 
6.9A), and was consistent between copies.  The density clearly indicates that the ligand is 
coordinated to the heme iron, consistent with the type II shift observed upon ligand binding 
(Figure 6.2).  As with orteronel, the naphthalene ring is positioned flat against the I helix.  
However, unlike the structures with all other CYP17A1 inhibitors, VT-464 does not appear to 
form hydrogen bonds with any residues on the F or G helices.  Instead, the hydroxyl group of 
carbon 1 participates in a hydrogen bond with the backbone carbonyl of V482 (average distance 
over four molecules = 2.9 ± 0.1 Å), while one of the nitrogens of the triazole coordinated to the 
heme iron is positioned within weak hydrogen bonding distance of the T306 side chain (average 
distance over four molecules = 3.1 ± 0.2 Å) (Figure 6.9B). 
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Figure 6.9: The 3.1 Å structure of CYP17A1 with VT-464.  A) Ligand density corresponding to 
VT-464 (orange sticks) in structure of CYP17A1 with VT-464.  Composite omit map with 
simulated annealing is shown as blue mesh contoured to 1.00 σ.  B) Interactions between 
CYP17A1 active site and VT-464.  Distances shown are averages from all four molecules. 
 
DISCUSSION 
 All cytochrome P450 17A1 inhibitors that have undergone clinical trials or FDA approval 
have been individually evaluated for inhibition of the target enzyme, CYP17A1 in one context or 
another.  These in vitro studies determine the each compound’s half-maximal inhibitory 
concentration (IC50) for CYP17A1, but this value can vary depending on substrate concentration 
and other experimental conditions as demonstrated by the wide range of IC50 values reported for 
abiraterone (Table 6.1).  Catalysis by cytochrome P450 enzymes is especially complex and 
depends on multiple partner proteins.  Since turnover is modulated by the quantities of these 
partner proteins relative to the cytochrome P450 and one another, the use of various catalytic 
systems (whole cells expressing P450 and catalytic partners, microsomes, or individual purified 
proteins) to evaluate cytochrome P450 turnover and inhibition contributes greatly to differences 
in experimental conditions and therefore apparent IC50 values. Moreover, CYP17A1 has two 
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physiologically relevant substrates for the 17α-hydroxylase reaction, and the concentration of 
substrate used in most studies is not often justified by kinetic characterization of the reaction  
 To summarize, cytochrome P450 inhibition studies are often not performed using a 
standardized set of conditions.  Although such studies can identify and determine rank order 
potency of inhibitors evaluated internally, comparisons of IC50 values between studies are not 
always useful.  Such comparisons are becoming more essential in the development of second 
generation steroidal and non-steroidal inhibitors which are increasingly being evaluated for 
selective inhibition of the 17,20-lyase reaction over the 17α-hydroxylase reaction. 
This study uses tightly controlled conditions including known quantities of highly 
purified enzyme and partner proteins with substrate concentrations based on the individual 
kinetic parameters of the reaction under study.  This allows the determination of IC50 values that 
can be used to make meaningful comparisons across inhibitor types.  These comparisons can be 
used to establish rank order potency for inhibitors of the enzyme, which significantly impacts 
clinical efficacy.  More importantly, it allows us to compare potency of inhibition between target 
and off-target reactions and determine whether selective inhibition of the 17,20-lyase reaction is 
indeed possible for compounds that inhibit CYP17A1 through direct coordination to the heme 
iron. 
 In previous studies using microsomes and purified CYP17A1 with partner proteins, the 
steroidal inhibitor abiraterone (often the only inhibitor used as a control) is a more potent 
inhibitor of both the 17α-hydroxylation and the 17,20-lyase reaction than non-steroidal 
inhibitors.   The other steroidal inhibitor, galeterone, has only been evaluated for 17,20-lyase 
inhibition alongside abiraterone using whole cell systems, and was reportedly nearly 3-fold more 
potent than abiraterone. 
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 Among the inhibitors tested for the desired inhibition of the 17,20-lyase reaction herein, 
the steroidal inhibitors abiraterone and galeterone were the most potent.  This is consistent with 
binding data, which suggests that abiraterone and galeterone have the highest affinity for the 
CYP17A1 active site.  Abiraterone exhibited the highest potency overall (36 ± 3 nM).  Its 
estimated IC50 in this system with purified protein is broadly consistent with previous studies in 
microsomes and purified protein systems, which report IC50 values between 3 and 27 nM1,3,4.  
Galeterone exhibited nearly 3-fold lower potency than abiraterone in the current studies.  Since 
abiraterone and galeterone are both based on the steroidal scaffold, differences in potency likely 
indicate that the benzimidazole substituent of galeterone coordinates the heme iron less 
effectively than the pyridine ring of abiraterone. Previous reports of galeterone as a more potent 
inhibitor than abiraterone in a whole cell system may instead reflect other factors such as 
differences in cellular penetration between the inhibitors evaluated2.  
The most potent non-steroidal inhibitor was S-orteronel (IC50 = 210 ± 20), which was 5.8-
fold less potent than abiraterone in inhibiting of the 17,20-lyase reaction. VT-464 exhibited an 
even lower potency (IC50 = 430 ± 40 nM; 12-fold lower than abiraterone) for inhibition of 17,20 
lyase activity.  Binding data suggests that VT-464 has higher affinity for the CYP17A1 active 
site than S-orteronel. This apparent incongruity between affinity for the CYP17A1 active site and 
inhibition of the 17,20-lyase reaction may suggest that inhibition of the 17,20-lyase reaction by 
S-orteronel is not mediated entirely through heme coordination, but estimated affinities for 
CYP17A1 by VT-464 and S-orteronel (31 ± 7 and 40 ± 7, respectively) are too low to be 
determined with a high degree of certainty as discussed previously.  The ranking of inhibitor 
potency based on IC50 values is therefore more meaningful. 
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The R- enantiomers of both non-steroidal inhibitors demonstrated lower potency for 
17,20-lyase inhibition than the S- enantiomers used in clinical trials.  R-orteronel was 2.2-fold 
less potent an inhibitor of the 17,20-lyase reaction compared to S-orteronel, while VT-463 was 
nearly 12-fold less potent than its S-enantiomer, VT-464.  Binding data suggests that VT-463 has 
a much lower affinity for the CYP17A1 than VT-464, but while R-orteronel may have lower 
affinity for the CYP17A1 active site than S-orteronel, the margin between these two enantiomers 
is much smaller.  Overall, there appears to be an advantage to S-stereochemistry at the chiral 
center in potency for 17,20-lyase inhibition. 
Rank order potency determined by the current study is consistent the clinical success of 
CYP17A1 inhibitors.  Abiraterone has been successful in clinical trials, successfully improving 
overall survival in Phase III clinical trials19.  Decreased potency for 17,20-lyase inhibition by S-
orteronel when compared to abiraterone is consistent with its failure to achieve this end point in 
Phase II clinical trials20.  Based on the failure of S-orteronel to improve overall survival in Phase 
II clinical trials, it is improbable that an even less potent inhibitor of 17,20-lyase activity such as 
VT-464 will demonstrate improved efficacy in a clinical setting.  This, however, assumes that 
overall survival by the steroidal inhibitors is solely mediated by CYP17A1 inhibition, which is 
almost certainly not the case, as steroidal inhibitors have been reported to both antagonize2,21 and 
cause degradation of the androgen receptor22, and VT-464 has also been reported to act as an 
anti-androgen23.  Nonetheless, inhibition of 17,20-lyase activity of CYP17A1 is an important 
contributor to success of these compounds in a clinical setting. 
Inhibitors of CYP17A1 not only interfere with the 17,20-lyase reaction responsible for 
generating androgens, but also the 17α-hydroxylation reactions mediated by CYP17A1 and 
necessary for glucocorticoid biosynthesis.  Side effects observed in patients receiving abiraterone 
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as treatment, including hypertension and peripheral edema19,24, are believed to be the result of 
17α-hydroxylase inhibition and require coadministration with a synthetic glucocorticoid, 
typically prednisone24.  The selectivity of abiraterone for the 17,20-lyase reaction over the 17α-
hydroxylase reaction has been estimated to range anywhere from 0.1-fold to 1.4-fold depending 
on the hydroxylase substrate identity and concentration as well as the system under study1,3,4. 
Using purified CYP17A1 and partner proteins, we observed 2- to 3.3-fold selectivity for 17,20-
lyase inhibition over progesterone and pregnenolone 17α-hydroxylation, respectively.  The other 
steroidal inhibitor evaluated, galeterone, demonstrated ~1.5-fold selectivity for desired inhibition 
of the 17,20-lyase reaction over hydroxylation of either progesterone or pregnenolone.  The side 
effect profile of galeterone based on data from Phase I/II clinical trials has not been reported in 
the literature.  Since galeterone also exhibits poor selectivity for 17,20-lyase inhibition over 
hydroxylase inhibition similar to abiraterone, it is likely to cause similar side effects related to to 
secondary mineralocorticoid excess. 
The S-enantiomers of the non-steroidal inhibitors (S-orteronel and VT-464) have been 
reported in the literature to be 5- and 10-fold more selective for 17,20-lyase inhibition compared 
to 17α-hydroxylase inhibition3,4.  Consequently they have been developed as CYP17A1 
inhibitors with potentially improved side effect profiles.  S-orteronel has been reported to be 
slightly more than 5-fold selective for inhibition of the 17,20-lyase reaction compared to 
pregnenolone hydroxylation3.  In the current study, S-orteronel demonstrated 3.3- to 4.5-fold 
selectivity for the 17,20-lyase inhibition over pregneneolone hydroxylase inhibition or 
progesterone hydroxylase inhibition.  It is unknown if this slight increase in selectivity for 17,20-
lyase inhibition would significantly improve the side effects resulting from secondary 
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mineralocorticoid excess in vivo, because S-orteronel was still co-administered with prednisone 
in clinical trials20. 
VT-464 has been reported to be an even more selective inhibitor of the 17,20-lyase 
reaction, purportedly demonstrating 10-fold selectivity for lyase inhibition over pregnenolone 
17α-hydroxylase inhibition in studies using CYP17A1 in yeast microsomes4. When evaluated 
using purified CYP17A1 and partner proteins in this study, VT-464 demonstrated only 2- to 3-
fold selectivity, similar to abiraterone.  Clinical trial data for VT-464 has yet to be reported in the 
literature, however, the similarity of its selectivity profile to abiraterone suggests that this non-
steroidal inhibitor will produce similar side effects to abiraterone. 
Both non-steroidal inhibitors in clinical trials (orteronel and VT-464) include 
stereocenters with S- configuration. These enantiomers were pursued since they demonstrated 
better potency for 17,20-lyase inhibition than their R-enantiomers4,8. There have been no reports 
in the literature on whether or not the R-enantiomers exhibit more, less, or equal selectivity for 
17,20-lyase inhibition compared to 17α-hydroxylase inhibition.  To evaluate the effect of the 
stereocenter on inhibitor 17,20-lyase selectivity, R-orteronel and VT-463 (the R-enantiomer of 
VT-464) were evaluated for inhibition of the relevant reactions.  VT-463 demonstrated 
significantly lower potency than VT-464, with no significant difference in selectivity for the 
17,20-lyase reaction compared to progesterone hydroxylation (2.7-fold and 2.3-fold selectivity 
for VT-464 and VT-463, respectively).  Although S-orteronel demonstrated higher potency, R-
orteronel actually exhibited better selectivity for 17,20-lyase inhibition compared to inhibition of 
either hydroxylase reaction.  R-orteronel inhibited the 17,20-lyase reaction 8-fold better than 
progesterone hydroxylation and 11-fold better than pregnenolone hydroxylation.  This indicates 
that the configuration of orteronel’s stereocenter has an impact on selectivity for 17,20-lyase 
 139 
inhibition compared to hydroxylase inhibition and suggests that selectivity can be modulated 
even with inhibitors that coordinate the heme iron.  
Although the decreased potency exhibited by R-orteronel in suppressing 17,20-lyase 
activity would likely make it a poor candidate for clinical development, it may provide insight 
into a possible mechanism for selective 17,20-lyase inhibition.  The 2.2 Å crystal structure of 
CYP17A1 co-crystallized with a racemic mixture of S- and R- orteronel reveals ligand density 
corresponding to S-orteronel in two of four CYP17A1 molecules comprising the asymmetric 
unit.  In these two molecules, the ligand is both coordinated to the heme iron and forms hydrogen 
bonds with R239 on the G Helix.  Although there was apparent ligand density coordinated to the 
heme iron in the other two molecules of CYP17A1 comprising the asymmetric unit, this density 
did not appear to form interactions with any of the G-helix residues and appeared to be engaged 
in a hydrogen bond with N202 of the F helix.  S-orteronel was not a reasonable fit to this density, 
which did resemble R-orteronel.  A particularly interesting observation is that molecules of 
CYP17A1 with S-orteronel occupying the active site exhibit significant changes in the F/G loop 
region of the enzyme when compared to those housing ligand density consistent with the R-
orteronel (Figure 6.10).  The affected F/G region of the enzyme is known to be highly flexible 
and believed to interact with the membrane. Although this conformational difference in the F/G 
helical region is observed in most structures of CYP17A1 with inhibitors and substrates, usually 
the ligand adopts the same orientation in the active site of CYP17A1, regardless of the F/G loop 
conformation.  The observation that both R- and S- orteronel are not observed in the active site of 
every molecule of CYP17A1 at partial occupancy suggests that S-orteronel is selectively bound 
to CYP17A1 displaying one conformation of the F/G loop while R-orteronel selectively 
populates the active site of CYP17A1 displaying the alternate conformation of this loop.  In other 
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cytochrome P450 enzymes, movement of the F/G loop with respect to the B! helix is indicated in 
substrate access to the active site25, which may suggest that the stereochemistry of orteronel (and 
the selectivity for 17,20-lyase inhibition associated with different stereochemistry) affects ligand 
entry and exit.  This is consistent with recent work by Pallan et al. which demonstrated that the 
processivity of the two sequential reactions performed by teleost CYP17A1 affects whether or 
not orteronel is selective for 17,20-lyase inhibition over hydroxylase inhibition12.  For substrates 
that were more likely to leave the CYP17A1 active site after the 17-hydroxylase reaction and 
prior to the 17,20-lyase reaction, S-orteronel demonstrated ~10-fold selectivity for 17,20-lyase 
inhibition.  In contrast, using substrates that were less likely to dissociate from the active site 
between 17-hydroxylase and 17,20-lyase reactions, only 2-fold selectivity for 17,20-lyase 
inhibition was observed.  Processivity of human CYP17A1 with different substrates has not been 
reported, which prevents direct comparisons with the human enzyme at present, but these studies 
of teleost CYP17A1 inhibition by orteronel coupled with the structure of human CYP17A1 with 
orteronel are consistent with a mechanism for 17,20-lyase selectivity of orteronel that involves 
modulation of intermediate release or reentry from or to the active site of CYP17A1. 
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Figure 6.10: The ligand occupying the CYP17A1 active site (R-orteronel shown in magenta and 
S-orteronel in teal) depends on the conformation of the CYP17A1 F/G loop, a region implicated 
in ligand entry and exit for other mammalian cytochrome P450 enzymes. 
 
Unlike the structure of CYP17A1 with orteronel, the structure of CYP17A1 with the 
much less selective VT-464 demonstrated consistent ligand density in all four molecules of the 
protein comprising the asymmetric unit.  The CYP17A1/VT-464 complex crystallizes exhibiting 
both F/G-loop conformations, similar to CYP17A1 structures with abiraterone and galeterone.  
This observation, coupled with the lack of selectivity for 17,20-lyase inhibition exhibited by VT-
464 as part of this study, further supports the role of the F/G loop, and likely ligand access to the 
CYP17A1 active, in the apparent 17,20-lyase selectivity of orteronel.  The structure of CYP17A1 
with VT-464 is, however, the first structure of CYP17A1 with an inhibitor that does not appear 
to interact with either the F or G helix.  Optimization of this inhibitor to form hydrogen bonds 
with relevant residues in the F or G helix may improve the potency of VT-464. 
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In conclusion, parallel examination of a panel of clinically-relevant steroidal and non-
steroidal CYP17A1 inhibitors established rank order potency for inhibition of the 17,20-lyase 
reaction necessary for androgen biosynthesis.  More importantly, tight control over experimental 
conditions allows us to determine whether reported selectivity for 17,20-lyase inhibition against 
inhibition of the 17α-hydroxylase reaction, believed to cause corticosteroid-related side effects, 
is possible using compounds that coordinate the heme iron.  The steroidal inhibitors were more 
potent inhibitors than the non-steroidal inhibitors evaluated.  The 10-fold selectivity for 17,20-
lyase inhibition over 17α-hydroxylase inhibition reported for non-steroidal inhibitor VT-4644 
was not observed, with no improvement in selectivity detected for its less potent enantiomer, 
VT-463. In contrast S-orteronel demonstrated ~3-5-fold selectivity for 17,20-lyase inhibition 
over 17α-hydroxylase inhibition similar to that reported previously4.  The less potent enantiomer, 
R-orteronel, exhibited even greater selectivity (8- to 11-fold) for 17,20-lyase inhibition.  To 
better elucidate a structural basis for the observed selectivity of the orteronel enantiomers, 
CYP17A1 was crystallized in the presence of orteronel, which was later found to be a racemic 
mixture of R- and S- enantiomers.  The resulting 2.2 Å structure demonstrates different 
conformations of the F/G region depending on which enantiomer (S- or R-) occupies the active 
site.  This observation, coupled with studies on CYP17A1 processivity and its effects on the 
apparent selectivity of R-orteronel, seem to suggest that the selectivity of R-orteronel is may be 
in part mediated by promoting exit of intermediate product, and/or preventing lyase substrate 
reentry.  A better understanding of how CYP17A1 inhibitors such as R-orteronel achieve 
selectivity for the target 17,20-lyase reaction compared to off-target reactions performed in the 
same active site could help inform the development of more selective and potent inhibitors of 
this enzyme for the treatment of prostate cancer. 
 143 
 
ACKNOWLEDGEMENTS 
Synthesis of VT-464 and VT-463 and chiral separation of R-orteronel and S-orteronel were 
performed by Dr. Steven Rogers. 
 
REFERENCES 
(1) Potter, G. A.; Barrie, S. E.; Jarman, M.; Rowlands, M. G. J. Med. Chem. 1995, 38, 2463. 
(2) Handratta, V. D.; Vasaitis, T. S.; Njar, V. C.; Gediya, L. K.; Kataria, R.; Chopra, P.; 
Newman, D., Jr.; Farquhar, R.; Guo, Z.; Qiu, Y.; Brodie, A. M. J. Med. Chem. 2005, 48, 
2972. 
(3) Yamaoka, M.; Hara, T.; Hitaka, T.; Kaku, T.; Takeuchi, T.; Takahashi, J.; Asahi, S.; 
Miki, H.; Tasaka, A.; Kusaka, M. J. Steroid Biochem. Mol. Biol. 2012, 129, 115. 
(4) Rafferty, S. W.; Eisner, J. R.; Moore, W. R.; Schotzinger, R. J.; Hoekstra, W. J. Bioorg. 
Med. Chem. Lett. 2014, 24, 2444. 
(5) Al-Masoudi, N. A.; Ali, D. S.; Saeed, B.; Hartmann, R. W.; Engel, M.; Rashid, S.; Saeed, 
A. Arch. Pharm. (Weinheim, Ger.) 2014, 347, 896. 
(6) Jagusch, C.; Negri, M.; Hille, U. E.; Hu, Q.; Bartels, M.; Jahn-Hoffmann, K.; Pinto-
Bazurco Mendieta, M. A.; Rodenwaldt, B.; Muller-Vieira, U.; Schmidt, D.; Lauterbach, 
T.; Recanatini, M.; Cavalli, A.; Hartmann, R. W. Bioorg. Med. Chem. 2008, 16, 1992. 
(7) Bruno, R. D.; Vasaitis, T. S.; Gediya, L. K.; Purushottamachar, P.; Godbole, A. M.; Ates-
Alagoz, Z.; Brodie, A. M.; Njar, V. C. Steroids 2011, 76, 1268. 
(8) Kaku, T.; Hitaka, T.; Ojida, A.; Matsunaga, N.; Adachi, M.; Tanaka, T.; Hara, T.; 
Yamaoka, M.; Kusaka, M.; Okuda, T.; Asahi, S.; Furuya, S.; Tasaka, A. Bioorg. Med. 
Chem. 2011, 19, 6383. 
(9) Copeland, R. A. In Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for 
Medicinal Chemists and Pharmacologists; 2nd ed.; John Wiley & Sons: Hoboken, NJ, 
2013. 
(10) Yoshimoto, F. K.; Zhou, Y.; Peng, H. M.; Stidd, D.; Yoshimoto, J. A.; Sharma, K. K.; 
Matthew, S.; Auchus, R. J. Biochemistry 2012, 51, 7064. 
(11) Petrunak, E. M.; DeVore, N. M.; Porubsky, P. R.; Scott, E. E. J. Biol. Chem. 2014, 289, 
32952. 
(12) Pallan, P. S.; Nagy, L. D.; Lei, L.; Gonzalez, E.; Kramlinger, V. M.; Azumaya, C. M.; 
Wawrzak, Z.; Waterman, M. R.; Guengerich, F. P.; Egli, M. J. Biol. Chem. 2015, 290, 
3248. 
(13) Kabsch, W. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 125. 
(14) McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; 
Read, R. J. J. Appl. Crystallogr. 2007, 40, 658. 
(15) DeVore, N. M.; Scott, E. E. Nature 2012, 482, 116. 
(16) Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Acta Crystallogr., Sect. D: Biol. 
Crystallogr. 2010, 66, 486. 
 144 
(17) Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; 
Headd, J. J.; Hung, L. W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; 
Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; 
Terwilliger, T. C.; Zwart, P. H. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 
213. 
(18) Schrodinger, LLC  2010. 
(19) Fizazi, K.; Scher, H. I.; Molina, A.; Logothetis, C. J.; Chi, K. N.; Jones, R. J.; Staffurth, J. 
N.; North, S.; Vogelzang, N. J.; Saad, F.; Mainwaring, P.; Harland, S.; Goodman, O. B., 
Jr.; Sternberg, C. N.; Li, J. H.; Kheoh, T.; Haqq, C. M.; de Bono, J. S.; Investigators, C.-
A.-. Lancet Oncol. 2012, 13, 983. 
(20) Saad, F.; Fizazi, K.; Jinga, V.; Efstathiou, E.; Fong, P. C.; Hart, L. L.; Jones, R.; 
McDermott, R.; Wirth, M.; Suzuki, K.; MacLean, D. B.; Wang, L.; Akaza, H.; Nelson, J.; 
Scher, H. I.; Dreicer, R.; Webb, I. J.; de Wit, R.; investigators, E.-P. Lancet Oncol. 2015, 
16, 338. 
(21) Richards, J.; Lim, A. C.; Hay, C. W.; Taylor, A. E.; Wingate, A.; Nowakowska, K.; 
Pezaro, C.; Carreira, S.; Goodall, J.; Arlt, W.; McEwan, I. J.; de Bono, J. S.; Attard, G. 
Cancer Res. 2012, 72, 2176. 
(22) Yu, Z.; Cai, C.; Gao, S.; Simon, N. I.; Shen, H. C.; Balk, S. P. Clin. Cancer Res. 2014, 
20, 4075. 
(23) Toren, P.; Pham, S.; Kim, S.; Adomat, H.; Zoubeidi, A.; Moore, W. R.; Gleave, M. E. In 
Genitourinary Cancers Symposium; American Society of Clinical Oncology: Vancouver, 
BC, Canada, 2014. 
(24) Attard, G.; Reid, A. H.; Auchus, R. J.; Hughes, B. A.; Cassidy, A. M.; Thompson, E.; 
Oommen, N. B.; Folkerd, E.; Dowsett, M.; Arlt, W.; de Bono, J. S. J. Clin. Endocrinol. 
Metab. 2012, 97, 507. 
(25) Poulos, T. L.; Johnson, E. F. In Cytochrome P450: Structure, Mechanism, and 
Biochemistry; 3rd ed.; Ortiz de Montellano, P., Ed.; Kluwer Academic / Plenum 
Publishers: New York, 2005. 
 
 145 
Chapter 7. 
Structure of Human Steroidogenic Cytochrome P450 21A2 (CYP21A2) 
INTRODUCTION 
 Cytochrome P450 21A2 (CYP21A2) is one of six P450 enzymes involved in human 
steroid biosynthesis.  CYP21A2 generates corticosteroids by hydroxylating the Δ4 steroids 
progesterone and 17α-hydroxyprogesterone on carbon 21 to form 11-deoxycorticosterone and 
11-deoxycortisol, respectively.  Metabolites of CYP21A2 are intermediates for molecules that 
regulate sodium balance, directly affecting water retention and therefore homeostatic functions 
such as blood pressure.  Even further downstream, other metabolites regulate stress response, 
particularly inflammation.  Thus, impairment of CYP21A2 function can greatly disrupt 
homeostasis. 
 The consequences of hindered CYP21A2 activity have been observed in human patients 
with congenital adrenal hyperplasia.  The most common cause of this disorder (>90% of all 
cases) is mutation of CYP21A21. The degree to which CYP21A2 function is compromised 
directly affects the severity of the resulting phenotypes. When CYP21A2 is impaired >98%, 
symptoms include severe hypokalemia (low levels of circulating potassium ions), low blood 
pressure, and cardiovascular disorders due to deficient production of corticosteroids1,2.  
Substrates for CYP21A2 also accumulate and are alternatively metabolized by CYP17A1, 
resulting in an excess of androgens and some gender-dependent phenotypes including ambiguous 
genitalia in women and extreme virilization in men1.  Overproduction of androgens can also 
occur in individuals with as much as 60% retention of CYP21A2 activity.  However, the 
resulting phenotypes, such as infertility and polycystic ovarian syndrome in women, are 
generally less severe than those associated with the more complete reduction in CYP21A2 
 146 
activity.1,3 The effects of CYP21A2 dysfunction on androgen biosynthesis further demonstrate 
the interconnection between different branches of human steroidogenic pathways. 
 In addition to sharing the substrates progesterone and 17α-hydroxyprogesterone, 
CYP21A2 and CYP17A1 have 39% sequence identity.  To some extent, these enzymes even 
exhibit further overlapping metabolic profiles.  CYP17A1 has been shown to convert 
progesterone to very small amounts 11-deoxycorticosterone.  Although this is only ~1% of total 
product formation in the wild type CYP17A1 enzyme4, it can be increased to 5% by the A105L 
mutant4.  CYP21A2 has also demonstrated the capacity to produce 16α-hydroxyprogesterone, 
which is a minor metabolite of CYP17A1 progesterone hydroxylation4,5. It is therefore not 
surprising that inhibitors of CYP17A1, especially those based on the steroidal scaffold, have also 
been shown to interact with CYP21A26. 
 Inhibitors of CYP17A1 have recently been developed to prevent the production of tumor-
promoting androgens in patients with prostate cancer.  FDA-approved abiraterone is based on the 
structure of pregnenolone, a steroidal substrate of CYP17A1.  Abiraterone is very effective in 
preventing catalysis by CYP17A1. However, treatment with abiraterone and related inhibitors 
often also result in clinical side effects due to glucocorticoid deficiency and an excess of 
mineralocorticoids.  This corticosteroid imbalance is believed to partially result from inhibition 
of progestagen hydroxylation by CYP17A1.  However, the ubiquitous steroidal core on which 
abiraterone is based makes these compounds likely to interact with many other physiological 
targets, but especially the other cytochrome P450 enzymes involved in steroid biosynthesis and 
metabolism. 
 Abiraterone has been shown to both bind and inhibit human CYP21A2.  Titration of 
CYP21A2 with abiraterone results in a Type II spectral shift, consistent with coordination of the 
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inhibitor’s nitrogen-containing heterocycle to the heme iron (Victoria Jasion, unpublished data, 
Figure 7.1A).  This is the same interaction mode observed for abiraterone with human 
CYP17A1.  Although an accurate Kd has yet to be determined, it is currently estimated to be <1 
µM (Victoria Jasion, unpublished data).  Additionally, abiraterone demonstrates dose-dependent 
inhibition of progesterone 21-hydroxylation by CYP21A2 with an IC50 value (determined in a 
system with purified enzymes) of 300 ± 30 nM (Figure 7.1B)6.  This is 8-fold higher than the 
IC50 for inhibition of CYP17A1-mediated 17,20-lyase activity by CYP17A1 (CYP17A1 17,20-
lyase IC50 = 36 ± 2) and ~2-4-fold higher than the IC50 for CYP17A1-mediated 17α-hydroxylase 
reactions (CYP17A1 17α-hydroxylase IC50 = 121 ± 7 and 76 ± 5 for pregnenolone and 
progesterone as substrates, respectively). 
 
Figure 7.1: Abiraterone interacts with CYP21A2.  A) Binding of abiraterone to CYP21A2 results 
in a type II spectral shift as evidenced by an increase in absorbance at 424 nm and a decrease in 
absorbance at 409 nm.  Increasing inhibitor concentrations are shown from red/orange to 
blue/magenta.  Data provided courtesy of Victoria Jasion (unpublished).  B) Abiraterone 
demonstrates dose-dependent inhibition of progesterone 21-hydroxylation by human CYP21A2 
with an IC50 of 300 ± 30 nM6. 
 
 The physiological impact of off-target CYP21A2 inhibition by abiraterone is largely 
unknown since inhibitors that selectively interact with CYP17A1 compared to CYP21A2 have 
not been tested in vivo.  However, the potential effects of CY21A2 deficiency are known based 
on mutations in human patients as discussed above (Figure 7.2A).  Therefore, it is logical to 
suggest that mineralocorticoid production would also be reduced for abiraterone and other 
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compounds that inhibit both CYP17A1 and CYP21A2 (Figure 7.2B) compared to CYP17A1 
inhibitors that do not inhibit CYP21A2 (Figure 72.C). However in patients it is observed that 
dual inhibitors depress glucocorticoid production, which ultimately leads to a secondary 
mineralocorticoid excess via the adrenocorticotropin hormone feedback loop. Additionally, 
undesired CYP21A2 inhibition could contribute to a build-up of CYP17A1 substrate capable of 
overwhelming CYP17A1 inhibition and facilitating resistance to traditional CYP17A1 inhibitors 
over time (Figure 7.2.B).    Therefore, development of CYP17A1 inhibitors that do not interfere 
with CYP21A2 activity will help illuminate contributions of CYP21A2 inhibition to therapeutic 
outcomes. 
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Figure 7.2: Effects of steroidogenic cytochrome P450 inhibition on steroid hormone levels.  A) 
CYP21A2 inhibition results in a decrease of mineralocorticoids and glucocorticoids with a 
concomitant increase in androgens.  B) Inhibition of both CYP17A1 and CYP21A2 would 
certainly result in a decrease in glucocorticoids and likely a decrease in mineralocorticoids, but 
an increase in CYP17A1 substrate could overwhelm CYP17A1 inhibition, resulting in an 
increase in androgen production over time.  C) Selective inhibition of CYP17A1 results in a 
decrease in androgens and glucocorticoids and an increase in mineralocorticoids. 
 
 Structural information regarding the CYP21A2 countertarget can be extremely beneficial 
in directing design of more selective CYP17A1 inhibitors.  At the time this project was initiated, 
the most relevant structural information about CYP21A2 was an X-ray crystal structure of 
bovine CYP21A2 in complex with substrate 17α-hydroxyprogesterone7.  Bovine and human 
CYP21A2 share 80% sequence identity and both perform 21-hydroxylation on both progesterone 
and 17α-hydroxyprogesterone, but the human enzyme is more catalytically efficient8.  Thus, the 
goal of the following study was to determine the X-ray crystal structure of human CYP21A2 in 
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complex with CYP17A1 inhibitor abiraterone approved for treatment of prostate cancer.  
However, shortly after I solved a structure of human CYP21A2, a structure of human CYP21A2 
in complex with substrate progesterone was published8.  Unfortunately, in our CYP21A2 X-ray 
crystal structure the ligand density for abiraterone in the active site is relatively weak, likely the 
result of poor occupancy, and this ultimately prohibited modeling of the ligand.  The remainder 
of the CYP21A2 structure I determined is very similar to that of the substrate-bound enzyme8.  
Both human CYP21A2 structures display significant differences compared to bovine CYP21A2, 
including translation of the I helix with respect to the heme cofactor.  Such structural information 
may help guide the design of CYP17A1 inhibitors with lower affinity for CYP21A2, and help 
inform the biochemical consequences of CYP21A2 inhibition in prostate cancer treatment. 
 
METHODS 
Expression of CYP21A2 
 The gene encoding CYP21A2 bearing a truncation of the N-terminus (residues 2-28 and a 
leading sequence of “AKKTSSKGK”, and a C-terminal 4x histidine tag was cloned into the 
pCWori+ vector by Linda Blake (pCW/CYP21A2dH)9.   
 pCW/CYP21A2dH (1 µL, 211 ng/mL) was transformed  into 100 µL of DH5α/pGro7 
competent cells.  The cells were incubated with vector at 4°C for 30 minutes, heated to 42°C for 
30 seconds, and returned to ice for two minutes.  Cells were incubated in 1 mL super optimal 
broth for 45 minutes at 37°C with 220 rpm shaking.  Following outgrowth, 600 µL of the cells 
were spread onto a lysogeny broth agar plate with 100 µg/mL carbenicillin and 30 µg/mL 
chloramphenicol. 
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All media in the following expression was supplemented with 100 µg/mL carbenicillin 
and 30 µg/mL chloramphenicol to select for the pCWori+ and pGro7 vectors, respectively.  A 
starter culture of 5 mL lysogeny broth was inoculated with single colony from the 
aforementioned plate and incubated at 37°C with 220 rpm shaking for 8 hours.  An overnight 
culture of 200 mL lysogeny broth was inoculated with 200 µL starter culture and incubated for 
~16 hours at 37°C with 220 rpm shaking.  Terrific broth (1L / 2.8 fernbach flask) was inoculated 
with 20 mL overnight culture and incubated at 37°C with 220 rpm shaking.  At a 1.10 optical 
density at 600 nm, CYP21A2 expression was induced by addition of β-D-1-
thiogalactopyranoside to a concentration of 0.5 mM and 1 g/L arabinose was also added to 
induce chaperone expression.  The heme precursor δ-aminolevulinic acid was added at a 
concentration of 1 mM.  Flasks were incubated at 25°C with 120 rpm shaking for 48 hours.  
Cells were pelleted by repeated centrifugation at ~6000 x g and resuspended in buffer containing 
20 mM KPi, pH 6.8, and 20% glycerol.  Resuspended cells were stored at -80 °C until 
purification. 
 
Purification of CYP21A2 
 All stages of the purification were conducted at 4 °C.  Resuspended cells were thawed 
and stirred in the presence of lysozyme (0.3 mg/mL) for 30 minutes.  The mixture was treated 
with an equal volume of deionized water and stirred for an additional 10 minutes prior to 
centrifugation at 9900 x g for 15 minutes.  The resulting pellet was resuspended in buffer 
containing 500 mM KPi, pH 6.8, 300 mM NaCl, and 20% glycerol, and homogenized using a 
tissue grinder.  Resuspended cells were lysed by sonication (6 x 30 seconds with 1 minute 
intervals on ice), and cellular debris removed by centrifugation at 9900 x g for 15 minutes.  
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Membrane proteins were extracted from the supernatant by stirring for 60 minutes in the 
presence of 1% (v/v) detergent Emulgen-913 (Desert Biologicals), followed by centrifugation at 
100,000 x g for 60 minutes.   
Supernatant was loaded onto a column of ~30 mL Ni-NTA resin (Qiagen) that was pre-
equilibrated with nickel buffer (100 mM KPi, pH 6.8, 20% glycerol, 300 mM NaCl, and 0.2% 
Emulgen-913).  The resin-bound protein was washed with 4 column volumes (CV) of nickel 
buffer, followed by 5 CV of nickel buffer supplemented with 12 mM histidine.  Protein was 
eluted using 4 CV of nickel buffer supplemented with 80 mM histidine.  Fractions were pooled 
based on absorbance at 417 nm, the λmax for the heme Soret peak.   
Pooled fractions were diluted 3-fold in buffer containing 5 mM KPi, pH 6.8, 20% 
glycerol, 1 mM EDTA, and 0.2% Emulgen-913.  Diluted protein was loaded onto a 5 mL 
carboxymethyl sepharose fast-flow column (GE Healthcare) and washed with 24 CV of buffer 
containing 5 mM KPi, pH 6.8, 20% glycerol, and 1 mM EDTA.  Protein was eluted using 5 CV 
of buffer containing 50 mM KPi, pH 6.8, 20% glycerol, 350 mM NaCl, and 1 mM EDTA.  
Fractions were pooled based on absorbance at 417 nm and concentrated to ~1 mL. 
Concentrated protein was injected onto a 120 mL Superdex 200 gel filtration column (GE 
Healthcare) pre-equilibrated with CM buffer containing 50 mM KPi, pH 6.8, 20% glycerol, 350 
mM NaCl, and 1 mM EDTA.  Fractions corresponding to the major peak with absorbance at 417 
nm were collected and pooled. 
Protein concentration was determined by measuring the absolute absorbance as described 
in Chapter 2. 
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Crystallization, Data Collection, and Structure Determination 
 CYP21A2 (36 mg/mL) in 50 mM KPi, pH 6.8, 20% glycerol, 350 mM NaCl, 1 mM 
EDTA, 75 µM abiraterone, and 3 mM n-dodecyl-N,N-dimethylglycine was mixed in a 1:0.8 ratio 
with precipitant to form a 1.8 µL drop.  The precipitant solution consisted of 150 mM MES, pH 
6.5, 12% PEG-20,000, 6% glycerol.  1,6-Hexanediol (50%, 0.2 µL) was added to the drop.  The 
protein/precipitant drop was equilibrated against 750 µL precipitant solution at 20°C.  The small 
resulting crystals were seeded into 2 µL drops consisting of a 1:0.8:0.2 mixture of protein, 
precipitant solution (as described above) and 50% 1,6-hexanediol, which were also equilibrated 
against 750 µL precipitant at 20°C.  Crystals were cryoprotected in a 7:3 mixture of mother 
liquor to 80% glycerol and flash cooled in liquid nitrogen. 
 Data were collected on beamline 12-2 of the Stanford Synchrotron Radiation Lightsource 
and processed using XDS10.  Data collection and refinement statistics are shown in Table 7.1.  
Initial phases were determined by molecular replacement in Phaser11.  The bovine CYP21A2 
structure with heme cofactor (PDB ID: 3QZ1) was first used as a search model, yielding a 
solution with a log likelihood of 1,570.  After the coordinates for the structure of human 
CYP21A2/progesterone complex with heme cofactor (PDB ID: 48YW) were deposited into the 
PDB, phases were again determined using the coordinates of human CYP21A2 as a search 
model, yielding a log likelihood of 3,372.  Model building and iterative refinement were 
performed using COOT12 and PHENIX13, respectively.  Active site voids were analyzed using 
VOIDOO14 (probe radius = 1.4 Å, grid spacing = 0.33).  Overlays between structures of human 
CYP21A2, bovine CYP21A2, and CYP17A1 were generated using the secondary structure 
matching algorithm in COOT12, and optimized using a least-squares fit to overlay heme 
cofactors.  Figures were generated in PyMOL15. 
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Table 7.1:  Statistics for x-ray data collection and refinement of CYP21A2 crystallized with 
abiraterone. 
Data Collection  
Space group P1211 
Cell dimensions  
    a, b, c (Å) 118.95, 54.99, 166.29 
    α, β, γ (°) 90.00, 106.82, 90.00 
Molecules/a.u. 4 
Resolution (Å)* 28.91 – 2.74 (2.89 – 2.74) 
Total reflections* 334,649 (42,852) 
Unique reflections* 53,642 (7,417) 
Redundancy* 6.2 (5.8) 
Rpim* 0.047 (0.528) 
<I/σ(I)>* 9.5 (1.5) 
Completeness* 97.8 (93.5) 
Refinement  
Resolution (Å) 38.91-2.74 
No. reflections 53,444 
R/Rfree (%) 22.98 / 30.06 
Ramachandran (%)  
    Favored 92.35 
    Allowed 6.56 
    Outliers 1.08 
Wilson B Factor (Å2) 69.05 
No. Atoms/B Factors (Å2)  
    Protein 14302 / 77.8 
    Heme     172 / 46.9 
    Water       47 / 54.9 
RMSD bonds (Å) 0.008 
RMSD angles (°) 1.228 
Coordinate error (maximum-likelihood based) 
(Å) 
0.47 
 
RESULTS 
Overall Structure of CYP21A2 
 Data collected on a crystal of CYP21A2 grown in the presence of 75 µM abiraterone was 
processed to 2.74 Å in the P1211 space group.  The phases were first estimated by molecular 
replacement using molecule A of the bovine CYP21A2 structure (Top LLG = 1570).  However, 
shortly thereafter, release of the human CYP21A2 structure in complex with progesterone 
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allowed molecular replacement with this structure as an improved search model (Top LLG = 
3372).  The asymmetric unit is comprised of four molecules of enzyme, all of which exhibited 
the traditional cytochrome P450 fold (Figure 7.3) including 12 major helices (A-L), 4 smaller 
helices conserved among all four molecules (B!, F!, G!, K!), two smaller helices observed in at 
least one of the four molecules (A! and K!!) and 9 beta strands participating in three separate 
sheet systems (two near the N-terminus and one near the C-terminus).   Some surface loop 
regions, including those between helices J and K, and between K! and K!!, were not modeled due 
to poor electron density.  These same regions were not modeled in the structure of human 
CYP21A2 with progesterone, suggesting that these regions are dynamic parts of the enzyme.  
Additionally, the loop between helices H and I could be modeled in only one of four molecules, 
again, suggesting higher flexibility in this region.   
 
Figure 7.3: CYP21A2 2.74 Å global structure shown from the distal face (left) and perpendicular 
to the I helix (right).  Molecule C is shown in Jones’ rainbow (ranging from the blue N-terminus 
to the red C-terminus). Molecule D is shown overlaid in gray to demonstrate small variations in 
the protein backbone between copies in the asymmetric unit. 
 
Three of the four copies of the enzyme comprising the asymmetric unit were very similar 
(average RMSD among all Cα = 0.65 ± 0.04 Å).  However one copy of the enzyme, molecule D 
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in our structure, deviates somewhat from the other three (average RMSD among all Cα = 1.05 ± 
0.07 Å compared to molecules A, B, and C). The most significant changes in backbone structure 
between molecule D and the other three copies appear N-terminal to the poorly-ordered H/I loop 
(average local RMSD over Cαs from residues 250-270 = 3.5 ± 0.3 Å).  Molecule C, while very 
similar to other copies of the protein, displays some differences in the B!, G!, and G helices as 
well as their surrounding loops. 
 
Active Site 
 Although reasonable density permits modeling of both backbone and side chains of active 
site amino acids and the heme cofactor, there is not sufficient electron density to support the 
modeling of abiraterone.  Fo-Fc difference maps demonstrate a fragment of positive electron 
density protruding from the distal face of the heme in all four copies of the enzyme, suggesting 
that there is a ligand coordinated to the heme iron (Figure 7.4).  This density is likely the result 
of a strong interaction between the nitrogen heterocycle of abiraterone and the heme iron, albeit 
at partial occupancy.  There may not be sufficient interactions between the remainder of the 
steroid and the active site to stabilize the remainder of the ligand in a single orientation.  The C3 
substituent of progesterone in the structure of human CYP21A2 with progesterone forms a 
hydrogen bond with R234, equivalent to R239 in CYP17A1, on the G helix.  The C3 substituent 
of abiraterone in its structure with CYP17A1, forms a hydrogen bond with N202 on the F helix.  
The corresponding residue in human CYP21A2 is an isoleucine, which would not be able to 
participate in a similar hydrogen interaction.  Therefore, it is possible that pyridine ring 
coordination to the heme iron might not be ideal for formation of a C3 hydrogen bond between 
abiraterone and R234.  A lack of hydrogen bonding between the C3 substituent of the steroid 
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may prevent stabilization of the steroid core in a single orientation within the active site and 
therefore poor density associated with this part of the ligand.  Alternatively, the CYP21A2 (660 
µM) used to generate the crystal on which data was collected had been exchanged into buffer 
containing a lower concentration of abiraterone, 75 µM, which is near the solubility limit of this 
ligand in aqueous solution.  Although abiraterone appears to have reasonable affinity for the 
enzyme (<1 µM), this ligand concentration would have been insufficient to occupy all available 
CYP21A2 active sites, resulting in partial occupancy.  Although crystallization of abiraterone at 
higher ligand concentrations might result in higher ligand occupancy, this would require addition 
of ligand past its solubility limit in aqueous buffer.  At partial occupancy, as observed in the 
structure described herein, a lack of substantial interactions to order the steroid core in a single 
orientation would be consistent with the absence of electron density for this part of the ligand 
molecule. 
 
Figure 7.4: The active site of human CYP21A2 in the 2.74 Å structure demonstrates clear 
density for the heme prosthetic group and some adjacent density.  Difference maps (Fo-Fc maps 
contoured to 3σ and shown as green mesh) show positive density over the heme suggesting a 
coordinating ligand, as expected for abiraterone. However, Fo-Fc maps and  2Fo-Fc maps (shown 
in gray mesh and contoured to 1σ) are not sufficient to support modeling of a steroidal four-
membered ring. 
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 Despite similar backbone structure between copies of the protein, the active site volume 
varies widely between them.  The active site volumes of molecules A and B are isolated from the 
protein surface and are 430 and 415 Å3 (Figure 7.5), very similar in size to that of progesterone-
bound human CYP21A2 (Average active site volume = 520 ± 10 Å3).  However, the remaining 
two copies of CYP21A2 in the partially-occupied complex with abiraterone have significantly 
larger active site cavities (1014 and 686 Å3 for molecules C and D, respectively), both of which 
demonstrate channels connecting the active site with the protein surface.  This extension of the 
active site cavity is observed in all four molecules of the bovine structure of CYP21A2 structure, 
yielding an average active site volume of 1250 ± 60 Å.  
These substantial differences in both the size of the active site itself and access are 
largely the result of repositioning the B! helix (Figure 7.5.C).  Changes in the backbone of this 
helix are also accompanied by differences in side chain torsions (particularly tyrosine 98) which 
also expand the active site in this region.  However, the structural elements responsible for 
exposure of the active site to the enzyme’s substrate access channel (observed in molecules C 
and D) are more subtle, apparently mediated by small changes in backbone as well as side chain 
torsions for residues Y98 (B! helix), W202 (F helix), V470 (loop region between C-terminal β 
strands), V360, and L364 (K/K! loop) (Figure 7.5C).  An additional difference between the 
structure of bovine CYP21A2 and both structures of human CYP21A2 is the position of the I 
helix relative to the heme cofactor.  The I helix is significantly closer to the heme cofactor in 
both human CYP21A2 structures solved to date, whereas a kink in the helix of the bovine 
CYP21A2 structure provides more space above the heme.  It has yet to be determined whether or 
not the difference in I helix between human and bovine CYP21A2 structures is the consequence 
of the ligand bound to the bovine CYP21A2 structure, 17α-hydroxyprogesterone, which has a 
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hydroxyl group projected toward the I helix, or if it is a fundamental difference between the two 
enzymes.   
 
 
Figure 7.5: Variation in active site size between bovine CYP21A2 and different copies of human 
CYP21A2.  A) The active site cavities of bovine CYP21A2 (red ribbons, cavity shown in red 
mesh) is substantially larger than that of the closed conformation for the human enzyme (cyan 
ribbons, molecule A cavity shown in cyan mesh), largely as a result of differences in the B! and I 
helix and variations in the F-G region of the enzyme.  The bovine CYP21A2 active site over the 
heme is accessible via a channel from the surface that was occupied by a second copy of the 17α-
hydroxyprogesterone substrate (shown as gray sticks).  B) The human CYP21A2 structure 
determined herein with partial abiraterone occupancy demonstrates substantial variation in active 
site volume between molecules B (magenta, cavity shown in magenta mesh) more similar to the 
structure of bovine CYP21A2 and C (green, cavity shown in green mesh) more similar to the 
structure of human CYP21A2 with progesterone.  C) Comparisons of molecules B (magenta, 
cavity shown in magenta mesh) and C (green, cavity shown in green mesh) human CYP21A2 
from the mouth of the channel opening shows that this is the result of small changes in backbone 
and side chain torsions of surrounding residues.  
 
A second copy of the ligand, 17α-hydroxyprogesterone, was observed in the structure of 
bovine CYP21A2 in a cavity ~10 Å from the active site ligand7.  This cavity forms a surface-
exposed channel that is likely involved in ligand entry and exit (Figure 7.5A).  Density 
corresponding to a second ligand in the human CYP21A2 structure with progesterone was also 
observed, albeit at a lower occupancy, and the peripheral ligand was therefore not modeled.  This 
suggests that steroidal ligands are less stabilized in this peripheral binding site of human 
CYP21A2 than the active site.  In the CYP21A2 structure described herein, there is little 
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evidence for a ligand in this peripheral site.  However, the active site was not fully occupied, so 
the absence of density in this second, likely lower affinity binding site is not surprising.   
 
DISCUSSION 
 CYP21A2 is one of six cytochrome P450 enzymes involved in steroid biosynthesis, 
including CYP17A1 involved in androgen production.  Agents designed to inhibit CYP17A1-
mediated androgen production have also been shown to interfere with CYP21A2 metabolism.  
Abiraterone, which was specifically designed to inhibit CYP17A1 and therefore interrupt 
androgen biosynthesis in patients with hormone-dependent prostate cancer also binds and 
inhibits human CYP21A26.  A more thorough understanding of how coincident CYP21A2 
inhibition affects biochemistry, physiology, and clinical outcomes for those undergoing 
abiraterone treatment would require the development of inhibitors more selective for CYP17A1 
over CYP21A2.  The crystal structure of countertarget enzyme CYP21A2 with abiraterone was 
expected to provide useful structural information for the design of more selective inhibitors of 
CYP17A1. 
 Toward this end, CYP21A2 was crystallized in the presence of abiraterone, and the X-ray 
crystal structure of one such crystal was determined at a resolution of 2.74 Å.  Unfortunately, 
complete ligand density was not observed in any of the four copies of protein.  This is likely the 
result of partial ligand occupancy within the CYP21A2 active site due to inadequate 
concentrations of ligand present during crystallization.  However, density was apparent 
coordinated to the heme iron, which is likely the pyridine ring of abiraterone, and would be 
consistent with spectral changes observed upon titration of CYP21A2 with abiraterone.  
Although incomplete ligand density frustrated efforts to model abiraterone into the active site, 
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the structure of human CYP21A2 described herein can be compared to a recently-published 
structure of human CYP21A2 bound to one of its substrates, progesterone. 
 The structures of human CYP21A2 with progesterone and partially-occupied abiraterone 
are more similar to one another (average RMSD over all Cα = 0.90 ± 0.07 Å) than either 
structure is to the bovine CYP21A2 structure.  Relative to the bovine CYP21A2 structure, the 
human CYP21A2 substrate-bound and inhibitor-bound structures demonstrate have average Cα 
RMSD of 1.90 ± 0.04 and 2.03 ± 0.03 Å, respectively.  Some of the larger deviations observed 
between the substrate bound human and bovine CYP21A2 structures, include changes in the I 
helix that draw it closer to the heme cofactor, as well as the orientation of the F!/G! region.  
However, these features were conserved between substrate-bound and partially-inhibitor bound 
structures of human CYP21A2.  Some regions of the protein demonstrated variability between 
the substrate-bound structure and the structure with inhibitor bound at partial occupancy, and 
even between copies of protein in the latter structure.  Those elements of the enzyme include the 
B! helix and the loop between helices H and I, demonstrating the flexibility of these components 
within the human enzyme.  One of these changes, the conformation of the B! helix seems to 
affect the active site topography, and could reflect a critical role of this structural feature in 
substrate access to the active site. 
 Although there was little ligand density to direct modeling of abiraterone into the 
CYP21A2 active site based on crystallographic data, spectral shift assays strongly suggest the 
nitrogen of the pyridine ring coordinates to the heme iron.  Moreover, it is very likely that the 
steroidal core of the ligand assumes an orientation similar to substrate progesterone in the active 
site, with the 3β-hydroxyl group oriented toward the G-helix8.  If abiraterone is modeled in this 
orientation and overlaid with the CYP17A1/abiraterone structure (Figure 7.6), differences in 
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active site configuration and distinct ligand interactions are revealed that could be exploited to 
design inhibitors more selective for CYP17A1 versus CYP21A216.  One substantial difference is 
that the CYP17A1 active site extends over the top of the I helix beyond the C3 hydroxyl group of 
abiraterone, but this is not observed in the CYP21A2 active site (Figure 7.6A).  Functionalization 
of C3 with bulky substituents may therefore selectively hinder inhibitor binding to CYP21A2 
compared to CYP17A1.  Alterations in the A ring of steroidal inhibitors may facilitate this 
approach (Chapter 4).  There is also some unoccupied space in the CYP17A1 active site in the 
plane of the steroid near carbons 1 and 11 that is not available as part of the CYP21A2 active 
site.  Functionalization and modification of the steroid at these positions may also assist in 
achieving selectivity by introducing steric interference with the CYP21A2 active site. 
 
Figure 7.6: Overlay of CYP17A1 (gold ribbons and mesh active site) and CYP21A2 (magenta 
ribbons and active site mesh) by least squares fit demonstrates differences in the two active sites.  
Comparison suggests the presence of some accessible space in the CYP17A1 active site that is 
not available in the CYP21A2 active site, particularly near steroidal carbons C3 (A), C1, and 
C11 (B). 
 
 Comparison of the CYP17A1 and CYP21A2 active sites also suggests a basis for 
selectivity observed for some CYP17A1 inhibitors against CYP21A2.  One such analog of 
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abiraterone with an oxime substituent at carbon 6 was reported (C. Fehl, unpublished data) to 
demonstrate nearly 70-fold selectivity for CYP17A1 progesterone 17α-hydroxylation (IC50 = 150 
± 10 nM) over CYP21A2 progesterone 21-hydroxylation (IC50 = 10,300 ± 600)6.  An X-ray 
crystal structure of this inhibitor bound to CYP17A1 determined by Charlie Fehl revealed that 
the C6 oxime hydrogen bonds with the A105 backbone and D298 side chain of CYP17A1 
(Figure 7.7A)6. When this same steroidal inhibitor was modeled into the CYP21A2 active site 
with the steroidal core positioned similar to progesterone in the human CYP21A2 structure with 
substrate is positioned ~4.8 Å and ~4.7 Å from the corresponding residues (D288 and V101) 
(Figure 7.7B).  The absence of available hydrogen bond contacts in CYP21A2 compared to 
CYP17A1 could account for the disparate inhibitory potency for CYP21A2-mediated 
progesterone 21-hydroxylation compared to CYP17A1-mediated progesterone 17α-
hydroxylation.  
 
Figure 7.7: Interactions of a C6-substituted analog of abiraterone6 70-fold selective for inhibition 
of CYP17A1 over CYP21A2.  A)  In the X-ray crystal structure of CYP17A1 with this 
abiraterone analog, the C6 oxime hydrogen bonds with the backbone carbonyl of A105 and the 
side chain of D298. B) In the proposed orientation within the human CYP21A2 active site, this 
C6-substituted abiraterone analog is not positioned to hydrogen bond to corresponding residues 
V101 and D288. 
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In conclusion, human CYP21A2 was successfully crystallized in the presence of 
abiraterone and the X-ray crystal structure of the enzyme was solved at a resolution of 2.74 Å.  
Unfortunately, there was not sufficient electron density in the CYP21A2 active site to model 
abiraterone, suggesting only partial occupancy due to insufficient ligand concentrations during 
crystallization.  This structure is very similar to a recently published structure of CYP21A2 
bound to substrate progesterone. There are some small changes in the helices on the distal face of 
the enzyme between molecules of the human CYP21A2 structure described herein, including B!, 
F!, and G!, which can have substantial effects on the active site topography.  Conformational 
dynamics in these regions may modulate access to the active site from the surface of the enzyme.  
The active site of CYP21A2 in some copies of the asymmetric unit is accessible to the substrate 
access channel, a space reported to be ligand-occupied in the bovine and human structures of 
CYP21A2. 
Despite our inability to model abiraterone into the human CYP21A2 structure based 
solely on crystallographic data, we can hypothesize the orientation of the steroidal ligand within 
the active site is supported by spectral binding data consistent with heteroatom/heme 
coordination, as well as the structure of human CYP21A2 bound to its steroidal substrate, 
progesterone.  Comparison of abiraterone modeled into the CYP21A2 active site and the 
experimental complex with CYP17A1 suggest that functionalization of steroidal inhibitors on C3 
of the steroid or near C1 or C11 might interfere with binding to human CYP21A2 and may 
demonstrate more selectivity for CYP17A1.  If C6-substituted analogs of abiraterone adopt a 
similar orientation within the CYP21A2 active site, the hydrogen-bonds observed between these 
inhibitors and CYP17A1 would not be formed with corresponding residues in CYP21A2.  At a 
minimum, development of CYP17A1 inhibitors with greater selectivity over the countertarget 
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CYP21A2 is crucial to understanding the biochemical and physiological impacts of CYP21A2 
inhibition by abiraterone.  However such studies also have the potential to inform the design of 
more selective and effective CYP17A1 inhibitors for the treatment of prostate cancer. 
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Chapter 8. 
Conclusions 
 The overall goal of the research described herein is to gain a better understanding of 
steroidogenic cytochrome P450 function by 1) using systems of purified proteins to establish 
whether inhibitors and loss of function mutations can selectively disrupt a single reaction 
performed in the same active site and 2) comparing interactions between these enzymes and 
corresponding substrates and inhibitors to address questions of substrate specificity and 
regioselectivity and inhibitor potency and selectivity.  The functional analysis performed in this 
work is intended to inform the design of more potent and selective therapeutics targeting 
cytochrome P450 17A1.  Catalysis by cytochrome P450 enzymes is complex, and is further 
complicated by the fact that CYP17A1 carries out two different reactions in the same active site.  
The results described as part of this work advance our modest understanding of this enzyme’s 
function, and suggest further steps in developing a more complete understanding of CYP17A1, 
which should allow the subsequent design of better therapeutics for the treatment of prostate 
cancer. 
 First, structural studies of CYP17A1 with inhibitors suggest a possible mechanism for 
selective inhibition of the targeted 17,20-lyase reaction versus off-target inhibition of the 17α-
hydroxylation.  The structure of CYP17A1 with S- and R-orteronel demonstrates a single 
enantiomer occupying the active site of the enzyme depending on the conformation of the F/G 
loop.  Conformation A, which was observed to bind the more lyase-selective R-orteronel, may be 
more likely to allow for intermediate product release than conformation B, which was observed 
to bind the less lyase-selective S-orteronel (Figure 8.1).  If released from the enzyme, the 
intermediate 17α-hydroxylase product should be less likely to undergo the 17,20-lyase reaction.  
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Rebinding to CYP17A1 would require a second productive interaction between CYP17A1 and 
intermediate product.  Additionally, dissociation would allow an inhibitor or a 17α-hydroxylase 
substrate to compete for occupancy of the CYP17A1 active site.  The X-ray crystal structure of 
CYP17A1 with inhibitor (2), determined at 2.0 Å, substantiated the presence of a peripheral 
binding site near the flexible F/G loop when it assumes conformation B, but not conformation A.  
Inhibitor effects on CYP17A1 processivity may therefore be the result of occupation of this 
peripheral site by an inhibitor in contrast to active site binding.  Binding of less selective 
inhibitors such as S-orteronel and abiraterone to the peripheral binding site in conformation B 
may prevent intermediate product release.  Inversion of the stereocenter of S-orteronel to R-
orteronel appears to be inconsistent with occupation of this peripheral site, and could facilitate 
increased dissociation of intermediate product, ultimately yielding increased selectivity for the 
17,20-lyase reaction.   
 
 
Figure 8.1: Proposed mechanism for 17,20-lyase selectivity of R-orteronel.  Conformation A 
(left) is stabilized by R-orteronel and does not feature a peripheral ligand binding site.  
Conformation B (right) is stabilized by S-orteronel and observed to bind ligands in the peripheral 
site.  Ligand binding to the secondary site in conformation B may prevent release of intermediate 
product, facilitating 17,20-lyase turnover.  In contrast, conformation A may allow dissociation of 
intermediate product and allow R-orteronel to compete with the intermediate product for the 
active site. 
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Future studies should include determination of the X-ray crystal structure of CYP17A1 
with purified R-orteronel.  If R-orteronel does not interact with CYP17A1 in conformation B, 
this may destabilize the B conformation and may prevent normal crystal packing under 
conditions currently used to crystallize CYP17A1.  Alternatively, if CYP17A1 can adopt 
conformation B without binding R-orteronel we would likely observe little to no electron density 
in the two molecules of the asymmetric unit that adopt conformation B.  If the first scenario is 
true, then crystallization of CYP17A1 with R-orteronel might therefore require more thorough 
investigations into different crystallization conditions for this complex.  Structure determination 
of CYP17A1 with inhibitors that occupy the peripheral binding site at higher resolution (below 
2.0 Å) would help further define the site and verify the identity of the ligand present.  This could 
be achieved by using femtosecond crystallography1.  This technique uses lower levels of 
radiation, which should prevent reduction of the heme iron from the Fe3+ state to the Fe2+ state, 
improving homogeneity of the heme oxidation state, and potentially producing higher resolution 
data. 
 The proposed mechanism for 17,20-lyase selectivity could also be supported by kinetic 
studies that determine the mode of inhibition by R-orteronel and non-selective inhibitors.  If the 
proposed mechanism is correct, R-orteronel would demonstrate only competitive inhibition for 
both 17α-hydroxylase and 17,20-lyase reactions.  If the reduced selectivity of the other evaluated 
inhibitors results from occupying the peripheral binding site, inhibition of the hydroxylase and 
17,20-lyase reaction would exhibit a much more complicated kinetic profile, likely more 
consistent with non-competitive inhibition.  In summary, characterization of this peripheral 
binding site may be crucial to the development of 17,20-lyase selective therapeutics, however 
this will require a much more thorough characterization of the aforementioned site.   
 169 
 Since cytochrome b5 is reported to selectively augment the 17,20-lyase reaction2, it is 
tempting to suggest that therapeutics that block CYP17A1 and cytochrome b5 interactions might 
be a reasonable strategy for achieving selective inhibiton of the 17,20-lyase reaction.  The lack of 
selective 17,20-lyase deficiency demonstrated in vitro by CYP17A1 with mutations to the 
cytochrome b5 binding site suggest that interruption of cytochrome b5 binding without 
compromising interaction with NADPH-cytochrome P450 reductase may be a challenging 
pursuit. 
 The final consideration for the development of more successful prostate cancer 
therapeutics is whether or not CYP17A1 should be pursued as a single therapeutic target.  The 
consequences of interactions between intended CYP17A1 inhibitors and some biological targets, 
such as CYP21A2, are largely unknown.  While interaction with some of these targets could 
result in detrimental side effects or more rapid progression of resistance to treatment, the A-ring 
modified inhibitor (1) was recently reported to exhibit its anticancer activity by acting as an 
inhibitor or an antagonist at multiple targets3.  If inhibitors affect the right set of enzymes and 
receptors, a multi-target approach could improve therapy by delaying the onset of resistance4.  
Therefore, next generation inhibitors of CYP17A1 may be designed to interact with more than 
one enzyme or receptor.  Compounds designed to interact with a variety of steroid-metabolizing 
enzymes and nuclear receptors will very likely inhibit other steroidogenic cytochrome P450 
enzymes such as CYP21A2 and CYP11B1.  A more thorough understanding of such enzymes, 
including physiological consequences of their inhibition, will be necessary to determine whether 
their inhibition negatively impacts treatment and if so, what level of priority should be put on 
designing inhibitors that avoid inhibition of these targets.  Studies that examine the physiological 
effects of dual CYP17A1/CYP21A2 inhibition against selective CYP17A1 vs. CYP21A2 
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inhibition in animal models would be crucial to address such questions.  Analogs of inhibitor (3) 
with bulky substituents projecting from carbon 3 may access an extension of the CYP17A1 
active site cavity unavailable to CYP21A2, and such inhibitors could demonstrate selective 
inhibition of CYP17A1 over CYP21A2 as described in Chapter 7. 
 In conclusion, the studies described herein improve our knowledge of CYP17A1.  The 
complex catalysis performed by this enzyme makes its inhibition both a strategy for the 
treatment of prostate cancer and the source of adverse corticosteroid-mediated effects.  The 
crucial steps made in understanding selective inhibition of the 17,20-lyase inhibition as part of 
this work and the determination of the X-ray crystal structure for potential countertarget 
CYP21A2 represent progress toward the development of more effective therapeutics for the 
treatment of prostate cancer. 
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